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Abstract 
The supramolecular derivatisation, via co-crystallization and cyclodextrin (CD) inclusion of three 
active pharmaceutical ingredients (APIs), was attempted with the aim of generating new solid 
forms with potential pharmaceutical application. The APIs under investigation included allopurinol 
(used for the treatment of gout and kidney stones), 6-thioguanine (used to treat acute 
myelogenous leukaemia) and valproic acid (for treatment of epilepsy and bipolar disorders). 
Allopurinol and 6-thioguanine were fairly intractable, yielding very limited results following co-
crystallization trials with a series of co-formers. However, a new polymorph of one of the co-
formers, namely isonicotinamide, was discovered serendipitously and thoroughly characterized 
using thermal analysis and single crystal X-ray diffraction. Phase solubility studies with a variety of 
CDs showed that the poor aqueous solubility of allopurinol and 6-thioguanine was not significantly 
modified in the presence of CD solutions. However, a more accurate aqueous solubility value for 6-
thioguanine was achieved, namely 0.078 ± 0.003 mg.cm-3 at 25 oC.   
Six new CD complexes of valproic acid (VAL) were isolated by kneading and/or co-precipitation 
methods and characterized by thermal analysis, powder X-ray diffraction and spectroscopic (1H 
NMR and FT-IR) techniques. The six CD complexes (with host-guest stoichiometries in parentheses) 
included -CD·VAL (2:1), -CD·VAL (1:1), -CD·VAL (4:3), DMB·VAL (1:1), TMB·VAL (1:1) and 
TMA·VAL (1:1). The -CD·VAL, -CD·VAL, and -CD·VAL complexes were assessed for their ability to 
alter the aqueous solubility of the drug at 23 oC. The SCD/So ratios for these CD complexes (SCD being 
the solubility of VAL in the form of the CD complex and So the solubility of pure VAL) were 0.39, 
0.42 and 0.41 respectively and thus CD complexation reduced the aqueous solubility of valproic 
acid. Single crystal X-ray structures of four of the CD-valproic acid complexes were determined, 
those with native CDs featuring fully disordered guest molecules, while those with permethylated 
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A wide variety of active pharmaceutical ingredients (APIs), either established or previously 
discarded, have potent bioactivity, yet with the disadvantage of inadequate physicochemical 
properties. Examples of such properties include insufficient aqueous solubility, hygroscopicity and 
low dissolution rate, poor compressibility, low thermal stability, low bioavailability, high volatility, 
low resistance to oxidation, hydrolysis, light and heat, and vile odours or tastes.1-3 Despite 
technological advances and the increase in research, development and funding for the discovery of 
new pharmaceutical drugs, there has been a steady decline in the number of new drugs being 
produced. This decline has been apparent for the last sixty years and is associated with the 
increasing amount of financial investments and innovation required to produce each new drug.4 As 
a result of this decline, alternative methods have been discovered and implemented in order to 
overcome the shortage in new pharmaceuticals. These methods involve changing the solid form of 
established or discarded pharmaceuticals by modifying their properties, which thus may improve 
the physicochemical properties of the API in question.3 
1.2) Improving the physicochemical properties of an active 
pharmaceutical ingredient (API) 
The traditional approach for improving the physicochemical properties of an API was to create a 
new formulation with a combination of extreme pH conditions, organic solvents and surfactants, 
which would often result in irritation and other side effects depending on the components used.3 In 
recent years, more advanced methods of improving the physicochemical properties of an API have 
been studied and have subsequently replaced the traditional form of API adaptation. These include 
co-crystallization and the formation of cyclodextrin (CD) inclusion complexes with a particular 
API.1,3,5 Both of these methods are preferred, and offer advantages such as improved aqueous 
solubility, dissolution rate, reduced hygroscopicity, compressibility, stabilisation, as well as 
disguising the taste of the API and reducing its volatility. In addition, the bioactivity of the 
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respective API is not compromised during application of either of these methods.1,3,5 In order to 
understand how the physicochemical properties of an API are improved, a chemical understanding 
of both co-crystals and CD inclusion complexes is necessary. For this reason, the chemistry of both 
co-crystallization and CD inclusion complexation is discussed in detail below.  
1.3) Co-crystals 
A co-crystal is defined as “a multiple component crystal in which all components are solid under 
ambient conditions when in their pure form. These components co-exist as a stoichiometric ratio of 
a target molecule and a neutral molecular co-crystal former(s)”.6 From a pharmaceutical 
perspective, the co-crystal comprises two neutral molecules where the one molecule is an API and 
the other is the co-crystal co-former.1,7 Pharmaceutical co-formers are typically “Generally 
Recognized As Safe” (GRAS) compounds which are pharmaceutically acceptable for human 
consumption and they do not compromise the bioactivity of the API. There is a wide range of 
compounds which are classified as GRAS, for example, oxalic acid, malonic acid, succinic acid, adipic 
acid, nicotinamide, ascorbic acid and saccharin.8 However, in some cases the co-former may be 
another drug other than the API in question, for example theophylline, theobromine, caffeine, and 
phenazine.1,9 
1.3.1) Bonding in co-crystals 
The bonding in co-crystals involves non-covalent interactions, which include combinations of 
hydrogen bonds, ionic bonds, π-π stacking and van der Waals interactions.10 Co-crystals are often 
produced between molecules, regardless of their shape or size, which have complementary 
hydrogen bond functionalities in order to form a particular synthon. Synthons are defined as 
“structural units within supermolecules which can be formed and/or assembled by known or 
conceivable intermolecular interactions”.11 Examples of ring synthons involving hydrogen bonding 
in the 1:1 co-crystal of trans-1,4-cyclohexanedicarboxylic acid and 4,4′-bipyridine can be seen in 









1.3.2) Conditions for co-crystal formation 
There are multiple variables that determine whether a co-crystal will form from a particular API and 
co-former. These include API and co-former molar ratio, solvent, crystallization technique, and the 
pressure and temperature of the system.1 In addition, a co-crystal will only form if the co-crystal is 
thermodynamically more stable than the individual crystals of each component.1,13-14 During co-
crystallization no covalent bonds are either broken or formed and consequently the bioactivity of 
the API is not affected.1,9,15-16 As a result of these non-covalent interactions in co-crystals, the latter 
have a different crystal structure from the original components which formed the respective co-
crystal. Therefore, co-crystallization can produce a wide range of new solid forms of either 
established drugs or previously discarded drugs. These products have the potential to improve the 
physicochemical properties of the untreated drug.1  
1.3.3) Co-crystallization – a pharmaceutical perspective 
From a pharmaceutical perspective, co-crystallization offers the opportunity to produce new 
varieties of a given API, which in turn improve the physicochemical properties of the native drug.17 
These properties include insufficient aqueous solubility, hygroscopicity and low dissolution rate, 
poor compressibility (which can prevent tablet formation), and low thermal stability, reflected in a 
low melting point.1,18 In addition, a further advantage of co-crystallization is that it extends the 
patent life of known drugs. The implication of this is that the time it would usually take to develop a 
new drug for commercial use (approximately 13.5 years) can be drastically reduced by modifying or 
improving the properties of known drugs already in use. Thus, this process allows the increasing 
demand for treatments to be met at a much earlier stage and to be safely feasible for human use.19 





1.3.4) Co-crystals versus salts 
For many years it has been known that salts of bioactive compounds are suitable as 
pharmaceuticals owing to their relatively high aqueous solubility. However, co-crystals have the 
added advantage that their formation does not depend on the presence of inherent acid and base 
functionalities in their components. This is in contrast to pharmaceutically acceptable salts, as the 
number of molecules that can be ion-paired to form salts is limited. As a result, the advantage of 
co-crystallization is that it allows for a much wider spectrum of components to be used to create 
new solid forms of the drug.1,20 
1.4) Cyclodextrin (CD) inclusion complexes 
CD inclusion complexation with a particular API can also improve the physicochemical properties of 
an API, but it involves a different preparative methodology in comparison to co-crystallization.3 CDs 
are cyclic oligosaccharides which consist of multiple glucopyranose units linked together by α-(1,4) 
bonds.3,21 CDs are formed by an intramolecular transglycosylation reaction as a result of the 
degradation of starch by a CD glucanotransferase enzyme.3,22 The native CDs include α-CD, β-CD 
and -CD which consist of 6, 7 and 8 glucopyranose units respectively. The structure of a CD is 
toroidal in shape with a hydrophobic, non-polar cavity at the interior and a hydrophilic exterior.3,23 
X-ray studies have indicated that the secondary hydroxyl groups, which are located at C2 and C3, are 
situated at the wider end of the toroidal shape while the primary hydroxyl groups, which are 
located at C6, are situated at the opposite, narrower end of the toroidal structure. This can be 
observed in Figure 1.2. In addition, the ether-like (glycosidic) oxygen atoms and non-polar C3 and C5 















1.4.1) The formation of a cyclodextrin (CD) inclusion complex 
The formation of solid inclusion complexes is one of the most important features of CDs in the 
pharmaceutical industry. The interior of a CD acts as a cavity which can accommodate guest 
molecules. This cavity of the CD creates a microenvironment in which a correctly sized, non-polar 
guest molecule can enter in order to form an inclusion complex.3,26 This can be observed in Figure 
1.3. The binding strength of the CD complex is dependent on how well the guest molecule fits into 
the CD cavity. In solution, the guest molecule is not necessarily permanently situated in the CD 
cavity, but rather a dynamic equilibrium (CDG ⇌ CD + G) exists between the free host and free 
guest molecule, and the CD complex. Furthermore, it is not a requirement that the entire guest 
molecule should be situated inside the CD cavity, and successful CD inclusion complexation can also 
be achieved when only a hydrophobic residue of the guest molecule enters the cavity of the CD 
molecule.3,27-28 As with the formation of co-crystals, during the formation of a CD inclusion 
complex, no covalent bonds are formed or broken.3,29 CD inclusion complexation is an enthalpy-
favoured reaction where the cavity releases enthalpy-rich water molecules. The hydrophobic guest 
molecules displace the water molecules from the hydrophobic cavity in order to attain non-
polarnon-polar interactions between the CD cavity and guest molecules. This results in a decrease 
in the ring strain of a CD and thus the CD inclusion complex is in an overall more stable, lower 
energy state.3,22 In summary, there are two main factors which result in the formation of a CD 
Figure 1.2: The left-hand image displays the O2 and O3 hydroxyl groups on the wider secondary rim, while 
the O6 hydroxyl groups are on the narrower primary rim. The central image displays the glycosidic oxygen 
atoms pointing towards the interior of the toroidal-shaped β-CD molecule. The right-hand image is a 
schematic diagram of β-CD, which displays two (of the seven) pairs of H3 and H5 atoms that are directed 







inclusion complex. The first factor is determined by the relative sizes between the CD cavity and the 
guest molecule. The second factor is the thermodynamic favourability of the complexed state 




1.4.2) The lower energy state and equilibrium of cyclodextrin (CD) inclusion 
complexes 
There are four factors which contribute to this previously mentioned lower energy state of the CD 
inclusion complex. These include: polar water molecules being displaced from the hydrophobic 
cavity; an increase in hydrogen bond formation when the displaced water enters the bulk aqueous 
medium of the solvent; reduced repulsive interactions between the aqueous solution and guest 
molecules; and an increase in the hydrophobic interactions when the guest molecule enters the CD 
cavity.3 CD inclusion complexation involves a double equilibrium process, whereby the initial 
equilibrium is reached rapidly as a result of the enthalpy-driven factors mentioned above. However, 
the second equilibrium takes longer to reach, as it involves fine conformational changes of the 
guest molecule inside the CD cavity in order to exploit the van der Waals forces that are present.3 
1.4.3) The molecular geometry of a cyclodextrin (CD) 
The molecular geometry of the CD molecule is often distorted, initially with crystallisation and 
furthermore with complexation, owing to the change in the electrostatic environment with the 
advent of the guest molecule.31 As a result, geometrical parameters (based on an idealised O4-
polygon drawn within the CD molecule) were defined within the macrocycle in order to quantify 






such distortions (Figure 1.7).31-32 These geometrical parameters include the parameter l  that 
measures the distance from each O4 atom to the centroid of the O4-polygon, the parameter D that 
measures the consecutive O4···O4 distances of the O4-polygon, the parameter  that measures 
O4A(n-1)···O4A(n)···O4A(n+1) angles of the O4-polygon, and the parameter d that measures the 











Furthermore, the value D3 (which is not directly related to the O4-polygon) measures the OO 
distances of the O2(n)-HO3(n-1) / O2(n)H-O3(n-1) hydrogen bonds between consecutive 
glucose units. In addition, the parameter α measures the deviation from planarity of the O4-
polygon, which is achieved by comparing the deviation of each O4 atom from the O4 mean plane 
(Figure 1.8a). Lastly, the value τ2 is defined by the acute angle between the O4 mean plane and a 
second plane that passes through the O4, C4, C1 and O4′ atoms of each glucose unit. This angle 




























1.4.4) Cyclodextrins (CDs) – a pharmaceutical perspective 
From a pharmaceutical perspective, CDs have the ability to enhance the delivery of drugs through a 
biological membrane. A CD inclusion complex achieves this by retaining the hydrophobic drug 
molecule in the aqueous medium. The majority of drugs based on CD formulation are delivered 
orally. In this case the aqueous medium is the gastrointestinal (GI) fluid and the biological 
membrane of interest is the GI tract. The CD molecule remains in the aqueous medium and is 
eventually degraded by enzymes, while the drug molecule diffuses through the membrane into the 
bloodstream.3,33 Thus, CDs have a wide range of applications in the pharmaceutical industry. For 
Figure 1.8a: The O4 mean plane of the O4-heptagon in β-CD.  
Figure 1.8b: The angle τ2 is indicated by the acute angle between the O4 mean plane and a second 





example, CD inclusion complexes can aid in managing liquid APIs, which can be transformed into 
solids as CD inclusion complexes, and can thus allow tablet formation of the respective API to be 
produced. This can sometimes also result in an improved bioavailability (due to the hydrophilic 
exterior of the CD molecule), which would thus result in a lower dosage of the drug being 
administered. The stability of an API can also be improved via CD inclusion complexation, as it 
improves the resistance of the API to oxidation, hydrolysis, light and heat.3 Furthermore, CD 
complexation can protect various organs in the human body, should the untreated API cause 
irritating effects during administration. Lastly, bitter tastes or vile odours of various APIs can also be 
disguised by forming CD inclusion complexes, which can result in a more acceptable administration 
of the drug from the point of view of the patient.3 Possible guest molecules that can form CD 
inclusion complexes from a pharmaceutical perspective include drugs from many classes.3,28 
1.5) General aims and objectives 
The aim of this Master’s project was to synthesize, characterise and isolate pharmaceutical 
supramolecular derivatives of APIs which may display modified properties, via co-crystallization and 
cyclodextrin inclusion complexation. Consequently, these supramolecular derivatives would be 
further investigated for their potential to alter the aqueous solubility of the native APIs. The APIs 
under investigation included allopurinol (used for the treatment of gout, kidney stones and certain 
cancers), 6-thioguanine (used for the treatment of leukaemia) and valproic acid (used for the 
treatment of epilepsy and bipolar disorders). The structures of these APIs can be seen in Figure 1.9. 
All three of these pharmaceutical drugs are currently in use and available commercially. In addition, 
they have the potential to form hydrogen bonds, which is the main criterion for co-crystallization.1 
Furthermore, they were selected as a result of their low aqueous solubility, which is the major 
shortcoming of these drugs in terms of bioavailability. A detailed description of each API is provided 










Table 1.1: Selected properties of the APIs.34-40 
Property Allopurinol 6-Thioguanine Valproic acid 
Molecular formula C5H4N4O C5H4N5S C8H16O2 
Molar mass (g.mol
-1
) 136.112 167.193 144.211 
Aqueous solubility (mg.cm
-3
) 0.480 – 0.569  (25 
o
C) < 1  (22.5 
o








C) 350 > 360 – 
 
1.5.1) Allopurinol 
Allopurinol (systematic name 1H-pyrazolo[3,4-d]pyrimidin-4-ol)37 is classed as a xanthine oxidase 
inhibitor and it is used for the prevention of gout attacks, the treatment of kidney stones and the 
excessive production of uric acid.41 It is administered orally twice per day in the form of a pill and it 
is used to treat the above mentioned conditions by decreasing the levels of uric acid production in 
the human body.41 The mechanism of action of allopurinol operates by inhibiting the activity of the 
enzyme xanthine oxidase, which produces uric acid through the oxidation of the oxypurines, 
hypoxanthine and xanthine. Consequently, serum and urinary uric acid levels can be controlled in 
the body.34,42 
The literature values for the aqueous solubility of allopurinol are 0.48 mg.cm-3 at 25 oC,43 and 0.569 
mg.cm-3 at 25 oC,40 and 80 – 90 % of the drug is absorbed in the gastrointestinal tract.34 Therefore, 
the major shortcoming of this drug is its aqueous solubility. As a result, an improved aqueous 
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solubility would be of pharmaceutical interest, as it could potentially reduce the cost of the drug, 
since less of the active ingredient would be required.  
1.5.2) 6-Thioguanine 
The drug 6-thioguanine (systematic name 2-amino-6-mercaptopurine)38 is currently used to treat 
acute myelogenous leukaemia and it is administered orally; however, the dosage depends on the 
weight of the patient and on whether this medication is part of a combination therapy. For 
example, the dosage for adults is 2 mg.kg-1 per day for single agent therapy, and if no improvement 
is observed after four weeks, then the dosage may be increased cautiously to 3 mg.kg-1 per day.44  
6-Thioguanine is categorised as an antimetabolite,44 and therefore it would be more feasible to gain 
an overall understanding of the background with regard to the mode of action of an antimetabolite, 
in order to contextualise the mechanism of action for this drug. Antimetabolites contain either 
purine- or pyrimidine-based functionalities (in this case 6-thioguanine contains a purine functional 
group) and they have similar structures to the naturally occurring enzyme molecules used in DNA 
reproduction. As a result, the antimetabolites are ‘disguised’ as the naturally occurring enzyme 
molecules and diffuse into the cell and are thus transformed into analogues of cellular nucleotides. 
Consequently, they then prevent any of the naturally occurring enzymes from being incorporated 
into the cell during the S phase of the cell’s life cycle, which would be critical for DNA synthesis and 
replication of the cell.45-46  
In the context of 6-thioguanine, it is metabolised via the enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HGPRTase), and converted to the corresponding ribosenucleoside 6-
thioguanine monophosphate (6-TGMP).47-48 High concentrations of 6-TGMP accumulate 
(approximately 0.1 mM),47 even after therapeutic doses, which prevents many natural enzymes 
from being involved in the purine-based biosynthesis of the cell. Furthermore, 6-TGMP is converted 
into 6-thioguanine diphosphate (6-TGDP) and 6-thioguanine triphosphate (6-TGTP) via the enzyme 
phosphorylation. The three derivatised ribosenucleosides, 6-TGMP, 6-TGDP, 6-TGTP (collectively 
named 6-thioguanine nucleotides (6-TGN)) are all cytotoxic. This toxicity occurs via the 
incorporation of the 6-TGNs into the cell during its S-phase, which thus prevents the growth and 
division of the cell.47-48   
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6-Thioguanine is classed as ‘insoluble’ since less than 1.0 mg dissolves in 1 cm3 of water at 22.5 °C.38 
Consequently, an improved aqueous solubility would be of interest and this could also enhance the 
bioavailability of the drug. 
1.5.3) Valproic acid  
The drug, valproic acid (systematic name, 2-propylpentanoic acid),39 is currently used as an 
anticonvulsant, primarily to treat epilepsy and bipolar affective disorder.36,49 The drug is 
administered orally in the form of a gelatine tablet, in a liquid formulation, or as a powder.36 The 
mechanism of action as a therapeutic anticonvulsant is not well understood and consequently 
several theoretical explanations for this exist.36,49-50 Valproic acid dissociates into the ion, valproate, 
in the gastrointestinal tract. One theory suggested that the valproate ion causes an increase in the 
concentration of gamma-aminobutyric acid (GABA) in the brain.36 The valproate ion prevents 
enzymes from catabolising GABA and therefore an increased concentration of GABA is observed. 
The function of GABA is to inhibit neurotransmission and thus an increase in concentration will 
amplify this effect.36 A second theory for the mechanism of action proposed that valproic acid can 
block the voltage sensitive sodium channels and thereby reduce repetitive neuronal firing.36,51 
Valproic acid is also currently under investigation for other pharmaceutical therapies, as it has also 
displayed various anti-cancer and anti-HIV activities.36,52 In this case results have indicated that 
valproic acid appears to inhibit the in vitro activity of the enzyme histone deacetylase 1 (HDAC1) by 
binding to its catalytic centre.36,49,52 According to Göttlicher et al.,52 animal experiments have 
displayed reduced growth in cancerous tumours following treatment with valproic acid.52 In 
addition, HIV requires the activity of HDAC1 in order to remain in infected cells. The results from a 
study performed in 2005 indicated that the combination of valproic acid with highly active 
antiretroviral therapy can result in the HIV infection being reduced by 75 % in the patient.36 
Another study conducted in 2008 also provided evidence for the treatment of HIV-1 with valproic 
acid as a HDAC1 inhibitor.53 
Sodium valproate is an alternative, derivatised form of valproic acid that is currently available 
commercially. It has a high aqueous solubility of 2.0 x 103 mg.cm-3 at 20 oC,54 as opposed to pure 
valproic acid which is quoted as having a solubility “less than 1 mg.cm-3 at 22.2 oC”,39 and 1.3 
mg.cm-3 (temperature not specified)36,39. In addition, a study reported that sodium valproate 
slightly lowered the number of gastrointestinal side effects;55 however, despite this advantage 
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there was a significant amount of controversy around the financial cost of sodium valproate.55-56  
According to Schwartz, et al. it is approximately 120 times the cost of valproic acid at $1162.80 per 
patient per year,55 and these authors also maintain that this high cost does not warrant the use of 
sodium valproate as a replacement for the acid form, despite the fewer reported side effects.55-56  
As a result, further supramolecular derivatisation is warranted for valproic acid, which could render 
improved solubility, lower costs and less frequent pre-absorption side effects. Therefore, co-
crystallization and CD inclusion complexation of this drug were considered worthy of investigation 
by the author of this dissertation. 
1.6) Specific objectives 
Thus, the objectives of this project were to synthesize co-crystals with each individual drug (namely 
allopurinol, 6-thioguanine and valproic acid) and a series of corresponding co-formers. In addition, 
the synthesis of CD inclusion complexes with all three APIs was to be attempted with the native CDs 
(namely α-CD, β-CD and -CD) and the methylated CDs (namely DMB, TMB and TMA). The intended 
syntheses anticipated the growth of single crystals of the desired products for further analytical 
studies. In addition, such products would be assessed for their drug solubility enhancement value. 
Lastly, phase solubility studies with -CD, RAMEB and HPBCD were also intended to be performed 
with allopurinol and 6-thioguanine in order to assess the possible solubility enhancement of the 
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2.1) Materials           
2.1.1) Active Pharmaceutical Ingredients (APIs) 
The APIs, which consisted of allopurinol (C5H4N4O), 6-thioguanine (C5H5N5S) and valproic acid 
(C8H16O2) were purchased from Sigma-Aldrich Chemie Gmbh (Steinheim, Germany). 
2.1.2) Cyclodextrins (CDs) 
-Cyclodextrin (-CD; C42H70O35), hexakis(2,3,6-tri-O-methyl)--cyclodextrin (TMA; C54H96O30), 
heptakis(2,6-di-O-methyl)--cyclodextrin (DMB; C56H96O35), heptakis(2,3,6-tri-O-methyl)--
cyclodextrin (TMB; C63H112O35), randomly methylated -cyclodextrin (RAMEB; (C42H70-nO35)(CH3)n, 
where n = 12) and hydroxypropyl -cyclodextrin (HPBCD; (C42H70-nO35)(C3H7O)n, where  n = 4.5) 
were purchased from Cyclolab (Budapest, Hungary). -Cyclodextrin (-CD; C36H60O30) and -
cyclodextrin (-CD; C48H80O40) were purchased from Wacker, Biosolutions (Halle, Germany).   
2.1.3) Co-formers 
The co-formers used in co-crystallization experiments were purchased from Sigma-Aldrich Chemie 
Gmbh (Steinheim, Germany) and Acros Organics (New Jersey, USA). The co-formers are listed in the 
Appendix under section 1, Table 1.1, p. 2.    
2.2) Co-crystal screening 
2.2.1) Virtual co-crystal screening 
The first phase of the co-crystal screening included a qualitative computer-based investigation. This 
investigation firstly involved observing the type of supramolecular synthons that occurred between 
the API molecules in their own crystals. Secondly, it assessed different molecular fragments of the 
APIs for their potential to form stable, hydrogen bonded supramolecular ring synthons with 
carboxylic acid and amide functional groups. The frequency for the formation of these various 
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hydrogen bonded ring synthons was noted and thus indicated which co-formers to select 
preferentially. This analysis was performed with the Cambridge Structural Database (CSD) in 
Conquest,1 where the structures were imported into X-SEED,2 and Mercury.3 
2.2.2) Dry co-grinding    
The second phase of the co-crystal screening involved dry co-grinding experiments. This process 
involved adding the API and one co-former into a mortar and grinding the mixture with a pestle. 
Equimolar quantities of the API and co-former were mixed and the time allocated to perform these 
experiments was 15 minutes, unless stated otherwise. These experiments were performed in order 
to assess whether a new crystalline phase could be synthesized after dry co-grinding the API with 
the co-former.  
2.2.3) Liquid-assisted grinding (LAG) 
This process involved the same experimental set-up and method as the dry co-grinding experiment, 
except that small measured volumes of organic solvent were added into the mortar during the co-
grinding process.  
2.2.4) Co-precipitation 
The third phase of the co-crystal screening involved co-precipitation experiments. This process 
incorporated the separate dissolution of the API and the co-former in an equimolar ratio (unless 
stated otherwise) with a common solvent, while stirring at a constant temperature. The 
temperature used to dissolve both components was dependent on the organic solvent used. Once 
both the API and co-former were dissolved, each solution was filtered into a common vial with a 
nylon 0.45 μm microfilter. The resulting solution was subjected to varying conditions to allow co-
precipitation to occur, as described below.  
Slow cooling: This method of co-precipitation allowed the saturated solution, which contained the 
API and co-former, to cool slowly without any evaporation taking place. The individual solutions of 
the API and co-former were filtered into a common vial. The vial was subsequently sealed and 
placed in a Dewar flask, which had been filled with water and pre-heated to the temperature at 
which the solutions were dissolved.  
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Slow evaporation: This procedure involved allowing the solvent to evaporate slowly in order to 
permit the dissolved product to precipitate. Therefore, once the individual solutions of the API and 
co-former were filtered into a common vial, the vial was sealed with parafilm, subsequently 
punctured with a few pin-sized holes and left on the laboratory bench in order to allow evaporation 
to take place over a controlled, extended period.  
2.3) Cyclodextrin inclusion   
2.3.1) Kneading 
This technique involved mixing the API and CD in a mortar and kneading them with a small amount 
of Milli-Q water4 for 30 – 40 minutes. Kneading experiments were performed with both the native 
CDs and methylated CDs. However, with the experiments that involved the latter class of host 
compounds, only a miniscule measured volume of water was added at five minute intervals, owing 
to their high aqueous solubility. 
2.3.2) Co-precipitation   
Co-precipitation experiments with the native and methylated CDs involved different methods of 
preparation. As a result, each will be described separately.  
Native cyclodextrins (CDs): The co-precipitation experiments that involved the native CDs, namely 
-CD, -CD and -CD, were performed by dissolving the CD in water at 70 oC while stirring at a 
continuous rate. The volume of water was dependent on the type of CD used and the respective 
mass, and thus the volume is specifically stated for each experiment.  
In the case where the API was a solid (for example, allopurinol and 6-thioguanine), the API in 
powder form was added very slowly to the aqueous CD solution. In contrast, where the API was a 
liquid (for example, valproic acid), the API was added dropwise to the aqueous CD solution. The 
resultant solution was left to stir for a period varying between 3 and 6 hours, unless stated 
otherwise. Thereafter, the solution was filtered using a nylon 0.45 μm microfilter and complex 
crystals were allowed to co-precipitate either through slow cooling or slow evaporation.  
Methylated cyclodextrins (CDs): These methylated CDs, namely TMA, DMB and TMB, were 
dissolved in water at room temperature while stirring at a constant rate. Once again, the volume of 
water was dependent on the type of CD used and its respective mass, and thus the volume is 
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specifically stated for each experiment. Miniscule amounts of the API were added slowly to the 
solution of the methylated CD. Subsequently, temperature cycling was employed which entailed 
repetitive cycles of heating the stirring solution to 70 oC and then suddenly cooling it to 4 oC. The 
aim of this process was to promote inclusion complexation of the API with the methylated CD. The 
solution was then filtered into a clean vial with a 0.45 μm nylon microfilter and the vial was then 
sealed and placed in the oven at 60 oC in order to allow complex crystallization to occur.  
2.4) Powder X-ray Diffraction (PXRD) 
Powder X-ray diffraction (PXRD) patterns were recorded for the co-ground, kneaded and co-
precipitated materials, as well as for their respective reactants. This was performed in order to 
assess whether unique crystalline products had formed and was achieved by comparing the PXRD 
pattern of the co-ground, kneaded or co-precipitated material with the PXRD pattern of each 
individual reacting component. This analysis was performed at room temperature using a D8 
Advance diffractometer using CuK1 radiation (λ = 1.5406 Å) with an X-ray generator set at 30 kV 
and 40 mA. The sample preparation involved grinding the material into a very fine crystalline 
powder in order to minimise the effect of preferred orientation. This sample was subsequently 
placed onto a silicon zero background sample holder. The scanning range was 4o – 40o 2 with a 
step size of 0.0164o and a primary beam path slit of 0.6 mm. 
2.5) Single Crystal X-ray Diffraction (SCXRD) analysis  
Crystals of adequate quality, obtained from co-precipitation experiments, were analysed using a 
single crystal four-circle X-ray diffractometer in order to determine the structural properties of the 
crystal. The crystals were removed from the mother liquor and immediately coated in Paratone oil5 
to prevent the loss of solvent molecules that may have been included in the crystal structure. 
Where necessary, the crystals were cut to an appropriate size and subsequently placed on the 
diffractometer for analysis. Initially, a unit cell measurement was performed at room temperature. 
This technique established the unit cell parameters of the single crystal in question and 
consequently these were compared with the parameters of all the crystal structures reported in the 
CSD.1 This confirmed whether the single crystal under analysis was new, in which case a full data-
collection was performed in order to determine the crystal structure. The instruments that were 
used to perform unit cell determinations were the Bruker KAPPA APEX II DUO single crystal X-ray 
diffractometer and the ENRAF Nonius FR 590 KappaCCD diffractometer. However, full data-
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collections were only performed on the Bruker KAPPA APEX II DUO instrument, owing to its 
superior detector sensitivity. Subsequently, the collected data sets were read into the program 
XPREP6 which determined the respective space groups, and the structures were solved with the 
direct methods program SHELXS-97,7 (or SHELXD-97,7 for more complex structures). Thereafter the 
structures were refined by full-matrix least-squares techniques with SHELXL-97,7 implemented in 
the X-SEED2 interface.  
A few of the CD inclusion complex structures were solved by the method of isomorphous 
replacement. This process involved identifying a CD inclusion complex from the CSD with very 
similar unit cell parameters and a common space group. The atomic co-ordinates of the selected 
complex were placed in the .ins file of the new CD inclusion complex. Subsequently, all the guest 
atoms, the water molecules, as well as the O6 atoms on the CD molecule (that can freely rotate), 
were deleted. Thus, only the rigid skeleton of the CD molecule remained as the trial model and it 
was thereafter refined isotropically and the remaining atoms of the new CD inclusion complex 
could be placed from subsequent difference Fourier maps. Once the structure of the host molecule 
was settled, the difference electron density () peaks of the guest molecule were assigned, and 
refined initially isotropically and thereafter anisotropically.  
Oxygen atoms of the water molecules in the CD inclusion complexes were identified by measuring 
the distances between the oxygen atoms on the CD molecule and unassigned  peaks and gauging 
whether they were in the range expected for OO distances associated with O-HO hydrogen 
bonds. The  peaks of height 2.0 e Å-3 or greater, were then assigned as water O atoms with a 
full site-occupancy, as they displayed acceptable isotropic thermal parameters (Uiso) after 
refinement. However, candidate oxygen atoms with  less than 2.0 e Å-3 were pre-set to have 
constrained Uiso values equal to the average of those for the fully-occupied water oxygen atoms, 
and their individual site-occupancies were treated as variables. Furthermore, several water oxygen 
atoms were disordered over two positions, such that the distance between the disorder 
components was less than 2.5 Å. In the final cycles of refinement, the fully-occupied water oxygen 
atoms were treated anisotropically, while their disordered counterparts were refined isotropically. 
 
2.6) 1H Nuclear Magnetic Resonance (1H NMR) Spectroscopy 
Proton NMR experiments were conducted in order to quantify the host-guest stoichiometric ratios 
of the CD inclusion complexes. The samples of pure inclusion complexes were dissolved in 
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deuterated dimethyl sulfoxide (DMSO-d6) at 20 C. These experiments were performed on the 
Bruker Ultrashield 400 Plus spectrometer and the data were analysed using the program 1D NMR 
processor.8 
2.7) Fourier Transform Infrared (FT-IR) Spectroscopy  
FT-IR experiments were conducted in order to observe specific frequency shifts for CD inclusion 
complexes. This was achieved by analysing the natural vibrational frequencies of the bonds in the 
compounds. This technique was employed to compare the FT-IR spectra of the starting materials 
with the FT-IR spectrum of the CD inclusion complex. The samples were pressed between sodium 
chloride windows and the spectra were thereafter recorded on the PerkinElmer Spectrum Two 
instrument.  
2.8) Thermal analysis 
Three different thermal techniques were employed in order to analyse the changes in the physical 
properties of the compounds as a function of temperature. The methods used were hot stage 
microscopy (HSM), thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC).  
2.8.1) Hot Stage Microscopy (HSM) 
HSM was performed in order to correlate the thermal events from the TGA and DSC analyses with a 
visual representation of these thermal events. The experiment involved placing the crystals on a 
glass slide and coating them with silicone oil. The analysis was viewed through a Nikon SMZ-10 
stereoscopic microscope fitted with a Linkam THM600 hot stage and Linkam TP92 temperature 
control unit. The images at various temperatures were captured by a real-time Sony Digital Hyper 
HAD colour video. The captured images were viewed with the Soft Imaging Program AnalySIS.9 A 
temperature range of 23 oC – 400 oC was used to analyse the crystals with a standard heating rate 
of 10 K.min-1, unless stated otherwise.   
2.8.2) Thermal Gravimetric Analysis (TGA) 
The TGA was used to measure the percentage weight loss as a function of temperature. The data 
obtained supplied information with regard to the number of water molecules present in the CD 
inclusion complexes. In addition, the thermal stability of the inclusion complex could be 
established. The samples prepared for the TGA experiment had a mass of between 0.9 mg and 3.5 
mg and were pre-dried on filter paper prior to the experiment. The analysis took place in an open 
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aluminium pan under dry nitrogen gas with a constant flow rate of 60 cm3.min-1. The samples were 
heated at a constant rate of 10 K.min-1 to a maximum temperature of 400 oC. This experiment was 
performed on the TA-Q500, with Universal Analysis 2000 software.10  
2.8.3) Differential Scanning Calorimetry (DSC) 
The DSC technique was used to analyse the energy difference between an empty reference pan and 
a pan containing the sample. The DSC detects the changes in energy between the two pans while 
they are heated at a constant rate. These energy changes are represented as either endothermic or 
exothermic deviations from the baseline. The endothermic and exothermic events can be 
associated with thermal events, for example, polymorphic transitions, dehydration, 
recrystallization, melting and decomposition.  
The samples prepared for the DSC experiment were pre-dried on filter paper and had a mass that 
ranged between 1.0 mg and 3.0 mg and were subsequently placed in a crimped aluminium pan that 
was vented. The analysis took place under dry nitrogen gas with a constant flow rate of                   
60 cm3.min-1. The samples were heated at a constant rate of 10 K.min-1 to a maximum temperature 
of 250 oC, unless stated otherwise. These experiments were performed on two different machines. 
The polymorph of isonicotinamide was analysed on the DSC-Q200 apparatus  (TA Instruments) with 
Universal Analysis 2000 software,10 while the CD inclusion complexes with valproic acid were 
analysed on the DSC XP-10 instrument (THASS: Thermal Analysis & Surface Solutions GmbH, 
Friedberg, Germany) with the software package Differential Scanning Calorimeter, version 3.3.0.7 
(D).11 
Owing to the sensitivity of the DSC machines, it was not possible to take any samples to 
decomposition, and thus no comparison with respect to decompositions recorded on the TGA or 
HSM instruments could be made. 
2.9) Solubility analysis 
2.9.1) Phase solubility analysis with allopurinol and 6-thioguanine 
The CDs that were selected for the phase solubility study were -CD, HPBCD and RAMEB. A 
predetermined mass of each CD was dissolved in water in a separate volumetric flask and stirred 
for 72 hours. Thereafter, ten solutions of varying CD concentrations ranging from 10 % - 100 %, 
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were prepared for each chosen CD. An excess amount of API was added to each solution and stirred 
vigorously for 72 hours at 25 oC, after which the solutions were subsequently filtered with 0.45 μm 
nylon microfilters. Thereafter, 0.1 cm3 of each solution was diluted to 5 cm3 (in order to be within 
the linear range of the UV-vis instrument) and the respective UV-vis absorbance readings were 
recorded. Three absorbance readings were recorded for each solution and averaged. These entire 
experiments were performed in duplicate and the results were averaged as they correlated within 
an acceptable range. The UV-vis absorbance readings were measured on a UV Cary 60 
spectrophotometer (Agilent Technologies, Santa Clara, California, USA). 
2.9.2) Solubility determination via mass increments for the native CD inclusion 
complexes with valproic acid   
Solubility investigations were conducted using a method of adding pre-weighed incremental 
amounts of valproic acid CD inclusion complexes (namely -CD·VAL, -CD·VAL and -CD·VAL) into 
3.0 cm3 of water. The resultant suspension was stirred at a constant rate for 72 hours at 25 oC. An 
estimation of the aqueous solubility was established visually, its value being recorded as the range 
between those measured for solutions containing the penultimate and the final masses of CD 
inclusion complex added, since the final amount resulted in saturation. The aim of this method was 
not to achieve high accuracy, but rather to serve as a guideline for a reasonable estimation of an 
approximate solubility enhancement factor. Unfortunately, a more accurate determination was not 
possible with UV-vis spectrophotometric analysis, because the λmax value of valproic acid (< 200 nm) 
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Chapter 3  
Supramolecular Derivatisation of Allopurinol 
3.1) Introduction 
 
Various methods of supramolecular derivatisation have been performed on allopurinol.1-2 
According to one article, six different products were synthesized, which include solid dispersions 
(co-evaporates) of allopurinol with urea, with sodium salicylate and with -CD, as well as the co-
crystallized products of allopurinol with urea, sodium salicylate and -CD.1 The co-evaporates were 
prepared in 1:1 and 1:2 stoichiometric ratios of the drug to the host/carrier. However, the 
crystallization process involved dissolving allopurinol in dimethyl sulfoxide (DMSO) and adding a 5 
% w/v aqueous solution of urea and sodium salicylate respectively, and a 1.9 % w/v aqueous 
solution of -CD.1 No crystal structures were obtained for these derivatised products, as their 
particle sizes ranged between 60 and 120 μm after filtering and drying under vacuum. 
Nevertheless, the results indicated varying levels of increased drug release rate relative to 
untreated allopurinol, with the exception of the crystallized product of allopurinol with 1.8 % w/v -
CD. This product resulted in a slower release rate of the drug in comparison to its native form.1  
Furthermore, -CD inclusion complexes were synthesized with allopurinol in its neutral and anionic 
form in equimolar ratios.2 These complexes were analysed through NMR diffusion experiments 
where the resulting structures were theoretically calculated using a computational model 
(Parameterized Model number 3). The conclusion was that the anionic form of allopurinol had a 
greater attraction to the cavity of the -CD molecule than the neutral form.2   
With regard to co-crystallization, the authors of two studies have claimed to have produced co-
crystals with allopurinol;3-4 however, the published research did not provide convincing evidence 
for the isolation of allopurinol co-crystals. With regard to the first study, published in 2014,3 the 
authors claimed that co-crystals of allopurinol and benzoic acid, as well as allopurinol and D-tartaric 
acid, had been synthesised in 1:1 stoichiometric ratios.3 In addition, the authors indicated that an 
improved aqueous solubility of allopurinol was achieved via these products. However, the only 
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evidence that the authors presented for the formation of co-crystals was that the powder X-ray 
diffraction (PXRD) pattern of the product material was different from the sum of the PXRD patterns 
of the starting materials in each case.3 However, the difference in PXRD patterns can only indicate 
that one has obtained different material from that of the physical mixture of the starting materials, 
and therefore the product could instead be polymorphs of either starting material, or a salt, or a co-
crystal. In other words, a PXRD analysis is not solely definitive to claim the synthesis of co-crystals. 
To characterise both products, further experimentation, such as a 1H NMR study, would need to be 
performed in order to determine the stoichiometry of a product synthesised via co-precipitation. In 
addition, if a single crystal of adequate quality were to be grown, then a single crystal X-ray 
diffraction analysis could be performed in order to determine the structure of the product. This 
would indicate the bonding connectivity of the molecules and it would be possible to determine 
whether a salt or co-crystal had formed by measuring the relevant bond lengths.5 Therefore, it is 
evident that the results of this research are inconclusive. 
The authors of a second study, which is from a book published in 2012, also claimed to have 
synthesised co-crystals of allopurinol.4 Unfortunately, due to a lack of access it was not possible to 
obtain the full text of this document. As a result, the co-formers of the putative co-crystals remain 
unknown. However, the title of the publication stated that the only method of preliminary 
characterisation was PXRD. The shortcoming of using this technique in isolation has already been 
alluded to above.  
As a result, there appeared to be a significant amount of interest in forming supramolecular 
derivatives with allopurinol, and therefore it would be worth investigating this field. The author of 
this Master’s dissertation will attempt to re-synthesize the claimed co-crystals of allopurinol3 (in 
order to attempt to characterise them fully), as well as to synthesize additional co-crystals of 
allopurinol. CD-inclusion complexation will also be attempted with the native CDs, which include -
CD, -CD and -CD. However, a different methodology from that provided in the literature1 will be 
employed, the rationale being the attempted isolation of single crystals for further analysis. 
Furthermore, DMSO, used in the previous study,1 will be avoided owing to the fact that it has a 
large affinity for CD cavities and it is often used to displace guest molecules from inclusion 
complexes. In addition, preparation of CD inclusion complexes will also be attempted with the 
derivatised CDs, namely, the methylated CDs, which include DMB, TMB and TMA. Lastly, the host 
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compounds -CD, HPBCD and RAMEB will also be investigated during phase solubility experiments 
for their ability to enhance the solubility of allopurinol in aqueous solution.  
3.2) Co-crystal screening 
3.2.1) Virtual co-crystal screening 
Initially, a computational investigation of potential co-crystal formation between allopurinol and 
the series of co-formers available in the laboratory, was launched.  These co-formers are listed in 
Table 1.1 in the Appendix under section 1, p. 2. There are three factors that are generally 
considered during the co-former selection process; these are the possible supramolecular synthons 
(which involve hydrogen bonding) that might occur between the API and the co-former, the ΔpKa 
value between the two components, and lastly the solubility of the co-former. The investigation 
primarily involved analysing the hydrogen bonding supramolecular synthons that could form with 
allopurinol. This was the fundamental criterion, because in the absence of hydrogen bonding 
between allopurinol and the co-former, the ΔpKa value and the solubility of the co-formers become 
null and void. The ΔpKa value would only indicate the potential to form either a co-crystal or a salt,
6 
while the solubility of the co-former would generally only influence the solubility of the drug within 
the co-crystal. Therefore, it was imperative first to establish the potential formation of hydrogen 
bonding between allopurinol and various co-formers. All the co-formers in the laboratory possessed 
a significantly higher aqueous solubility than allopurinol and thus had the potential to be a solubility 
enhancer.7-8 Therefore, the co-formers that indicated the highest potential to form supramolecular 
synthons were most desirable at this stage.  
As a result, an investigation took place with the use of the Cambridge Crystallographic Database 
(CSD)9 in order to identify likely supramolecular synthons that could form with allopurinol. Initially, 
the molecular structure was obtained from the CSD and viewed in X-SEED10 in order to identify the 
supramolecular synthons that form within the crystal packing of pure allopurinol. A complex dual 
ring system was evident, where one of the rings involved two allopurinol molecules, and the other 
ring involved three allopurinol molecules. The 8-membered dimeric ring system that involved only 
N-HN hydrogen bonds (Figure 3.1) was described as 𝑅2
2(8) (as designated with graph-set 
notation11). These H-bonds are inversion-related with a unique NN distance of 2.88 Å and N-HN 
angle of 164. The 10-membered trimeric ring system shares one of the hydrogen bonds with the 
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dimeric ring system to produce a 𝑅3
3(10) arrangement. This ring system involves two N-H···N 
hydrogen bonds, as well as a C-HO hydrogen bond. The NN distance of 2.87 Å and the N-HN 
angle of 163o confirm that this is a classical hydrogen bond. Furthermore, the C-HO bond has a 
CO distance of 3.21 Å (slightly shorter than the sum of the van der Waals radii of C and O, viz. 3.22 












A comprehensive study was conducted in the CSD and viewed in Mercury,12 where molecular 
fragments of the allopurinol molecule were assessed for their potential to form stable, hydrogen 
bonded, ring synthons with other molecules. There are nine tautomers of allopurinol, which are 
displayed in Figure 3.2, and therefore the selected molecular fragments of allopurinol had to 
account for this tautomerism. Furthermore, Figure 3.3 identifies the potential hydrogen bonding 
sites of the allopurinol molecule, which are circled in red.  
Figure 3.1: The hydrogen-bonded motif of allopurinol which displays the 


























Figure 3.2: The tautomers of allopurinol. 
 
 
Figure 3.3: The potential hydrogen bonding sites (circled in red). 
 
Consequently, the selected molecular fragments of allopurinol, which accounted for all the possible 
tautomers, are displayed in Figure 3.4. With reference to these molecular fragments, the atoms 
denoted as X accounted for any atom, and the respective X-C or X-N bonds were assigned as ‘any’ 
(i.e. single, double, aromatic). In addition, the bonds in the various N-C-N molecular fragments (3a – 




Figure 3.4: The various molecular fragments of allopurinol, which accounted for the possible tautomers. Atom X represents any 
atom, while the bond orders in C-X (1a-1e), N-X (2a-2c) and C-N (3a-3c) were unrestricted.   
 
The available co-formers that could potentially form ring synthons were those that contained 
carboxylic acid and amide functional groups. Consequently, hydrogen bonds were drawn to form a 
ring synthon between the carboxylic acid functional group of a co-former, and the nitrogen and 
oxygen atoms (or just the nitrogen atoms) of each allopurinol molecular fragment. This process was 
repeated for each allopurinol molecular fragment with the amide functional group in place of the 
carboxylic functional group. In addition, the hydrogen bond lengths were pre-set in the CSD to have 
a ON, OO or NN length that ranged between 2.5 and 3.2 Å.  
This method allowed the relevant functionalities of the allopurinol molecule to be assessed for the 
frequency of forming ring synthons with carboxylic acid and amide functional groups from potential 
1a 1b 1c 
1d 1e 
2a 2b 2c 
3a 3b 3c 
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co-formers in the laboratory. Any results that did not display a realistic bonding scenario, 
particularly within the molecular fragments of allopurinol where the bonds were denoted as ‘any’, 
were not retained.  
The results indicated that the amide functional group had a much higher frequency for forming ring 
synthons than the carboxylic acid functional group. This was particularly the case with the 
tautomeric fragment 1c (Figure 3.5), which accounted for 96 % of the amide ring synthon 
frequency. The remaining tautomeric fragments that engaged in ring synthons with the amide 
functional group were 1d, 1e, 3b and 3c (Figure 3.4). In addition, the tautomeric fragments 1c and 
3b were involved in a fair frequency of hydrogen bonded ring synthons with the carboxylic acid 
group and several were also observed to occur with the tautomeric fragment 2b (Figure 3.4).  
 
Figure 3.5: The most frequently occurring hydrogen bonded ring synthons, which involved the molecular fragment 1c (at the 
bottom) and either a primary or secondary amine (at the top). The atom X represents any atom and R1 is any organic moiety.  
 
It is important to note that this investigation did not take into account the frequency of formation 
of synthons other than those involving rings. As mentioned previously, the purpose of this 
investigation was to establish the frequency for the formation of stable ring synthons between a 
potential co-former and the allopurinol molecule. As a result, the co-formers that were selected 
contained the functional groups from either amides or carboxylic acids. Isonicotinamide and 
nicotinamide were selected not only because they are amides, but also because they are known to 
be more successful in forming co-crystals. D-tartaric acid and benzoic acid were also selected in 
order to confirm and extend the analysis by Alatas et al.,3 who claimed that it was possible to form 
co-crystals with allopurinol and these two co-formers separately. In addition, piperazine was also 
included, since it has the potential to form synthons of type C (‘chain’ synthon). As a result, the list 
of selected co-formers is displayed in Table 3.1. 
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3.2.2) Co-grinding, co-precipitation and recrystallization screening experiments   
The majority of the experimental co-crystal screening attempts did not produce successful results 
that could be analysed further. However, a new polymorph of one of the co-formers, 
isonicotinamide, was formed serendipitously during attempted co-crystallization between this co-
former and allopurinol. Owing to its novelty and the widespread use of this co-former in co-crystal 
research, a complete physicochemical analysis of the new crystal form was undertaken and is 
documented later in this chapter under section 3.2.3, pp. 36 – 74. A comprehensive analysis and 
detailed discussion of the remaining results, that either indicated preliminary degrees of success or 
those that were unsuccessful, have been placed in the Appendix under section 2, pp. 3 – 14. These 
partially successful results only included successful dry co-grinding experiments of allopurinol and 
isonicotinamide, allopurinol and piperazine, as well as allopurinol and maleic acid. An example of 
one of these successful dry co-grinding results is evident in Figure 3.6 which shows the PXRD 
patterns of allopurinol, piperazine and the PXRD pattern of the new crystalline phase in green 
(Figure 3.6). 
Number Selected co-former 
1 Benzamide 
2 Benzoic acid 
3 Fumaric acid 
4 Glutaric acid 
5 Isonicotinamide 









Figure 3.6: PXRD patterns of allopurinol, piperazine, and the product obtained by dry co-grinding the two components in a 1:3 
molar ratio for 15 minutes. 
 
The various co-grinding and co-precipitation experiments that were performed with the eleven 
selected co-formers included the following. With regard to the co-grinding experiments with 
allopurinol, these included dry co-grinding and LAG experiments with the respective solvents 
ethanol (EtOH), ethyl acetate, hexane, DMSO and chloroform. Furthermore, with regard to the co-
precipitation experiments, these were performed with the solvents, namely chloroform (via slow 
evaporation in equimolar ratios), and DMSO (via slow evaporation, as well as via slow cooling in 
equimolar ratios), with all eleven co-formers. Another set of experiments was also performed with 
DMSO, which incorporated the three co-formers that indicated successful dry co-grinding results 
(namely isonicotinamide, piperazine and maleic acid) in an assortment of different stoichiometric 
ratios which were prepared for slow evaporation. Lastly, recrystallization experiments were 
attempted, where a variety of solvents was used, with the successful dry co-ground products. None 
of these experiments produced successful results, other than those that have already been 
mentioned above. Figure 3.7 illustrates an example of a PXRD pattern with allopurinol and D-
tartaric acid, which displays a physical mixture of the two components, instead of a new crystalline 
phase.  
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Figure 3.7: PXRD patterns of allopurinol, D-tartaric acid, and the product of dry co-grinding these components in a 1:1 molar ratio 
for 15 minutes. 
It is of interest to note that all the co-grinding experiments that were performed with allopurinol 
and D-tartaric acid, and allopurinol and benzoic acid, were unsuccessful, despite the fact that Alatas 
et al.3 claimed to have synthesized new materials via these methods. There are two possible 
explanations for this occurrence; either product formation is dependent on the grinding pressure 
applied,13 or the authors were mistaken with regard to their PXRD interpretation.  
In conclusion, the co-grinding experiments with allopurinol and isonicotinamide, allopurinol and 
piperazine, as well as allopurinol and maleic acid, did produce new material; however, it was not 
possible to characterise this material any further. The reported methodology for generating the 
claimed co-crystals by Alatas et al.,3 of allopurinol and benzoic acid, as well as allopurinol and D-
tartaric acid, was repeated, but it was not possible to form the product that they had claimed. 
Instead a physical mixture of the two components resulted. The co-precipitation results did not 
produce co-crystals, although a new polymorph of isonicotinamide was discovered (this is 
described in detail in the subsequent section). The virtual co-crystal screening analysis indicated 
that possible stable ring synthons could occur between the allopurinol molecule and a co-former, 
which could conceivably result in the formation of either a co-crystal or a salt. However, physical 
and chemical properties, such as the high melting point and low solubility of the API, could have 
prevented the formation of these desired multi-component systems.  
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3.2.3) A new polymorph of isonicotinamide 
Another polymorph of isonicotinamide was discovered serendipitously during an attempt to co-
crystallize allopurinol with isonicotinamidea in chloroform. It was initially identified from a unit cell 
analysis, where its cell dimensions were unique in comparison to the other five known polymorphs 
of isonicotinamide. As a result, a full intensity data-collection was performed and the crystal 
structure was solved and confirmed to be a unique polymorph. This new crystal modification of 
isonicotinamide will be referred to as polymorph 6.   
Single crystal X-ray diffraction (SCXRD) analysis of polymorph 6  
This particular SCXRD analysis could not be performed with the conventional methods that utilise 
the automation of technology. This was due to the fact that the space group assignment required 
manual determination through the careful examination of the intensity-weighted reciprocal lattice 
and that a pseudo-centre of inversion exists in the asymmetric unit (ASU) of polymorph 6. As a 
result, this analysis indicated the importance of applying first principle methods, and the 
importance of not relying on the automation of technology in solving a crystal structure. 
Data-collection and space group determination 
The unit cell parameters did not match those of either allopurinol or any known polymorphs of 
isonicotinamide and thus a full set of intensity data was collected. The original unit cell parameters 
were a = 7.9929(9) Å,   b = 9.888(1) Å, c = 15.162(2) Å,  =  =  = 90o, V = 1198.3(4) Å3. 
The space group of polymorph 6 was determined manually by inspecting the reciprocal lattice, 
since XPREP14 failed to determine a possible space group. Initially the crystal system was 
established to be orthorhombic, as the intensity-weighted reciprocal lattice displayed mmm 
symmetry. The following conditions limiting possible reflections were initially identified, as listed in 




                                                          
a
 The form of isonicotinamide that was used in this experiment was polymorph 1. The crystallographic data for all the 
polymorphs of isonicotinamide are defined in a table below.  
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Table 3.2: The conditions limiting possible reflections for the crystal of polymorph 6. 
Number Conditions limiting possible reflections Deduction 
1 hkl: none Primitive lattice 
2 0kl: k = 2n b-glide plane perpendicular to the a-axis 
3 h0l: l = 2n c-glide plane perpendicular to the b-axis 
4 hk0: none - 
5 h00: h = 2n  (apparent) Screw axis parallel to the a-axis 
6 0k0: k = 2n Redundant condition (from 2 above) 
7 00l: l = 2n Redundant condition (from 3 above) 
 
This specific combination of conditions limiting possible reflections did not define any particular 
space group.  However, very faint reflections with h = 2n + 1 were observed in the reciprocal lattice 
along the axial line h00 where the zero intensity positions for a screw axis were expected to be 
located. As a result, the condition for a screw axis to be present parallel to the a-axis became null 
and void. Removal of this false condition gave rise to two possible space groups, which were 
determined from the International Tables for Crystallography,15 namely Pbcm (No. 57, 
centrosymmetric) and Pbc21 (non-centric), where Pbc21 can be transformed into the standard 
setting, Pca21 (No. 29). Table 3.3 displays the final unit cell parameters of polymorph 6 after the 
transformation had been applied, along with the unit cell parameters of the other five known 
polymorphs of isonicotinamide. Selection of the correct space group is described below.  
The program XPREP could not determine either of these two possible space groups, because the 
‘condition’ that limited the possible reflections h00: h = 2n was false. The intensities of these very 
weak reflections fell below the I > 3σ(I) value for observed reflections, which is the program’s 
default value. As a result, XPREP could not register the presence of these reflections and thus was 
unable to assign a possible space group. In order to prove this assumption of program failure, the 
intensity values of a few of the very weak h00 reflections with h = 2n + 1 were artificially increased 
above the I > 3σ(I) threshold in the hkl file, and thereafter XPREP was able to assign the two space 





Table 3.3: Selected crystal data for polymorphs 1 – 6 of isonicotinamide.9, 16-18 













1 10.176(1) 5.7319(6) 10.034(1) 90 98.042(3) 90 579.5(1) P21/c 173 EHOWIH01 
2 15.735(3) 7.998(1) 9.885(3) 90 105.59(1) 90 1198.2(5) P21/c 173 EHOWIH02 
3 10.1603(7) 7.3231(5) 15.8720(6) 90 90.0 90 1180.95(1) Pbca 173 EHOWIH03 
4 11.0819(6) 7.9976(4) 9.9850(5) 90 94.048(1) 90 882.75(8) Pc 100 EHOWIH04 
5 5.192(1) 9.466(3) 12.259(3) 90 91.217(7) 90 602.4(3) P21/c 300 EHOWIH05 
6 9.888(1) 7.9929(9) 15.162(2) 90 90 90 1198.3(4) Pca21 173 – 
 
Structure solution and refinement  
The decision for the selection of the correct space group from the two possibilities (Pbcm and 
Pca21) further complicated this analysis. The combined figure of merit (CFOM) for the 
centrosymmetric space group Pbcm was 3.22, while the CFOM for the non-centrosymmetric space 
group Pca21 was 4.51. Thus, the space group with the lower CFOM was pre-selected by XPREP. 
However, attempted structure solution in Pbcm using direct methods failed. In order to understand 
the reason for this failure, one must take note of the fact that there are eight molecules in the unit 
cell (Z = 8). The centrosymmetric space group Pbcm has eight equivalent positions in the unit cell, 
while the non-centrosymmetric space group Pca21 has only four equivalent positions in the unit 
cell. As a result, the asymmetric unit (ASU) in the space group Pca21 would have two 
isonicotinamide molecules in the ASU. On attempting to solve the structure in Pca21 using SHELXS-
97,19 a solution was readily obtained, yielding two molecules in the ASU, as displayed in Figure 3.8. 
Close inspection of the relative orientations of these molecules revealed that they are related by a 
pseudo-inversion centre. The presence of this pseudo-inversion centre resulted in the  E2-1  value 
being 0.895, which is closer to the theoretical value for centrosymmetric structures, (0.968, as 
opposed to 0.736 for non-centrosymmetric structures). Following successful refinement of the 
structure in the space group Pca21, a check on the space group symmetry using the program 

















Figure 3.8: The asymmetric unit (ASU) comprises two independent isonicotinamide molecules labelled A and B. The numbering 
scheme of isonicotinamide is indicated below the ASU. 
 
After the structure solution was obtained, the non-hydrogen atoms were all designated and refined 
isotropically and thereafter anisotropically, once the isotropic thermal parameters (Uiso) had 
converged. The hydrogen atoms were first located in the difference Fourier map and subsequently 
placed in idealised positions in a riding model and refined isotropically with Uiso values 1.2 times 




















Table 3.4: The crystal data and refinement parameters for polymorph 6. 
Parameter Value 




Temperature (K) 173(2) 
Wavelength (Å) 0.71073 
Crystal system Orthorhombic 
Space group Pca21 






















F (000) 512 
Crystal size (mm) 0.200 x 0.270 x 0.400 
-range scanned (
o
) 2.69 – 27.80 
Index range h: -13, 13; k: -10, 10; l: -19, 19 
No. of reflections collected 22107 
No. of unique reflections 2870 
Data completeness (%)  99.8 
Data/restraints/parameters 2870/1/163 
S (Goodness-of-fit on F
2
) 1.035 
Final R indices R1, wR2,  [I > 2σ(I)] 0.0532, 0.1415 
R Indices, all data (R1, wR2) 0.0564, 0.1456 
Largest diff. peak and hole (e. Å
-3







Intramolecular and intermolecular structural features 
Several structural features were assessed for molecules A and B in the crystal structure, which 
include the planarity of the aromatic rings, the angle of intersection of these two planes, possible π-
π stacking and an overlay of molecules A and B.  
The aromatic rings for both molecules A and B were confirmed to be planar within the expected 
range of deviation. For molecule A, the deviations of the atoms from the least-squares plane ranged 
between -0.004(2) Å and 0.005(3) Å for atoms C4A and C3A respectively, while, for molecule B, the 
deviations were between -0.007(3) Å and 0.004(3) Å for atoms C3B and N1B respectively.  
Furthermore, the plane of intersection of the aromatic rings of molecules A and B was 0.6(1)o, 
which further confirmed the fact that these two molecules are pseudo-centrosymmetrically related.     
In addition, there was no evidence for adequate π-π stacking occurring between the aromatic rings 
of either molecule A or B. The centroidcentroid distances between various aromatic rings ranged 
between 4.324(2) Å and 5.902(2) Å, which is too large for π-π stacking to occur.  
The results from the overlay of molecule A with the inverse of molecule B, further confirmed that 
they are pseudo-centrosymmetrically related. The results for the best fit of the two moieties 












Hydrogen bond interactions 
There are four independent H-bond motifs that occur in the crystal structure of polymorph 6. 
Figure 3.9 displays these H-bonds in the ASU, and their distances and geometrical characteristics 













Figure 3.9: The H-bond motifs in the ASU of polymorph 6.  
 
Table 3.5: Intermolecular hydrogen bond interactions for polymorph 6. 






N9A – H9A2N1A 2.975(3) 179 x,1+y,z 
(i) 
  N9A – H9A1O8A 2.954(3) 156 ½+x,2-y,z 
(ii) 
N9B – H9B2N1B 2.980(3) 175 x,-1+y,z 
(iii) 
N9B – H9B1O8B 2.935(3) 158 -½+x,1-y,z 
(iv) 
a
 No e.s.d. was reported for the D-HA angle, since the H atoms were placed in idealised positions.                      
b 






















Figure 3.10 displays the packing arrangement of polymorph 6 viewed down the a-axis (left), b-axis 









Polymorphic comparison  
A polymorphic comparison was performed for all six forms of isonicotinamide which involved 
assessing their respective molecular conformations, as well as their crystal packing features.  
Consequently, the torsion angles around the C4-C7 bond of all the polymorphs of isonicotinamide 
were compared, since this is the only significant bond that represents a conformational degree of 
freedom. The results are displayed in Table 3.6, and it indicated that all the torsion angles are 
















Table 3.6: The C3-C4-C7-O8 torsion angle magnitudes of the polymorphs of isonicotinamide.  




Polymorph 1 30.5(2) 
Polymorph 2 (molecule A) 24.0(3) 
Polymorph 2 (molecule B) 25.4(3) 
Polymorph 3 30.9(3) 
 Polymorph 4 (molecule A) 25.8(2) 
Polymorph 4 (molecule B) 23.4(2) 
Polymorph 4 (molecule C) 28.3(2) 
Polymorph 5 19.6(2) 
Polymorph 6 (molecule A) 24.2(4) 
Polymorph 6 (molecule B) 25.6(4) 
 
The ASU of polymorph 6 was compared with the corresponding two molecular entities from each of 
the other polymorphs of isonicotinamide through a structural overlay study. This test also indicated 
that all of the polymorphs were significantly different, except for polymorph 2 which appeared to 
be similar to polymorph 6. However, another study was subsequently performed where the 
molecular packing arrangement of these two similar crystal structures was compared over a longer 
range. Figures 3.11 – 3.13 display the overlays of polymorph 6 (pink) and polymorph 2 (green). 
Initially, the comparison of these similar polymorphs was established with the two unit cells 
orientated according to Figure 3.11, with the view down the b-axis, and with the two polymorphs 
being aligned to overlap at the left-hand side. With regard to this projection, a distinct difference 
can be observed over an extended range (from left to right) where polymorph 6 and polymorph 2 
begin to separate vertically. Figure 3.12 displays the projection of Figure 3.11 rotated 90o around 
the c-axis of the orthorhombic polymorph, polymorph 2 then being viewed down the c-axis and 
polymorph 6 down the a-axis. This projection confirmed that there was a direct overlap between 
the two polymorphs in this direction and as a result, this is consistent with the fact that only a 
vertical separation occurred between the two polymorphs over an extended range in Figure 3.11. 
Similarly, Figure 3.11 was rotated by 90 around the a-axis of the orthorhombic polymorph in order 
to generate the projections displayed in Figure 3.13a and 3.13b, where polymorph 6 is viewed 












the areas boxed in red were compared in order to conduct an adequate molecular comparison. This 
particular projection indicated that there was no overlap over the entire extended range and it can 
be observed that polymorph 6 has extended vertically in comparison to polymorph 2 by observing 
the height difference from the black reference line at the top of Figure 3.13b. There are some 
similarities with regard to the molecular arrangements between the two polymorphs, and this is 
particularly apparent in the space-filling image (Figure 3.13b). However, the most significant 
differences within the areas boxed in red are that polymorph 6 contains a small periodic void, 













Figure3.12: The molecular overlay of polymorph 2 (green) and polymorph 6 (pink), derived 
from Figure 3.11 by a 90
o
 rotation around the c-axis of the orthorhombic polymorph. 




















It is noteworthy that the intensity data for polymorph 2 and polymorph 6 were collected at the 
same temperature. As a result, the very significant differences between the two PXRD patterns of 
the respective polymorphs, calculated from their single crystal X-ray data at 173 K, confirm that 









Figure 3.13a: A wireframe representation of the molecular 
overlay of polymorph 2 (green) and polymorph 6 (pink), 
derived from Figure 3.11 by a 90
o
 rotation around the a-axis 
of the orthorhombic polymorph. 
Figure 3.13b: A space-filling representation of the molecular 
overlay of polymorph 2 (green) and polymorph 6 (pink), 
derived from Figure 3.11 by a 90
o
 rotation around the a-axis 





Figure 3.14: The calculated PXRD patterns of polymorph 2 and polymorph 6. 
 
Furthermore, upon closer inspection of the unit cells of polymorphs 2 and 6, the molecular packing 
arrangements are significantly different. Polymorph 2 displays a packing arrangement BAAB 
around a centre of inversion (Figure 3.15), while the molecular packing arrangement of polymorph 
6 followed an alternating ABAB packing arrangement (Figure 3.15). As a result, the SCXRD analysis 










































Further experimentation was performed in order to attempt to characterise polymorph 6 and 
compare it to the other five known polymorphs. This new polymorph did not correspond to the 
new crystalline phase obtained in the dry co-grinding experiments of allopurinol and 
isonicotinamide (polymorph 1). This is evident in the results shown in Figure 3.16, where the PXRD 
pattern of the product of dry co-grinding allopurinol and isonicotinamide (molar ratio 1:1) for 35 
minutes, did not correspond to the PXRD patterns of either the original reagents or to the 
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Figure 3.15: The packing arrangements of polymorph 6 (left) and polymorph 2 (right). Both polymorphs have Z′ = 2 molecules 




Figure: 3.16: PXRD patterns of allopurinol, isonicotinamide (polymorphic form 1), the product of dry co-ground allopurinol and 
isonicotinamide (1:1) for 35 minutes, and the calculated trace for polymorph 6. 
 
Polymorph 6 crystallized alongside the five other known polymorphs of isonicotinamide. The 
observation from the SCXRD analysis indicated that polymorph 6 and polymorph 3 appeared to 
crystallize in major amounts at the specific time of analysis, while the remaining polymorphs 
appeared to be present in a lesser quantity. It is important to note that this observation only takes 
into consideration the crystals that were of an adequate quality for SCXRD experiments. In addition, 
this observation was also time-dependent, since it was later reported by the author of this 
dissertation, that the polymorphs appear to transform over time. At the time of writing, the most 
reliable method for the isolation of polymorph 6 was in the presence of the API, namely allopurinol, 
as allopurinol initially appeared to act as a template for its formation.21 In addition, the method of 
preparation was very quantity-specific and any deviations or variations caused the new polymorph 
either to form in a lesser quantity and inferior crystal quality, or not to form at all.  
Furthermore, the use of allopurinol (which apparently behaved as a template) for the isolation of 
polymorph 6, was especially important if the crystallization was being performed for the first time 
in a laboratory. This deduction arose since there could have been a possibility that once polymorph 
6 was synthesized in a specific laboratory, the air was thereafter seeded with it. This is similar to 
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what occurred with the HIV drug, ritonavir.22 Towards the end of this investigation of polymorph 6, 
it was possible to produce it by recrystallizing isonicotinamide either from isopropanol, acetone or 
acetonitrile, without the templating influence of allopurinol.b Aakeröy et al. had already used 
acetone as a recrystallizing solvent for the possible formation of new polymorphs.16 However, since 
Eccles et al. did not report the existence of polymorph 6, one can conclude that either they were 
unable to discover it owing to a polymorphic transition of this form to another form having taken 
place, or that the subsequent formation of polymorph 6 in different organic solvents without 
allopurinol is dependent on an initial crystallization with allopurinol in order to seed the 
laboratory.18,22  
Polymorph preparation  
The initial preparative method involved dissolving equimolar amounts of allopurinol (5 mg; 0.0367 
mmol) and isonicotinamide (4.486 mg; 0.0367 mmol) in separate, clean vials. Approximately 2 cm3 
of chloroform was used to fully dissolve the isonicotinamide and 6 cm3 of chloroform was used to 
dissolve as much of the allopurinol as possible. The isonicotinamide solution and the suspension of 
allopurinol were tightly sealed and stirred for 12 hours at 35 oC. Subsequently, they were filtered 
into a common, clean vial (even though very little of the allopurinol had dissolved)23 and left for 
slow evaporation. This method produced the first batch of crystals in which polymorph 6 was 
discovered.  
A more refined preparative method was subsequently discovered, which produced more reliable 
crystals in terms of single crystalline quality and quantity. This variation involved increasing the 
amount of chloroform used to dissolve more of the allopurinol from 6 cm3 to 20 cm3. The rationale 
behind this was to allow more allopurinol into the system during the crystallization of polymorph 6 
and thus it might allow the allopurinol to act as a more effective template, which could increase the 
amount of desired polymorph. In addition, a larger volume of chloroform during slow evaporation 
would result in a slower precipitation process, which could allow for an improved, single crystalline 
quality. Owing to the high volatility of chloroform, only six holes were punctured into the parafilm 
that sealed the vial during slow evaporation.c This also allowed the solution to evaporate slowly 
                                                          
b
 Polymorph 6 appeared to crystallize as the major form with isopropanol in comparison to acetone and acetonitrile.  
c
 Furthermore, the parafilm was not stretched over the vial opening, as it was observed that the chloroform vapour 
reacted with the parafilm and produced large holes in any thin areas. 
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over two weeks, a period which appeared to yield the best quality and highest quantity of crystals 
of polymorph 6.  
Further variations in this methodology were attempted, with no success. These included: lowering 
the mass of allopurinol since not all of it had dissolved in the chloroform and thus was technically 
‘wasted’;23 stirring the individual chloroform and allopurinol solutions for a shorter period of time; 
attempting to produce polymorph 6 without the presence of allopurinol in the chloroform; 
attempting to produce polymorph 6 by adding the unfiltered allopurinol-chloroform solution into 
the filtered solution of isonicotinamide; and lastly, scaling up the quantity of the overall mass used 
while preserving the equimolar ratio.  
The refined preparative method, as described above, successfully produced over fifteen vials, each 
of which contained single crystals of polymorph 6, along with the other five known polymorphs. 
However, in the final attempts to reproduce single crystals of polymorph 6 towards the end of the 
investigation, difficulties were experienced. Even though the method was followed meticulously, 
the quality of the synthesized crystals was inadequate for SCXRD analysis. However, it is important 
to state that along with the fifteen batches that produced high-quality single crystals of polymorph 
6, there were additional vials that contained specimens of poorer crystalline quality. The latter 
included a crystalline, helical tape morphology, and a powdery residue of isonicotinamide. Thus, it 
was these two poorer morphological forms that were continuously obtained during the later 
attempts at isolating polymorph 6 with chloroform and allopurinol.  
Morphology 
The morphology of polymorph 6 appeared to be unique, as displayed in Figure 3.17a (with 
reference to the crystal on the right-hand side of the micrograph). This morphology was 
characterised by the shape of a bullet-head, where the bottom half of the crystal had a rectangular 
side which tapers midway to form a triangular point at the top. This was in contrast to polymorph 3, 
which as mentioned previously, was initially found to crystallize in approximately the same quantity 
as polymorph 6. Polymorph 3, as depicted in the left-hand crystal (Figure 3.17a), had a more 
rectangular morphology, where the shorter sides of the rectangular crystal were not parallel. This 
correlated with the morphology as described in the PhD thesis of Li.24 The bullet-head shaped 
crystals of polymorph 6 crystallized together by means of a type of radial conglomerate, where the 
bullet-head tips all pointed towards a common focal point. This conglomerate of crystals separated 
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when touched by a needle that was employed to assess the crystals for multiple SCXRD unit cell 
measurements. All the crystals with this unique morphology were determined to be polymorph 6 
by means of unit cell determinations. However, other crystals having a more rectangular, or even 
an irregular shape, also yielded the unit cell parameters of polymorph 6 within acceptable limits, as 
measured by the respective  and mosaicity values (Figure 3.17b). This could be as a result of the 
fact that the majority of the crystals crystallized on the sides of the vial during their formation and 
consequently the crystals could have been unintentionally shattered when they were removed with 
a spatula (in spite of the care taken to remove them). Therefore, the bullet-head shaped crystals 
appeared to represent the general morphology of polymorph 6, since these crystals all separated 









Even though polymorph 6 appeared to be distinctive from a morphological perspective in 
comparison to the other polymorphs, a unit cell assessment was performed for each crystal 
investigated, since, as mentioned above, specimens with other morphologies were also determined 
to correspond to crystals of polymorph 6. Approximately only one-fifth of the crystals collected for 
further experimentation displayed this unique bullet-head morphology. As a result, crystals having 
the other morphologies, which most likely occurred from crystal shattering, were also collected for 
further experimentation. In addition, despite the tedious task of individually separating and 
analysing the single crystals of this new polymorph by means of unit cell determinations, it 
provided a very accurate confirmation that the resulting sample was polymorphically pure. 
Figure 3.17a: Polymorph 3 (left) and polymorph 6 
(right). This micrograph displays the bullet-head 
shaped morphology of polymorph 6. 
Figure 3.17b: Polymorph 3 (left) and polymorph 6 
(right). This micrograph indicates that other 
morphological forms of polymorph 6 could also exist. 
53 
 
Unfortunately, no preparative method had yet been found to produce polymorph 6 exclusively and 
as a result, this separation method was imperative to guarantee purity.  
Powder X-ray diffraction (PXRD): experimental and calculated PXRD pattern comparison  
Obtaining a reliable experimental PXRD pattern of polymorph 6 was exceedingly challenging, and 
unfortunately it was not achieved. This was due to the fact that polymorph 6 did not crystallize in a 
pure form. As mentioned previously, there were the five other polymorphs of isonicotinamide also 
present, along with polymorph 6, in the vial after co-precipitation. This was also verified in the 
experimental PXRD pattern which analysed the whole co-precipitated product from the vial and 
thus indicated the presence of all six polymorphs, as displayed in Figure 3.18. This experimental 
PXRD pattern contains peaks from all six polymorphs, although with varying intensities in 
comparison to the individually calculated PXRD patterns of each polymorph. Furthermore, there 
were very slight shifts in the 2θ-positions between corresponding peaks in the experimental and 
calculated PXRD patterns. This was owing to the fact that the SCXRD data of the different 
polymorphs were collected at various temperatures in the range 100 – 173 K, as well as at 300 K 
(for polymorph 5), whereas the experimental PXRD pattern recorded by the author was obtained at 
room temperature (294 K). In addition, the experimental PXRD pattern contained at least one zero 
intensity peak for each polymorph in comparison to the calculated PXRD patterns.  
Despite the fact that the experimental PXRD pattern is a superposition of all six polymorphic forms, 
each peak can be assigned to the polymorph(s) to which it corresponds. These assignments are 
presented in Table 3.7.  
 
Table 3.7: The 2θ-positions from the experimental PXRD pattern that correlate with the 2θ-




1 17.5, 21.0, 23.0, 24.0, 25.5, 26.5, 30.0 and 33.0 
2 11.5, 14.7, 16.0, 18.5, 19.0, 19.1, 23.0, 24.5, 25.5, 28.5, 29.5, 30.5, 32.5, 35.0 and 37.5 
3 14.2, 17.5, 19.0, 21.5, 22.1, 24.3, 26.5, 27.0, 30.0, 31.0, 33.0, 33.5 and 37.2 
4 14.1, 19.0, 19.5, 21.2, 22.0, 23.0, 24.0, 24.5, 25.8, 26.5, 29.0, 30.0, 31.0, 32.5, 33.2 and 35.0 
5 11.5, 14.5, 19.0, 21.8, 24.0, 29.0, 30.5, 33.2, 35.0, 35.5, 37.5, 38.5 and 39.0, 





In order to obtain a PXRD pattern of pure polymorph 6, this new crystal form had to be separated 
from the other polymorphs. Approximately 1.8 mg of pure polymorph 6 was harvested (before it 
became challenging to reproduce polymorph 6), and confirmed to be polymorphically 
homogeneous via SCXRD unit cell determinations. The experimental PXRD pattern [Figures 3.19a 
(original trace) and 3.19b (intensity-enhanced trace)] was of very poor quality, as it indicated 
preferred orientation of the crystallites, even though the sample was lightly ground into a fine 
powder. Consequently, there is the appearance of the high intensity peak at 23.0o, with all the 
remaining peaks being dwarfed to a noise level. Even though this was the case, it was still possible 
to attempt to correlate almost all of the ‘very low’ intensity peaks with the calculated PXRD pattern 
of polymorph 6, albeit with approximately half a degree of offset on average. This half a degree 
offset could be due to the fact that the experimental PXRD pattern was recorded at 294 K, while the 
calculated PXRD pattern was recorded at 173 K. These peaks are at the 2θ-positions 11.5o, 14.5o, 






















Figure 3.18: Calculated PXRD patterns of the six polymorphs of isonicotinamide and the experimental PXRD pattern of the co-




19.0o, 22.5o, 24,5o, 25.5o, 32.5o, 35.0o and 36.8o. However, this correlation is not very reliable, since 
at such a low signal-to-noise ratio of those ‘low intensity peaks’, the results do become 
questionable. This unreliability could further explain why some of the peaks were missing and why 
there was an additional peak at the 2θ-position of 15.0o, which was not represented in the 
calculated PXRD pattern of polymorph 6.  
 
Figure 3.19a: The experimental PXRD pattern of pure polymorph 6 and the calculated PXRD pattern of polymorph 6. 
 
Figure 3.19b: Intensity-enhanced representations of the PXRD patterns shown in Figure 3.19a. 
 
The crystal structure of polymorph 6 provided a reason to account for the most intense peak at 2θ 
= 23.0o in the calculated PXRD pattern of polymorph 6. This reason did not account for the extreme 


































intensity of preferred orientation [which is displayed in the experimental PXRD pattern of pure 
polymorph 6 (Figure 3.19a and 3.19b)], since this could be caused by factors such as the crystal 
morphology and the level of grinding. The packing diagram of the unit cell viewed down the b-axis 
(Figure 3.20) displays a significant number of atoms from the isonicotinamide molecule, which are 
positioned in the close vicinity of the (004) planes. This resulted in significant constructive 
interference for the (004) reflection and thus gave rise to the most intense peak at 23.0o in the 









Figure 3.20: The unit cell of polymorph 6 which displays a significant number of atoms that straddle the (004) planes.  
 
Obtaining a more substantial mass of polymorph 6 was no longer possible through physical 
separation that was intended to improve the quality of the experimental PXRD pattern. However, 
an alternative option for improving the signal-to-noise ratio of the experimental PXRD pattern 
would be to record the pattern from 4o to 22o and from 24o to 40o, thus eliminating the peak 
suffering maximum preferred orientation. By collecting two separate PXRD patterns on either side 
of the peak at 23.0o, it should be possible to merge the patterns together and compile a ‘pseudo-
single’ PXRD pattern of polymorph 6. This would merely indicate whether the experimental PXRD 
pattern displayed the same 2θ peak positions as the calculated pattern. However, it would not be 
possible to compare the relative intensities accurately, as the peak of highest intensity had been 
eliminated. Unfortunately, these experimental PXRD pattern results were unsatisfactory, as 





ratio with only one peak at 11.5o. In addition, the other low intensity peaks that were present in the 
full experimental PXRD pattern of polymorph 6 up to 22o were not present in this pattern ranging 
from 4o to 22o. This could either be due to the fact that those peaks were merely undefined noise in 
the full experimental PXRD pattern, or it could indicate that the sample was becoming amorphous 
over time. If the latter applied, the possible reason could have been due to the two separate PXRD 
patterns ranging from 4o to 22o and 24o to 40o having been recorded 5 weeks after the full PXRD 
experimental pattern of polymorph 6 was obtained. Lastly, the PXRD pattern ranging from 24o to 
40o 2 displayed only noise.  
 
 











Consequently, a seeding experiment was attempted where two seed crystals of polymorph 6 were 
added to a chloroform solution containing 5 mg of isonicotinamide and then left to recrystallize. 
The PXRD pattern of the bulk crystallized material was recorded. However, it did not display a 
significant improvement (Figure 3.22a and 3.22b) despite the increased mass used for the analysis. 
Furthermore, there were both additional (extraneous) peaks and absent peaks in comparison to the 
calculated PXRD pattern of polymorph 6. As mentioned previously, this comparison was not a 
reliable indicator for any form of correlation, as the signal-to-noise ratio of the ‘low intensity’ peaks 
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was very low. This comparison was further complicated by the different temperatures that were 
used to record the experimental and calculated PXRD patterns. Nevertheless, as before, an attempt 
to correlate some of the peaks was performed. It appeared that there was the possibility to 
correlate the ‘low intensity peaks’ of the experimental PXRD pattern of polymorph 6 (produced via 
seeding) at the 2θ-positions 11.5o, 19.0o, 22.5o and 23.0o with the calculated PXRD pattern of 
polymorph 6. However, peaks at the 2θ-positions 15.0o, 18.5o, 21.0o, 22.0o, 26.0o, 29.0o and 30.2o of 
the experimental PXRD pattern of polymorph 6, were not reflected in the calculated PXRD pattern 
of polymorph 6. Therefore, this indicated that these ‘low intensity peaks’ were either from another 
polymorph, and thus the material produced via seeding was not polymorphically pure, or they were 
just variations of noise and should be disregarded. As a result, acquisition of a reliable experimental 
PXRD pattern of polymorph 6 via a seeding experiment was not achieved.   
 
Figure 3.22a: The calculated PXRD pattern of polymorph 6 and the experimental PXRD pattern of polymorph 6, which was 
produced via a seeding experiment. 
 



















Figure 3.22b: Intensity-enhanced representations of the PXRD patterns shown in Figure 3.22a. 
 
Lastly, two liquid-assisted grinding (LAG) experiments were also employed in order to attempt to 
produce polymorph 6. The first LAG experiment involved adding 5 mg of isonicotinamide into the 
mortar and grinding it with a few drops of chloroform for 30 minutes. The second LAG experiment 
involved the same process, except that a large quantity of chloroform was added until the 
isonicotinamide had the consistency of a slurry. Unfortunately, neither of these experiments 
yielded the anticipated results (Figure 3.23) and the experiment produced polymorph 1, as 
indicated by the direct correlation between the two products of the LAG experiments and the PXRD 
pattern for polymorph 1.9,16 



















Figure 3.23: The calculated PXRD pattern of polymorph 1, an experimental PXRD pattern resulting from an attempt to produce 
polymorph 6 via LAG with chloroform, and an experimental PXRD pattern resulting from an attempt to produce polymorph 6 via 
LAG with excess chloroform.
9,16 
 
In conclusion, all efforts to record a representative experimental PXRD pattern of polymorph 6 
consistent with the pattern calculated from the single crystal X-ray analysis failed, despite 
exhaustive attempts. 
Hot Stage Microscopy (HSM) analysis 
A hot stage microscopy (HSM) analysis was performed in order to compare the simultaneous 
thermal progression of five out of six of the polymorphs of isonicotinamide, namely polymorphs 1, 
2, 3, 4 and 6 at a heating rate of 1 K.min-1 The reason that polymorph 5 was omitted, was due to 
difficulties in reproducing an adequate single crystal of this form. The sequential micrographs 
displayed below (Figure 3.24) represent the thermal behaviour of the different polymorphs from 
27.5 oC to 161.0 oC, which included polymorphic transitions and the onset of the various melts. 
Image 1 displays the crystals at 27.5 oC where the various polymorphs were arranged clockwise in 
ascending serial order. No observable changes occurred with any of the polymorphs until 122.8 oC 
(Image 2) where the onset of opacity occurred sharply (within the range of 0.5 oC) in polymorph 3, 
while the other polymorphs remained unchanged. The onset of opacity in polymorph 3 represented 
a polymorphic phase transition taking place and this event correlated with a previous report by Li.24 
In the latter reported experiment, the onset of opacity occurred at 131 oC for polymorph 3 at a 
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heating rate of 10 K.min-1. However, when Li repeated the experiment at a heating rate of 1 K.min-1 
the onset of opacity occurred over a broad temperature range of 121 – 135 oC,24 instead of 
appearing as a sharp transition within half a degree, as observed in the current experiment. Li also 
reported that at 133 oC an onset of opacity occurred in polymorph 2,24 whereas this thermal event 
was not observed during the current experiment. At 128.9 oC (Image 3), polymorph 6 developed the 
onset of an extremely slow melt. It was deduced that prior to this extremely slow melt 
commencing, a polymorphic phase transition had taken place, as in an earlier HSM experiment 
(described in greater detail below) it was evident that nucleation sites began to occur within 
polymorph 6 at 119.0 oC. Unfortunately, this particular polymorphic phase transition was not 
observed in the second HSM analysis where the five polymorphic forms were compared 
simultaneously. It appeared, after considerable scrutiny, that the onset of a very slow melt began to 
occur for all the remaining polymorphs at 132.1 oC (Image 4). The decrease in size from the onset of 
melting with all the polymorphs was hardly discernible; however, this was carefully analysed by 
means of overlaying each individual crystal in consecutive HSM micrographs. Furthermore, the 
onset of opacity occurred in polymorph 4 at 141.9 oC, associated with a polymorphic phase 
transition (Image 5). The pace of melting increased significantly at 151.3 oC (Image 6) where 
polymorph 6 had completely melted (most likely owing to its more slender and comparatively 
smaller size). In addition, the fast-paced melt continued and polymorphs 1, 2 and 3 were 
completely molten at 155.1 oC (Image 7). In contrast, at this temperature, polymorph 4 hardly 
exhibited any comparative decrease in size. This possibly suggested that polymorph 4 had not yet 
transformed into the same phase as polymorphs 1, 2, and 3. Polymorph 4 completely melted at 










Figure 3.24: A series of HSM micrographs which display the thermal progression of polymorphs 1, 2, 






















Image 1: The initial appearance 
of the polymorphs at 27.5 
o
C. 
Image 2: At 122.8 
o
C the onset of 
opacity occurred within 
polymorph 3. 
Image 3: At 128.9 
o
C the onset 
of the melt occurred for 
polymorph 6. 
Image 4: At 132.1 
o
C the 
remaining polymorphs began to 
melt. 
Image 5: At 141.9 
o
C the onset of 
opacity occurred within 
polymorph 4. 
Image 6: At 151.3 
o
C the melting 
rate increased and polymorph 6 
completely melted. 
Image 7: At 155.1 
o
C polymorphs 
1, 2 and 3 had melted, while the 
melting rate of polymorph 4 
decreased significantly. 
Image 8: At 161.0 
o
C all the 










An earlier HSM experiment had been conducted, which compared polymorph 3 and polymorph 6 
simultaneously at the same heating rate of 1 K.min-1. Unfortunately, the resolution of the 
successive images was of inadequate quality; nonetheless, during this particular experiment a 
polymorphic phase transition in polymorph 6 was evident by the appearance of nucleation sites.  
The sequential micrographs displayed below (Figure 3.25) represent the thermal progression of the 
two crystals from 22.8 oC to 148.3 oC, which included polymorphic transitions and the onset of 
melting. Image 1 displays the crystals at room temperature (22.8 oC) with polymorph 6 on the right-
hand side and polymorph 3 on the left-hand side. No changes occurred to either crystal until 119.0 
oC, as displayed in Image 2, where polymorph 6 began to develop spots in the lower region of the 
crystal. It is this particular event that was not observed in the second HSM analysis. These spots are 
attributed to nucleation sites of another polymorph forming. It could be speculated that these 
spots were a result of the light reflecting off the surface of the crystal (as there were some 
reflective spots initially on the crystal at room temperature in image 1). However, there was no 
visual evidence of the crystal changing its morphological topography at this temperature (or even 
for the following 20 oC) which could have caused additional reflective light spots to appear. 
Furthermore, the original reflective light spots on the crystal had not changed, which further 
confirmed that the internal spots were a consequence of a polymorphic transition and not due to 
the reflective surfaces shifting from, for example, melting. Image 3 indicates the onset of opacity in 
polymorph 3 at 123.5 oC, while polymorph 6 remained unchanged. This onset of opacity 
represented a polymorphic transition taking place. Image 4 displays the development of nucleation 
sites occurring at 128.3 oC in polymorph 3. In addition, at this temperature, polymorph 6 developed 
a significant increase in nucleation sites all over the crystal as well as the onset of a very slow melt. 
The latter event was noticed by the slight shortening of the triangular, bullet-head shaped point at 
the bottom tip of the crystal of polymorph 6. Image 5 at 132.5 oC indicates a significant increase of 
nucleation sites for polymorph 3, while polymorph 6 continued to melt very slowly. Image 6, at 
142.0 oC indicates polymorph 3 fracturing internally, possibly as a result of the formation of internal 
bubbles, which were also observed. Simultaneously, the onset of the melt for polymorph 3 began, 
as the entire crystal began to shrink in size at an extremely slow rate. At the same temperature, 
polymorph 6 continued to melt; however, at an accelerated pace. Even though more spots were 
appearing on polymorph 6 during the melt, it was impossible to verify which were due to reflective 
light, and which were genuine nucleation sites forming. Image 7, at 143.1 oC displays a very slow 
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melt for polymorph 3 with vigorous internal bubbles, while polymorph 6 was experiencing a 
relatively faster melt. Image 8 at 148.0 oC indicates both crystals melting rapidly, to the point where 
they were completely molten at 148.3 oC as represented in Image 9.   
Figure 3.25: A series of HSM micrographs which display the thermal progression of polymorphs 3 



















Image 1: The Initial appearance 
of polymorph 3 (left) and 
polymorph 6 (right) at 22.8 
o
C. 
Image 2: Polymorph 6 (right) 
began to develop nucleation 
sites (in the form of spots) 
towards the bottom of the 
crystal at 119.0 
o
C. 
Image 3: The onset of opacity in 
polymorph 3 (left) at 123.5 
o
C. 
Image 4: At 128.3 
o
C, polymorph 
3 (left) developed nucleation 
sites (in the form of spots). In 
addition, polymorph 6 (right) 
developed a significant increase 
in nucleation sites all over the 
crystal as well as the onset of a 
very slow melt. 
Image 5: At 132.5 
o
C there was 
a significant increase in 
nucleation sites for polymorph 
3 (left), while polymorph 6 
continued to melt very slowly 
(right). 
Image 6: At 142.0 
o
C polymorph 
3 (left) began to fracture 
internally with internal bubbles 
forming. In addition, the onset 
of the melt for polymorph 3 
began. Polymorph 6 (right) 
continued to melt. 
Image 7: At 143.1 
o
C, 
polymorph 3 (left) experienced 
a very slow melt with vigorous 
internal bubbles. Polymorph 6 
(right) experienced an 
accelerated melt. 
Image 8: Both crystals were 
melting rapidly at 148.0 
o
C. 
Image 9: Both crystals were 
completely melted at 148.3 
o
C. 
3   6 
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The results from both of these analyses were inconclusive, as it was not possible to determine to 
which polymorphic phase the different crystals were transforming. Furthermore, although the 
same polymorphs were compared and assessed in various experiments, different thermal events 
were occasionally observed. It is important to note that this does not mean that the data reported 
by the previous authors, or that the data from the experiments described here, were inconsistent. 
It rather emphasizes the point that a visual comparison in isolation is not always accurate or 
justified.  
Differential Scanning Calorimetry (DSC) analysis of form 6  
The DSC trace indicated two thermal events, which occurred over the temperature range 20.2 – 
218.0 oC, as depicted in Figure 3.26 (n = 2). This DSC trace is the average of two experiments, where 
the heating rate was 10 K.min-1 for both of them. In addition, the sample used for both experiments 
consisted of single crystals that were individually evaluated for polymorphic purity by SCXRD 
analysis. These thermal events included a hardly observable, broad exothermic peak at 130.7 oC 
and a sharp endothermic peak at 156.3 oC. (There is a very small, sharp peak at 65 oC. This is 
attributed to an artefact, since firstly, no thermal event was observed at such a low temperature in 
the HSM analysis and secondly, the peak is too sharp to represent a thermal event. This artefact 
was also only present in one of the two DSC traces). 
The first thermal event was within the range 120.8 – 138.8 oC and corresponded to a phase 
transformation of polymorph 6, as this temperature correlated with the development of nucleation 
sites on the crystal in the HSM analysis. In addition, the onset of the endothermic peak, at 155.5 ± 
0.1 oC (peak temperature 156.3 ± 0.1 oC) corresponded to the melt, and the enthalpy of fusion was 
163  5 J.g-1. However, these temperatures did not correlate with the HSM analysis, which 
displayed a complete melt at 148.3 oC and 151.3 oC for the two separate experiments. A possible 
explanation is that the merits of comparing the temperatures of crystals melting on different sets of 
equipment are not always justified. Thus, it was not possible to easily differentiate or compare the 
different polymorphs of isonicotinamide, since the melting range of all the polymorphs indicated by 




Figure 3.26: The average DSC trace of polymorph 6 from two experiments. 
 
Solution-mediated transformation experiment 
A solution-mediated transformation experiment was conducted in order to assess whether 
polymorph 6 was a metastable phase relative to the most stable polymorph of isonicotinamide, 
which is polymorph 1. The preparation involved placing a single crystal of polymorph 1 and a single 
crystal of polymorph 6 in the centre of a Petri dish. A solution of EtOH that was saturated with 
isonicotinamided was added extremely slowly and carefully to the Petri dish by means of a syringe 
with a needle. As a result, the two crystals of isonicotinamide were submerged in a bath of EtOH 
saturated with isonicotinamide, with the surface level of the solution being about three times the 
height of the top of the crystals, in order to allow for crystal growth. The Petri dish was 
subsequently covered with a watch glass, to prevent evaporation of the EtOH, and the entire 
system was placed under a microscope.  
According to the literature, the expected result would be that polymorph 1 would increase in size at 
the expense of polymorph 6, if the latter were the metastable phase.25 However, this was not the 
case with the experiment described here. The successive micrographs (Figure 3.27) display the 
resultant growth of both polymorphs over the duration of 3 hours and 56 minutes. With reference 
to the first 30 minutes (Images 1 – 3 under Figure 3.27), noticeable growth had occurred on 
                                                          
d
 This solution was created by adding an excess amount of isonicotinamide to EtOH and stirring it for 72 hours at room 























polymorph 1 almost immediately, while, in contrast, polymorph 6 had undergone minimal growth. 
Furthermore, the initial type of growth that occurred on polymorph 1 was a repair of a fracture that 
had occurred on the crystal prior to the start of the experiment. The subsequent micrographs 
(Images 3 – 5) indicate the rapid expansion in all morphological directions that both crystals 
experienced over the duration of 30 minutes to 3 hours and 56 minutes. In addition, it was still 
possible to visually track the original crystals of both polymorphs within the expanded growth. 
Lastly, various satellite crystals began to grow in the Petri dish from 43 minutes onwards (Image 4) 
and also approximately at the same rate as the two polymorphs under inspection. However, it was 
possible to observe miniscule crystallization nuclei that eventually grew into these additional 
crystals from 20 minutes (Image 2). These additional crystals were formed as a consequence of the 
EtOH slowly evaporating and thus isonicotinamide was precipitating from the supersaturated 
solution. Despite the fact that a watch glass was used to cover the Petri dish to help prevent the 
evaporation of the EtOH, it had to be temporarily removed for photographic purposes. The slight 
evaporation of the EtOH was also further accentuated by the fairly warm light of the microscope. 

















Image 1: Initial appearance of polymorph 6 (left) 
and polymorph 1 (right) of isonicotinamide 
submerged in EtOH saturated with isonicotinamide. 
Image 2: 20 minutes. 
Image 3: 30 minutes. Image 4: 43 minutes. 
Image 5: 3 hours and 56 minutes. 
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Once the experiment was completed, the two main crystal forms under inspection, along with 
three satellite crystals that were adjacent to each polymorph, were removed from the Petri dish 
and placed in Paratone oil26 for further examination. With reference to polymorph 1, the crystal 
had a cubic shape that measured 904 μm along the horizontal and 1024 μm along the vertical. This 
indicated that the area of the crystal grew approximately 1818 %, as the original dimensions along 
the same two lengths were 238 μm and 214 μm respectively. The crystal was subsequently cut very 
carefully to recover the original fragment that was used to initiate the experiment. A unit cell 
determination was performed which revealed that the original fragment remained as polymorph 1. 
In addition, three fragments from the new growth on the crystal were selected and analysed for 
their unit cell parameters. These fragments were from the top left, top right and bottom right 
corners of the expanded crystal. The results confirmed that all three fragments belonged to 
polymorph 1, and thus the crystal grew isomorphically.  
The same procedure was followed for polymorph 6, where the crystal was cut to reveal its original 
fragment, and three other fragments from the growth were also selected and cut. However, 
obtaining the original crystal fragment of polymorph 6 proved to be more difficult than expected, 
especially as the morphology was in a crooked L-shape. The dimensions of the crystal at face-view 
measured 595 μm along the horizontal and 952 μm along the vertical. This indicates that the area 
of the crystal grew approximately 876 %, as the original dimensions along the same two lengths 
were 143 μm and 452 μm respectively. Nonetheless, the crystal fragment obtained did appear to 
come from the original crystal and the unit cell dimensions remained those of polymorph 6. 
However, the various fragments of the new crystal growth that coated the original polymorph 6 
single crystal, revealed unit cell dimensions that corresponded to polymorph 2.  
Furthermore, additional crystals that grew directly around the local vicinity of polymorph 1 and 
polymorph 6 were also selected and analysed. Three individual crystals that grew around 
polymorph 1 and another three crystals that grew around polymorph 6 also had unit cell 
parameters corresponding to those of polymorph 2. This suggested that the metastable polymorph 
2 readily precipitated under these conditions and the experiment was terminated before there was 
sufficient time for the crystals of polymorph 2 to transform into the most stable form (polymorph 
1). Furthermore, the original crystal fragment of polymorph 6 had polymorph 2 preferentially 
coating it instead of polymorph 6, and thus this suggested that polymorph 6 is a less metastable 
form than polymorph 2. In contrast, the original crystal fragment of polymorph 1 grew 
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isomorphically, possibly since polymorph 1 is the most stable polymorph of isonicotinamide. 
Presumably, all the other crystals that were in the system would have eventually changed to the 
most stable form after a sufficient time.e 
Lastly, an interesting observation occurred within the first 30 minutes. Prior to the start of the 
experiment, a small piece of polymorph 1 cracked off, damaging its cubic shape. However, during 
this half hour, it fully repaired that missing piece before expanding uniformly in a cubic 
morphology. Furthermore, polymorph 6 had minimal growth during this time period. However, it 
was possible to observe miniscule crystal growth at various areas on the crystal (Images 1 – 3). 
Presumably, what is thought to have occurred, is that polymorph 6 was slowly being coated with 
nucleation sites of polymorph 2, and only once the original crystal was fully coated in these 
nucleation sites, could it begin to expand as rapidly as polymorph 2.  
  
                                                          
e
 This was performed in a different experiment where a saturated EtOH solution of isonicotinamide was left to 
recrystallize for one month, and only polymorph 1 was present.    
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Attempts to crystallize polymorph 6 from a variety of solvents 
As a final attempt to reproduce polymorph 6, an alternative method was employed where three 
different organic solvents were used to dissolve and recrystallize approximately 20 mg of 
isonicotinamide in separate vials. These three organic solvents were acetone, acetonitrile and 
isopropanol, and the crystals were removed for analysis within a period of less than 24 hours after 
precipitating in the mother liquor. The general method of slow evaporation was used to execute 
the experiment, where the temperature for heating the solution was tailored accordingly for each 
organic solvent. The results are exhibited in Table 3.8. 
 
Table 3.8: The results from selected crystals of the recrystallization of isonicotinamide from 
acetone, acetonitrile and isopropanol.  
Solvent Product characteristics Method of 
analysis 
Results 
Acetone Large, rectangular, 
transparent crystals. 
SCXRD Polymorphs 6, 4 and 2 were found in 
approximately equal ratios by mass 
Acetonitrile Medium to large, 
rectangular, transparent 
crystals. 
SCXRD Polymorphs 6, 4, 2 were found in approximately 
equal ratios by mass 
Isopropanol Medium-sized, 
transparent crystals in the 
shape of parallelograms. 
SCXRD and PXRD A fair amount of single crystals of polymorph 6 was 
obtained (majority). However, a few of the other 
polymorphs (except for polymorph 5) were 
occasionally found (minority). 
The PXRD pattern closely resembled that of the 
low signal-to-noise ratio PXRD pattern of the 
experimentally harvested, ‘pure’ polymorph 6. 
 
In the communication reported by Eccles et al.,18 it was discovered that polymorphs 2 and 4 
crystallized in pure acetone before the solvent completely evaporated. However, in the experiment 
described here, which imitated the experiment performed by Eccles et al., polymorph 6 also 
crystallized in pure acetone.18 Thus, as mentioned before, either polymorph 6 transformed into 
another polymorph before Eccles et al. had the opportunity to report it, or nuclei of polymorph 6 
from the present author’s laboratory unintentionally seeded the solution. Furthermore, 
isopropanol and acetonitrile also produced polymorph 6. Thus, a similar explanation would follow, 
except that no literature studies have reported previous recrystallizations with either of those 
organic solvents. Consequently, this recrystallization investigation of isonicotinamide that 
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employed the organic solvents acetone, acetonitrile and isopropanol, indicated the first examples 
where polymorph 6 could be isolated without the presence of allopurinol. 
This recrystallization experiment was performed approximately one and a quarter years later, 
which was right at the end of the investigation of polymorph 6. The most plausible explanation for 
the appearance of polymorph 6, amongst the other expected polymorphs, especially in acetone,18 
is that the laboratory had a sufficient amount of time to become “seeded”, and thus polymorph 6 
could be produced by unintentional seeding. As a result, the metastable polymorph 6 was observed 
in acetone, acetonitrile and isopropanol before it transformed into the more stable forms. 
However, the most noteworthy point is that polymorph 6 actually crystallized during this 
recrystallization study and apparently not in any previous experiments that Eccles et al. had 
performed.18 
Lastly, a PXRD comparison was performed with the crystals obtained from isopropanol, as 
polymorph 6 appeared to crystallize as the predominant form at that particular time. A noteworthy 
observation was that when a small mass (of approximately 4 mg) was used, the PXRD pattern 
(Figures 3.28a and 3.28b) resembled the initial PXRD pattern that displayed preferred orientation as 
shown in Figure 3.19a and 3.19b. However, when a larger mass of isonicotinamide was 
recrystallized from isopropanol (approximately 20 mg), it produced a PXRD pattern that did not 
reflect any particular polymorph (Figure 3.29). This PXRD pattern contained a few peaks from each 
polymorph, although there were also an equal number of peaks absent from each polymorph. One 
possible argument for this occurrence is that polymorphic transitions were in the process of taking 





Figure 3.28a: The experimental PXRD pattern of polymorph 6 and the experimental PXRD pattern of isonicotinamide recrystallized 
in isopropanol. 
 











































Figure 3.29: The PXRD patterns of the calculated trace for polymorph 6, the experimental co-precipitated mixture containing all 6 
polymorphs, isonicotinamide recrystallized in isopropanol (ca 4 mg) and in isopropanol (ca 20 mg). 
 
 
In conclusion, the SCXRD analysis reported at the beginning of section 3.2.3 successfully confirmed 
the presence of the new polymorph of isonicotinamide, which is polymorph 6. The space group 
assignment and crystal structure solution required considerable manual intervention, which 
reiterated the point that the routine application of crystallographic computer programs to solve 
crystal structures cannot always be relied on. The polymorphic comparison between polymorphs 2 
and 6 indicated that there was much similarity between them; however, there were distinctive 
differences, particularly with regard to their molecular packing arrangements and hence their 
computed PXRD patterns, which confirmed their uniqueness.   
 


























3.3) Cyclodextrin inclusion with allopurinol 
 
The experiments that entailed the synthesis of solid CD inclusion complexes with allopurinol were 
all unsuccessful and the results, with their methodologies and analyses, have been placed in the 
Appendix under section 3, pp. 15 – 19. The CDs that were analysed with allopurinol included -CD, 
-CD, -CD, DMB, TMB and TMA. Kneading experiments, along with a variety of co-precipitation 
experiments in which three solvent media were involved, were performed. These included pure 
water, water that contained a small measured volume of EtOH, and water that contained one drop 
of Tween 80. In addition, experiments with aqueous solutions of potassium hydroxide (KOH) were 
attempted with -CD and allopurinol, in order to produce a -CD·allopurinol inclusion complex. 
However, this was unsuccessful as well. 
3.4) Solubility experiments 
 
Phase solubility studies were conducted as a final attempt to assess whether the solubility of 
allopurinol could be improved in a variety of aqueous CD solutions of varying concentration. Three 
CDs, namely -CD, HPBCD and RAMEB, were selected in order to conduct the phase solubility 
experiments in duplicate. The solubility value of allopurinol, that is quoted in the literature, is 0.48 
mg.cm-3 at 25 oC,27 and 0.569 mg.cm-3 at 25 oC.28 As a result, it was of interest to obtain an 
experimental aqueous solubility value of allopurinol and use it as a control, which could then be 
compared to the values obtained from the phase solubility experiments. The experimental value of 
allopurinol was determined through the extrapolation from an experimental calibration curve.  
The absorbance-concentration calibration curve is represented in Figure 3.30 and recorded at a λmax 
of 250 nm.23 The phase solubility studies were performed with UV-vis spectroscopic techniques, 
since allopurinol is UV-active, while the CDs are not. Therefore, the UV-vis absorbance of the 
solution of these components would be caused by allopurinol alone. Five absorbance readings were 
recorded for each solution and averaged.  Consequently, a calibration curve of allopurinol was 
plotted, which was achieved by dissolving 0.729 mg (0.00536 mmol) of allopurinol in 25 cm3 of 
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Milli-Q water at 25 oC. Thereafter, sixteen aqueous, standard solutions of differing concentrations 
were prepared, where the overall volume of each was 5 cm3.  
 
Figure 3.30: Calibration curve for allopurinol in an aqueous solution. 
 
It was important to note that the lowest reliable absorbance at a λmax of 250 nm was 0.174 at a 10 
% concentration of the stock solution. Concentrations lower than this value, resulted in a λmax of 
245 nm (instead of 250 nm) and consequently were not included in the calibration curve. 
Furthermore, the y-intercept of the straight line offset the mass determinations by a negligible 
amount. This offset amount in the mass value was caused by an accumulation of errors that were in 
the un-recordable range of the equipment used to produce the calibration curve. This value 
amounted to a mass error of 3.5054 x 10-4 mg. The calculation that furnished this value is supplied 
in the Appendix under section 4.1, p. 20. 
The aqueous solubility of allopurinol was determined by dissolving an excess amount of allopurinol 
in 5 cm3 of water, the resulting suspension being stirred vigorously for 72 hours at 25 oC. The 
solution was filtered into a clean vial. Thereafter, 0.1 cm3 was removed and further diluted to a 
ratio of 1:50 in preparation for the UV-vis analysis. The UV-vis spectrum was recorded at the λmax of 
250 nm and the results are reported in Table 3.9. 
 
y = 0.0796x - 0.0041 


















Concentration ( x 10-8 mol.cm-3) 
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1 0.627 7.928 396.420 0.540 
2 0.580 7.338 366.897 0.499 
3 0.589 7.451 372.550 0.507 
Average 0.624 7.891 394.535 0.515 
 
As a result, the experimental aqueous solubility of allopurinol was determined to be 0.515 ± 0.017 
mg.cm-3 at 25 oC in comparison to the literature values, which were 0.48 mg.cm-3 at 25 oC,27 and 
0.569 mg.cm-3 at 25 oC.28  
As mentioned previously, the phase solubility experiments were performed with -CD, HPBCD and 
RAMEB in anticipation of forming a complex in solution. Unfortunately, all the results indicated that 
the solubility of allopurinol was not improved, regardless of the different CDs employed and their 
respective varying concentrations – the solubility of allopurinol remained unaffected. A full analysis 
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Supramolecular Derivatisation of                       
6-Thioguanine 
4.1) Introduction  
Literature investigations, that included examining the CSD and various journal search engines, such 
as Scifinder, Science Direct and Google Scholar, indicated that only one article relating to the 
supramolecular derivatisation of 6-thioguanine, had recently been published in 2017.1 This article 
was discovered after the investigation of 6-thioguanine described in this Master’s dissertation had 
been completed. This article gave an account of the synthesis of a ternary system of 6-thioguanine 
with -CD and gold nanoparticles, which improved the aqueous solubility and stability of the native 
drug.1 The authors initially synthesized a 1:1 -CD6-thioguanine inclusion complex by dissolving the 
drug in water with 100 μl of ammonia. Subsequently, gold atoms were deposited onto the crystal 
faces of the inclusion complex in order to create the ternary system. Furthermore, molecular 
modelling was performed in order to study the structure of the derivatised species.1  
Even though -CD6-thioguanine complex crystals had been successfully synthesized and published 
in the literature, the particle size was too small for a SCXRD analysis.1 Furthermore, the author of 
this Master’s dissertation wished to assess the possibility of synthesizing a CD complex in a pure 
aqueous medium. This present study intended to emulate the same investigation that was 
executed for allopurinol, since the chemical structure of 6-thioguanine is quite similar. This would 
thus allow one to assess the possibility of synthesizing new supramolecular derivatised products; 
however, it would also allow for a comparison to be drawn between the potential for both 
allopurinol and 6-thioguanine to be derivatised via supramolecular methods. Therefore, the various 
CDs that were selected included the native host compounds, namely -CD, -CD and -CD, as well 
as methylated CDs, which included DMB, TMB and TMA. Furthermore, it was intended that 
solubility investigations should be performed with three selected CDs with the expectation of 
enhancing the aqueous solubility of 6-thioguanine in solution. These CDs included -CD, HPBCD and 
RAMEB. In addition, co-crystallization experiments were to be performed with the same co-formers 
that were employed for allopurinol. 
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4.2) Co-crystal screening  
4.2.1) Virtual co-crystal screening 
The identical virtual co-crystal screening investigation that was performed for allopurinol (as 
described in Chapter 3.2.1, p. 28) was performed for 6-thioguanine, which resulted in the same 
choice of co-formers, but for different reasons. As mentioned before, the virtual co-crystal 
screening investigation entailed the use of the Cambridge Structural Database (CSD)2 in order to 
identify the supramolecular synthons that could potentially occur with 6-thioguanine. Initially, the 
supramolecular synthons from the crystal packing of 6-thioguanine were assessed once the 
molecular structure was obtained from the CSD and viewed in X-SEED.3 The drug molecule formed 
a dual eight-membered ring dimer of type 𝑅2
2(8) (as designated with graph set notation),4 as well 
as a discrete synthon (Figure 4.1). This differed from the situation in crystalline allopurinol, which 
formed two ring synthons, where one of them was dimeric and the other trimeric. The hydrogen 





















































Figure 4.1: The hydrogen bonded motif in the crystal of 6-thioguanine, which 




A virtual co-crystal screening, very similar to that designed for allopurinol, was conducted for 6-
thioguanine. This study likewise involved only analysing the potential to form stable hydrogen 
bonded ring synthons between the API and other molecules.  There are several tautomeric forms of 
6-thioguanine to take into account (Figure 4.2), and the potential sites that could form hydrogen 





























Similarly to the study with allopurinol, Figure 4.4 displays the selected molecular fragments of 6-
thioguanine, which accounted for all the possible tautomers of the molecule.  The atoms that are 
denoted as X in these molecular fragments, accounted for any atom, and the bond orders in C-X 
(2a-2d) and C-N (3a-3c) were unrestricted in order to account for the multiple tautomers of the 












1a 1b 1c 1d 
2a 2b 2c 2d 
3a 3b 3c 
Figure 4.3: The potential hydrogen bonding sites (circled in red). 
Figure 4.4: The various molecular fragments which accounted for the possible tautomers of 6-thioguanine. Atom X 






As with allopurinol , the carboxylic acid and amide co-former functional groups were separately 
assessed for their potential to form stable ring synthons with each of the molecular fragments of 6-
thioguanine. (This procedure is fully outlined in the same study that was performed with allopurinol 
in Chapter 3, under section 3.2.1, p. 31). These results indicated a more equal frequency of both the 
amide and carboxylic acid functional groups forming such hydrogen bonded ring synthons.  
However, the only fragments that yielded results were 2a, 3b and 3c. Figure 4.5 displays an 
example of the formation of a hydrogen bonded ring synthon between the molecular fragment 3b 




Figure 4.5: The most frequently occurring hydrogen bonded ring synthon, which involved the molecular fragment 3b and a 
carboxylic acid. The atom X represents any atom and the bonds in the N-C-N fragment were also denoted as ‘any’. 
 
 
As a result, it was justified to employ the same co-formers that were chosen for the co-
crystallization with allopurinol. Even though allopurinol and 6-thioguanine are different molecules, 
there is a level of similarity between the two and it was of interest to compare the results of both 


















4.2.2) Experimental co-crystal screening  
An assortment of co-grinding and co-precipitation experiments was performed with 6-thioguanine 
and the eleven selected co-formers, with the intention of producing new multi-component 
products. The co-grinding experiments included dry co-grinding of the API and a respective co-
former and LAG with EtOH as the solvent. In addition, a set of co-precipitation experiments was 
performed with the solvent DMSO, as 6-thioguanine appeared to be soluble only in DMSO. 
However, all the results indicated that no new material was formed. Therefore, the detailed 
methodology and discussion of these results have been placed in the Appendix under section 5, pp. 
23 – 26. An example of a PXRD pattern that displayed a physical mixture of 6-thioguanine and D-
tartaric acid following their attempted co-crystallization is illustrated in Figure 4.6. 
Number Selected co-former 
1 Benzamide 
2 Benzoic acid 
3 Fumaric acid  
4 Glutaric acid 
5 Isonicotinamide  









Figure 4.6: PXRD patterns of 6-thioguanine, D-tartaric acid, and the product obtained by dry co-grinding the two components in an 
equimolar ratio for 15 minutes. 
 
4.3) Cyclodextrin inclusion  
The CD inclusion experiments that were performed with 6-thioguanine replicated the 
methodologies of the CD inclusion experiments with allopurinol. The native and methylated CDs 
selected for interaction with 6-thioguanine included -CD, -CD, -CD, DMB, TMB and TMA. 
Kneading experiments, along with a variety of co-precipitation experiments, were also performed. 
Three different solvent media were also selected during the co-precipitation experiments. These 
included pure water, water containing a small measured volume of EtOH, and water that contained 
one drop of Tween 80. Unfortunately, the results were also unsuccessful as no new material was 
synthesized. In addition, further experiments with -CD as the host and 6-thioguanine as the 
potential guest were performed where the pH of the aqueous medium was varied with the addition 
of KOH; however, these experiments also yielded unsuccessful results. Consequently, all of these 
results, with their respective methodologies and detailed discussions, have been supplied in the 
Appendix under section 6 (pp. 27 – 30). The lack of affinity of 6-thioguanine for CDs is possibly 
attributed to its extreme hydrophobicity and its high melting point (> 360 C).5-6 




















4.4) Solubility experiments  
Phase solubility studies were conducted in an attempt to assess whether the aqueous solubility of 
6-thioguanine could be improved in a variety of CD solutions of differing concentrations. These sets 
of experiments mirrored those that were performed with allopurinol, with the same three CDs (viz. 
-CD, HPBCD and RAMEB) being used.  Furthermore, the aqueous solubility of 6-thioguanine quoted 
in the literature is vague, being described as “less than 1 mg.cm-3” at 22.5 oC.7 It was therefore 
desirable to obtain a more definitive solubility value from a spectrophotometric calibration curve 
during the course of the phase solubility study.  
The absorbance-concentration calibration curve, recorded at a λmax value of 340 nm,
7 is 
represented in Figure 4.7. Phase solubility studies performed with UV-vis spectroscopic techniques 
were possible, as 6-thioguanine is UV-vis active, while the selected CDs are not. Therefore, the UV-
vis absorbance of CD/6-thioguanine complex solutions would be due to the 6-thioguanine alone. 
Five absorbance readings were recorded for each solution and averaged, and a calibration curve of 
6-thioguanine was plotted. This was achieved by dissolving 1.166 mg (0.00697 mmol) of 6-
thioguanine in 20 cm3 of Milli-Q water at 25 oC and preparing fourteen aqueous standard solutions 
of differing concentrations, where the final volume of each, after dilution, was 5 cm3.  
 
Figure 4.7: Calibration curve for 6-thioguanine in an aqueous solution. 
y = 0.2126x + 0.0013 




















Concentration (x 10 -8 mol.cm-3) 
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This calibration curve had a miniscule y-intercept, which indicated that the mass determinations 
were also offset by a negligible amount.  As described for allopurinol, this mass offset value was 
caused by an accumulation of errors that were in the un-recordable range of the equipment used 
to formulate the calibration curve. This value amounted to a negligible mass error of 5.1117 x 10-5 
mg. The full calculation can be viewed in the Appendix under section 7.1, p. 31. 
The aqueous solubility of 6-thioguanine was assessed by dissolving an excess amount of 6-
thioguanine in 5 cm3 of water and stirring the suspension vigorously for 72 hours at 25 oC. The 
solution was filtered into a clean vial and 0.1 cm3 was removed and further diluted to a ratio of 1:50 
in preparation for the UV-vis analysis. The UV-vis spectrum was recorded at the λmax value of 340 
nm and the results of the experiment repeated in triplicate are reported in Table 4.2. 
 
Table 4.2: The determination of the aqueous solubility of 6-thioguanine 


















1 0.209 0.977 48.848 0.082  
2 0.194 0.906 45.320 0.076 
3 0.191 0.892 44.614 0.075 
Average 0.198 0.925 46.261 0.078 
 
As a result, the experimental aqueous solubility of 6-thioguanine was determined to be 0.078 ± 
0.003 mg.cm-3 at 25 oC in comparison to the literature value of “less than 1 mg.cm-3” at 22.5 oC.6-7  
As mentioned above, the phase solubility experiments were performed with -CD, HPBCD and 
RAMEB with the expectation of forming the respective CD complexes in solution. Unfortunately, all 
the results indicated that the aqueous solubility of 6-thioguanine had not been improved, 
regardless of the different CDs used and their respective varying concentrations. A full analysis and 
discussion of these results is supplied in the Appendix under section 7.2, pp. 32 – 33.  
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In conclusion, it was not possible to form any supramolecular products with 6-thioguanine in spite 
of the multiple potential H-bonding sites on the molecule. The virtual co-crystal screening analysis 
had indicated that it was possible in principle to form amide and carboxylic acid ring synthons, but 
the chemical and physical properties, such as the high melting point and very low aqueous solubility 
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The literature investigation for valproic acid indicated that no attempts to synthesise co-crystals of 
this API have been conducted to date. However, two cyclodextrin (CD) inclusion complexes of 
valproic acid were synthesised via a freeze-drying method and characterised in 2004.1 The two 
complexes were hydroxypropyl-β-CD·valproic acid and sulfobutylether-β-CD·valproic acid, both 
with a 1:1 host-guest stoichiometry. The hydroxypropyl-β-CD·valproic acid inclusion complex 
displayed a 27-fold increase in the solubility of valproic acid, whereas the sulfobutylether-β-
CD·valproic acid inclusion complex yielded less satisfactory results and did not produce a significant 
solubility increase.1  
As a result, the author of this dissertation intended to synthesize co-crystals of valproic acid, as well 
as further investigate potential CD complexation with a variety of crystalline CD compounds and 
with a methodology that could potentially provide single crystals of the desired multi-component 
products for X-ray analysis.  
5.2) Co-crystal screening 
5.2.1) Virtual co-crystal screening 
The CSD2 contained no reported results for co-crystal or salt structures involving the title 
compound. As a result, it was not possible to investigate any hydrogen-bonded ring supramolecular 
synthons with the drug. However, since the structure of valproic acid is simple (there are no 
tautomers and the only functional group is a carboxylic acid), the drug can only form stable ring 
synthons with either another carboxylic acid functional group or an amide functional group. 
Consequently, a very general virtual co-crystal screening investigation was conducted using data 
from the CSD. This involved noting the frequency for the formation of ring synthons between two 
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carboxylic acid functional groups as well as between a carboxylic acid and an amide functional 
group (Figure 5.1). The hydrogen bond distances between the two oxygen atoms and between the 
oxygen and nitrogen atoms were pre-set to have a distance range of 2.5 – 3.2 Å. The results 
indicated that there was a higher frequency for the formation of a hydrogen bonded ring synthon 
between two carboxylic acid functional groups than between a carboxylic acid and amide functional 
group. Nevertheless, the selected 12 co-formers comprised mainly carboxylic acids, along with 







Figure 5.1: Hydrogen bonded ring synthons between two carboxylic acid functional groups (left)  
and between  a carboxylic acid and an amide functional group (right). The symbol X represents any atom.  
 
Table 5.1: The selected co-formers for co-crystallization screening experiments with valproic acid. 
Number Co-former 
1 Adipic acid 
2 Citric acid 
3 Glutaric acid 
4 Isonicotinamide 
5 Maleic acid 
6 Malic acid 
7 Nicotinamide 
8 Pimelic acid 
9 Piperazine 
10 Propionamide 
11 Pyroglutamic acid 






5.2.2) Co-precipitation  
The focus of the valproic acid investigation in this Master’s dissertation was primarily around the 
successful cyclodextrin (CD) inclusion complexation results. Therefore, the co-crystal screening 
experiments were few and incomplete since there was a limited supply of valproic acid. As a result, 
only one set of co-precipitation experiments was conducted with valproic acid (a liquid at ambient 
temperature), and no co-grinding experiments were performed. The co-precipitation experiments 
followed the method for slow evaporation as outlined in the Experimental Methods (Chapter 2) 
under section 2.2.4, pp. 18 – 19. These experiments were performed in an ethanol medium with 
the API and co-former present in an equimolar ratio. Five mg (0.03647 mmol; 5.434 μl) of valproic 
acid was used for each experiment. After approximately two weeks, these solutions concentrated 
into an oil, after which it took a further two months for either single crystals or a powdery residue 
to precipitate. The results were all the same for the individual experiments, namely that only the 
co-former had crystallized; however, more detail is supplied in the Appendix under section 8 (pp. 34 
– 35).  
5.3) Cyclodextrin inclusion  
5.3.1) Native cyclodextrin inclusion complexes  
The native CDs, which include α-CD, β-CD and -CD, formed authentic inclusion complexes with 
valproic acid. These complexes will be referred to as α-CD·VAL, β-CD·VAL and -CD·VAL. 
Furthermore, the β-CD·VAL and -CD·VAL complexes produced adequate single crystals for SCXRD 
analyses and structural characterisation. Each inclusion complex is described in detail below.  
5.3.1.1) The α-CD·VAL inclusion complex 
Method of preparation 
Preliminary preparation of the complex was based on a 1:1 stoichiometric ratio of α-CD and 
valproic acid. However, when crystals of the inclusion complex were subsequently analysed by 1H 
NMR spectroscopy (details below), they were found to have a 2:1 host-guest composition. Thus, the 
final method of reproducible preparation of the complex involved the latter ratio, as follows. A 
mass of 67.46 mg (0.06934 mmol) of α-CD was dissolved in 0.5 cm3 of water and the suspension 
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was heated to 70 oC while being stirred vigorously. Once the α-CD was fully dissolved, 5 mg 
(0.03467 mmol; 5.434 μl) of valproic acid was added dropwise to the vial containing the aqueous α-
CD solution. The valproic acid was added in minimal excess in order to ensure that all the α-CD had 
reacted. The resultant solution was stirred at 70 oC for 2 hours. Initially, when the valproic acid was 
added to the α-CD aqueous solution, it formed an oily immiscible layer on top of the aqueous 
surface. Within approximately twenty seconds, this oily layer had dissolved and the complex 
precipitated in the aqueous solution. Subsequently, the addition of a further 0.2 cm3 of water to 
the solution was necessary in order to allow the complex to fully dissolve at 70 oC. The solution was 
finally filtered and prepared for slow cooling. The crystals appeared after three days.  
Crystal morphology 
The resultant α-CD·VAL inclusion complex formed white, very fine, fibrous, whisker clusters, which 
readily trapped the mother liquor (Figure 5.2). Owing to the nature of the crystal size and 
morphology, a SCXRD analysis could not be performed; however, recrystallization from different 
solvents was executed in order to attempt to produce larger single crystals. Furthermore, the 
remaining characterisation could still be accomplished in spite of the adverse morphology and small 



















Figure 5.2: The morphology of the α-CD·VAL inclusion complex. 
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Attempts to obtain single crystal crystals of the α-CD·VAL complex via recrystallization 
Valproic acid appeared to have a strong affinity for the hydrophobic cavity of the α-CD molecule 
and thus readily displaced the water molecules from the cavity. This process was apparently very 
energy-favoured as the complex formed within 20 seconds. This rapid crystallization is what most 
likely gave rise to the poor crystalline quality. Consequently, a number of recrystallization attempts 
were performed, which included the use of water and a variety of organic solvents. Normally, it is 
not possible to use organic solvents in recrystallization experiments with CD inclusion complexes, as 
not only are most of them insoluble in organic solvents,3 but organic solvents also have a strong 
affinity for the hydrophobic cavity of the CD molecule, and thus the guest molecule may be 
displaced.4 However, with regard to the particular case of α-CD·VAL, there is a chance that the 
energy state of this inclusion complex could be lower than the resultant energy states of α-CD with 
various included organic solvents. Thus, the organic solvents that dissolve -CD, listed in increasing 
order of solubility, are propylene glycol, dimethyl sulfoxide (DMSO), pyridine, ethylene glycol and 
dimethylformamide (DMF).3 Propylene glycol was not used owing to its unavailability in the 
laboratory, and DMF was also not used due to the fact that α-CD is extremely soluble in it and thus 
it would take too long for single crystals to potentially form. In addition, DMF is also often used 
specifically to displace guest molecules from the CD cavity. The results from these recrystallization 
experiments in the four solvents (namely water, DMSO, ethylene glycol, pyridine), all had identical 
outcomes which were the same fine, fibrous, whisker clusters of crystals that were originally 
obtained. Unfortunately, achieving an improved crystalline morphology and larger crystallite size 
using these solvents was unsuccessful.   
1H NMR analysis of α-CD·VAL 
The 1H NMR solution-state spectral analysis of the α-CD·VAL inclusion complex, produced by co-
precipitation, indicated a 2:1 stoichiometry of α-CD to valproic acid. This experiment was 
performed at 298 K and with the complex crystals dissolved in DMSO-d6. The results are listed in 
Table 5.2 below, while the original 1H NMR spectrum can be viewed in the Appendix under section 





Table 5.2: The 1H NMR spectral analysis of α-CD·VAL.   
Assignment δ (ppm) 
 






2 x CH3 (valproic acid) 0.85-0.88 1.00* 6H 1.00 1 
4 x CH2 (valproic acid) 1.19-1.52 1.29 8H 1.03 1 
OH-6 (α-CD) 4.46-4.49 2.23 6H 2.23 2 
CH-1 (α-CD) 4.80-4.81 2.20 6H 2.20 2 
*reference integral  
Fourier Transform Infrared (FT-IR) spectroscopic analysis of α-CD·VAL  
The α-CD·VAL inclusion complex was also confirmed by a FT-IR analysis. A common portion of the 
FT-IR spectra of three species is shown in Figure 5.3, which highlights the region of importance for 
the confirmation of the identity of this inclusion complex. The full FT-IR spectra of the α-CD·VAL 
inclusion complex, α-CD and valproic acid can be viewed in the Appendix under section 9.1.2, p. 37. 
The comparison of the FT-IR spectra indicated the effect that complexation had on the carbonyl 
stretching frequency of the guest molecule, namely valproic acid. The FT-IR spectrum of the α-
CD·VAL inclusion complex followed a very similar trace in comparison to the FT-IR spectrum of α-
CD. This was partly as a result of a low mass ratio of the guest molecule in comparison to the host 
molecule.5 The C=O stretching frequency of valproic acid occurred at 1702 cm-1. However, for the α-
CD·VAL inclusion complex, the C=O stretching frequency of valproic acid was displaced to a higher 
value, measured at 1741 cm-1. This indicated that the extent of hydrogen bonding between the host 
molecule and the C=O group of valproic acid was less in the complex than the extent of the 














Figure 5.3: A portion of the FT-IR spectra of α-CD (red), valproic acid (blue) and α-CD·VAL (black).  
 
Powder X-ray Diffraction (PXRD) analysis of α-CD·VAL 
It is evident that the α-CD·VAL inclusion complex synthesized via co-precipitation corresponded to 
the α-CD·VAL inclusion complex produced by kneading, as depicted in Figure 5.4. The complex 
could be successfully formed by kneading α-CD and valproic acid in a 2:1 stoichiometry, with a small 
amount of water, for 30 minutes (Figure 5.4).  In addition, the PXRD patterns for the α-CD·VAL 
inclusion complexes (prepared by kneading and co-precipitation) appeared to correlate with an 
isostructural PXRD pattern for another α-CD inclusion complex that crystallized in the space group 
P1 (Figure 5.4).2,7 The isostructural complex is -cyclodextrin hemikis(2,2’-azodipyridine) hydrate 
clathrate (refcode QACCII) and it was the only α-CD inclusion complex that crystallized in P1 with 
the unit cell parameters of a = 13.699(1), b = 13.970(1), c = 15.772(1) Å, α = 93.18(<1)o, β = 
91.94(<1)o,  = 118.72(<1)o.2 The PXRD correlation of QACCII with α-CD·VAL is only approximate, as 
some of the peaks do coincide (for example at the 2θ-positions 6.0o and 19.5o. Furthermore, the 
overall profile of these PXRD patterns is very similar. However, since the guest molecule in QACCII is 
different, this may have resulted in the observed differences. As a result, provided this assumption 
is correct, α-CD·VAL (produced by kneading and co-precipitation) should have similar unit cell 
parameters to QACCII.7  
A-CD new
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Figure 5.4: The PXRD patterns of an isostructural α-CD inclusion complex that crystallizes in P1, as well as α-CD·VAL produced via 
co-precipitation (2:1) and kneading (2:1).
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Hot Stage Microscopy (HSM) analysis of α-CD·VAL 
The HSM analysis provided visual evidence for the thermal events that took place when the α-
CD·VAL inclusion complex was heated at a constant rate of 10 K.min-1 while immersed in silicone 
oil. The series of micrographs displayed below in Figure 5.5 (representing the thermal progression 
of the inclusion complex) indicates dehydration, the loss of crystallinity and the decomposition of 
the crystal. The initial photograph, Image 1, represents the original appearance of the crystal at 
28.4 oC. Image 2 indicates the first sign of dehydration at 58.0 oC, which reached a peak at 86.7 oC, 
as represented in Image 3. However, at 98.4 oC (Image 4) the onset of opacity commenced and the 
bubbling slowed down until it completely stopped at 180.0 oC, as depicted in Image 5. The bubbling 
was caused by the dehydration of the crystal; however, owing to the fibrous morphology of the 
crystal, a significant amount of surface water would have been trapped in between the crystal 
fibres. Consequently, it is difficult to conclude at which temperature the surface water stopped 
evolving and when only water from the crystal structure was being lost. However, it can be inferred 
that the water from the crystal structure was only released at a higher temperature, since it was 
hydrogen bonded in the crystal structure, and that possibly when the onset of opacity commenced, 
this water began to evolve. The onset of opacity was caused by the loss of crystallinity, which can 





















result from the loss of water from the crystal structure. Subsequently, the onset of decomposition 
commenced at 293.8 oC, as depicted in Image 6. The bubble that appears in that image remained 
from the loss of water. Decomposition bubbles evolved rapidly at 320.1 oC (Image 7) along with the 
expansion of the bubbles that were already present. Lastly, Image 8 depicts the total 
decomposition of the crystal with the absence of bubbling at 372.0 oC. Even though it appeared 
that the bubbling was continuing, these bubbles became frozen by a glassing effect of the silicone 
oil.   

















Image 1: The initial 




Image 2: The onset of 
bubbling occurred at 58.0 
o
C. 
Image 3: The bubbling reached 
a peak at 86.7 
o
C. 
Image 4: The onset of opacity 
commenced at 98.4 
o
C. In 
addition, the bubbling 
continued. 
Image 5: The bubbling 
completely stopped at 180.0 
o
C. 
In addition, the crystal became 
completely opaque. 
Image 6: The onset of 




Image 7: Vigorous, small, 
decomposition bubbles 
erupted at 320.1 
o
C. 
Image 8: The crystal was fully 






Thermal Gravimetric Analysis (TGA) of α-CD·VAL  
The TGA trace signified two distinctive mass losses for the α-CD·VAL inclusion complex which 
occurred over the temperature range 25.0 – 400.0 oC, as depicted in Figure 5.6. A mass loss of 10.4 
± 0.3 % is associated with the first thermal event which took place between 25.0 and 128.9 oC. This 
was attributed to the loss of water molecules from the hydrated α-CD·VAL inclusion complex. The 
loss of water molecules over this temperature range was confirmed by the HSM analysis, where at 
86.7 oC the bubbling had reached its peak and then began to slow down.  
The second thermal event took place between 271.7 oC and 369.6 oC and it was associated with a 
mass loss of 77.8 % for the decomposition of the anhydrous α-CD·VAL inclusion complex. In 
comparison to the HSM results, the loss of water occurred between 58.0 oC and 180.0 oC, while the 
decomposition process occurred between 293.8 and 372.0 oC. This indicated that the results did not 
correlate closely. This difference could possibly be due to the different conditions under which the 
sample is confined in the two sets of apparatus.  
Furthermore, the TGA analysis allowed the number of water molecules per CD molecule in the 
complex to be calculated. A 10.4  0.3 % (n = 2) mass loss of water for this inclusion complex is 
equivalent to 6.7  0.2 water molecules. This calculation can be viewed in the Appendix under 
section 9.1.3, p. 37. 
The TGA trace also indicated that the mass loss of the inclusion complex started immediately and it 
was fairly significant. Owing to the fibrous nature of the crystalline morphology, there would be a 
tendency for surface water to become trapped in between the fibrous needles. As a result, the 
immediate mass loss could be interpreted as the presence of surface water. However, this was 
unlikely, as the method that was used to remove the surface water involved spreading the sample 
over the surface of dry filter paper until the sample became a ‘dry’ powder. Consequently, this was 
the only method of removing the surface water from the material that gave reproducible and 
reasonable mass losses. Therefore, this process ensured that all the surface moisture was absorbed 
and that the immediate mass loss was in fact an inherent property of the α-CD·VAL inclusion 
complex. If this method of removing the surface water was not followed, a mass loss of 
approximately 40 % was recorded. Such behaviour is not characteristic of α-CD inclusion complexes 
and was thus a result of surface water. Consequently, it can be concluded that the water molecules 
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were weakly bound in the crystal structure and thus a mass loss is immediately observed in the TGA 
trace.    
 
Figure 5.6: The representative TGA trace of α-CD·VAL (n = 2). 
 
Differential Scanning Calorimetry (DSC) analysis of α-CD·VAL  
The DSC trace of α-CD·VAL (n = 2) displayed three significant endothermic events (Figure 5.7). The 
first endotherm is complex and contains a shoulder, while the latter two are single endothermic 
events. All of these thermal events were measured over the temperature range 20.0 – 240.0 oC and 
represent the loss of water in a stepwise manner. The onset of the first broad endotherm was at 
21.0 oC with the peak occurring at 61.6 ± 1.8 oC. Furthermore, the gradient of this initial complex 
endotherm significantly changed between the temperature ranges 21.0 – 45.5 oC ± 0.7 oC and 45.5 
oC – 61.6 ± 1.8 oC. This possibly indicated that the rate of water loss increased with a steeper 
decreasing gradient. In addition, the onset of the shoulder endotherm occurred at 81.1 oC ± 0.9 oC 
and possibly indicated a sudden release of water from another region in the crystals. The two 
subsequent endothermic peaks in the DSC trace represented smaller losses in water and the onsets 
were 120.9 ± 0.5 oC (peak endotherm at 133.8 ± 0.1 oC) and 155.9 ± 0.3oC (peak endotherm at 161.5 
± 0.1 oC). These additional endothermic events characterised the stepwise water loss from the 
























These endothermic events were evident in both the HSM and TGA results. With regard to the HSM 
analysis, the loss of water occurred through bubbling in the temperature range 58.0 oC – 180.0 oC.  
In addition, with reference to the TGA results the water loss occurred between 25.0 and 128.9 oC. 
Even though these temperatures did not correlate exactly between the various experiments, the 
trend is very evident and confirmed the loss of water with the DSC trace, further indicating that the 
water loss was a stepwise process.  
 
Figure 5.7: A representative DSC trace of α-CD·VAL (n = 2). 
 
In conclusion, it is evident that a hydrated CD complex, with the formula (α-CD)2·VAL·6.7H2O, was 
formed between α-CD and valproic acid. Even though it was not possible to obtain a crystal 




























5.3.1.2) The β-CD·VAL inclusion complex 
Method of preparation 
The β-CD·VAL inclusion complex was synthesized in a 1:1 stoichiometric ratio as confirmed by a 1H 
NMR analysis (which is described in detail below). The method of preparation was very similar to 
that outlined for the α-CD·VAL inclusion complex, except that the mass of β-CD, the volume of 
water and the time taken to produce this inclusion complex were specifically adapted.  Thus, a mass 
of 39.35 mg (0.03467 mmol) of β-CD was dissolved in 2.2 cm3 of water at 70 oC and the resultant 
aqueous solution was thereafter stirred for 6 hours. The oily immiscible layer that valproic acid 
formed on top of the solution (as described for the α-CD·VAL experiment), took about an hour to 
dissolve into the aqueous medium. The appearance of crystals was observed after three days. 
Crystal morphology of β-CD·VAL 
The β-CD·VAL inclusion complex formed transparent crystals with a rhombic-shaped crystalline 
morphology and the entire sample of crystals analysed contained equally sized specimens, as 
represented in Figure 5.8. Furthermore, the quality of these crystals was adequate for a SCXRD 
analysis to be performed, and as a result a full structural characterisation was achieved.  
 








1H NMR analysis of β-CD·VAL 
The results from the 1H NMR solution-state spectral analysis of the complex crystals dissolved in 
DMSO-d6 at 298 K confirmed an equimolar stoichiometry of β-CD to valproic acid. The results are 
listed in Table 5.3 below, while the original 1H NMR spectra can be viewed in the Appendix under 
section 9.2.1, p. 38.   
Table 5.3: The 1H NMR analysis of β-CD·VAL. 






2 x CH3 (valproic acid) 0.85-0.88 1.00* 6H 1.00 1 
4 x CH2 (valproic acid) 1.21-1.53 1.36 8H 1.02 1 
OH-6 (-CD) 4.42-4.44 1.26 7H 1.08 1 
CH-1 (-CD) 4.83-4.84 1.25 7H 1.07 1 
*reference integral 
 
Fourier Transform Infrared (FT-IR) spectroscopic analysis of β-CD·VAL 
The FT-IR analysis also confirmed the formation of the β-CD·VAL inclusion complex and a portion of 
the FT-IR spectrum is given in Figure 5.9, which emphasises the important region for analysis. As 
mentioned previously, the C=O stretching frequency of valproic acid occurs at 1702 cm-1. However, 
for the β-CD·VAL inclusion complex, the C=O stretching vibration of valproic acid was present at 
1704 cm-1, representing a negligible shift upon complexation. This suggests that the extent of 
hydrogen bonding between the host molecule and the C=O group of valproic was nearly the same, 
if not slightly less, in the complex as compared with the extent of the intermolecular hydrogen 
bonding within pure valproic acid.6 The full FT-IR spectrum can be viewed in the Appendix under 























Powder X-ray Diffraction Pattern (PXRD) analysis of β-CD·VAL 
In addition, the successful synthesis of the β-CD·VAL inclusion complex (formed via co-
precipitation) was also confirmed by the correlation of its PXRD pattern with the isostructural PXRD 
pattern for β-CD inclusion complexes that crystallize in the space group C2 (Figure 5.10).7 This space 
group identification from PXRD was vindicated by the subsequent single crystal X-ray analysis, as 
described below. Furthermore, it was possible to synthesize the same β-CD·VAL inclusion complex 
Figure 5.9: A portion of the FT-IR spectra of β-CD (red), valproic acid (blue) and β-CD·VAL (black). 
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via kneading the reagents for 30 minutes in an equimolar stoichiometry with a small amount of 




Hot Stage Microscopy (HSM) analysis of β-CD·VAL 
The simultaneous HSM analysis of the β-CD·VAL inclusion complex and β-CD conveyed visual 
evidence for thermal events that took place when the crystals of these two species were immersed 
in silicone oil and heated at a constant rate of 10 K.min-1. The series of micrographs (Figure 5.11) 
represents the thermal progression of both crystals. The initial micrograph, Image 1, was recorded 
at 21.0 oC to depict the features of the β-CD·VAL inclusion complex (left) and the β-CD crystals 
(right) prior to heating. The first sign of bubbling occurred at the top right-hand corner of β-CD at 
96.4 oC (Image 2) while no change was observed for the inclusion complex. The β-CD·VAL inclusion 
complex only began to bubble at 256.3 oC as displayed in Image 3. This bubbling process was very 
slow, as only one bubble was released periodically. This process lasted for a further 16 oC until the 
onset of decomposition commenced at 267.8 oC for the β-CD·VAL inclusion complex, as depicted in 
















inclusion complex C2 
β-CD·VAL (1:1) 
kneaded 
Figure 5.10: The PXRD patterns of β-CD·VAL produced via co-precipitation (1:1) and kneading (1:1), and that of an isostructural 





Image 4. However, at 317.2 oC (Image 5) the onset of decomposition of -CD began, while the β-
CD·VAL inclusion complex was vigorously decomposing and producing decomposition bubbles. 
Finally, both crystals were completely decomposed, with decomposition bubbles, at 351.1 oC, as 
depicted in Image 6. 
 












of β-CD·VAL (left) and β-CD 
(right). 
Image 2: Very slight bubbling 
occurred at the top right of β-CD 
(right) at 96.4 
o
C. No change was 
observed for β-CD·VAL (left). 
Image 3: β-CD·VAL (left) began to 
bubble very slowly at 256.3 
o
C. β-CD 
(right) remained unchanged. 
Image 4: The onset of decomposition 
decomposition at 267.8 
o
C for β-
CD·VAL (left). β-CD (right) remained 
unchanged. 
Image 5: The onset of decomposition 
for β-CD (right) at 317.2 
o
C. Vigorous 
decomposition of β-CD·VAL (left). 
Image 6: Both β-CD·VAL (left) and β-
CD (right) are fully decomposed at 
351.1 
o




Thermal Gravimetric Analysis (TGA) of β-CD·VAL 
The TGA trace of the β-CD·VAL inclusion complex (n = 2) also indicated two distinct mass losses (as 
described for the α-CD·VAL inclusion complex), which occurred over the temperature range 16.7 – 
400.0 oC, as depicted in Figure 5.12. A mass loss of 11.5 ± 1.0 % was associated with the first 
thermal event which occurred between 16.7 oC and 128.6 oC. This mass loss was also attributed to 
the loss of water molecules from the β-CD·VAL inclusion complex. In addition, the second thermal 
event took place between 258.7 and 366.3 oC and was associated with a mass loss of 73.8 % which 
represented the decomposition of the anhydrous β-CD·VAL inclusion complex. In comparison with 
the HSM analysis, which showed no water loss, dehydration was evident from the TGA analysis. 
However, the onset of decomposition occurred at 267.8 oC in the HSM analysis, which correlated to 
some extent with the onset temperature of decomposition as reported in the TGA trace.  
The mass percentage of water loss was 11.5  1.0 % (n = 2) which is equivalent to 9.2  0.8 water 
molecules per complex unit. This calculation can be viewed in the Appendix under section 9.2.3, p. 
39. 
In the TGA trace there was a small plateau where a miniscule mass loss occurred and then the 
significant mass loss occurred. The method for drying the β-CD·VAL crystals was simpler than that 
for the α-CD·VAL crystals (as mentioned above) and it also yielded reproducible results. The 
rhombus-shaped morphology of the β-CD·VAL crystals allowed the surface water to be removed 
when they were pressed and gently rubbed between two dry filter papers. Furthermore, another 
experiment also ensured that no internal water was lost. A cluster of crystals was dried on filter 
paper and subsequently ground in a mortar. The resultant crystalline powder was used for a TGA 
experiment and the results indicated the same mass loss as when the material was dried using the 
first procedure. Even though this is considered an unconventional practice, it supported the 




Figure 5.12: Representative TGA trace of the β-CD·VAL inclusion complex (n = 2). 
 
Differential Scanning Calorimetry (DSC) analysis of β-CD·VAL 
The DSC trace of the β-CD·VAL inclusion complex also indicated a stepwise loss of water, but to a 
lesser extent than the α-CD·VAL inclusion complex, as observed in Figure 5.13. The trace is 
characterised by a very broad endothermic event where the onset occurred at 65.2 oC, with the 
peak occurring at 67.9 oC. This endotherm is reflected in the TGA trace where the majority of the 
mass loss, attributed to water, takes place in the temperature range 25.0 – 54.0 oC. The onset of 
the subsequent, very small endothermic peaks in the DSC trace occurred at 65.5 oC (peaking at 67.9 
oC) and 118.0 oC (peaking at 120.0 oC) and represented smaller, stepwise losses of water, which are 
attributed to different binding strengths of water molecules from different environments in the 
crystal. These events are relatively too small to be noticed as individual steps in the TGA 
experiment, and thus once again, in the TGA trace they blurred as a general mass loss over the 

































Figure 5.13: DSC trace of β-CD·VAL. 
 
Single Crystal X-ray Diffraction (SCXRD) analysis 
Data-collection and space group determination    
The intensity data from a single, block-shaped crystal were collected at 173 K. The Laue group of 
the intensity-weighted reciprocal lattice was 2/m which indicated the monoclinic system. The 
lattice type was determined to be C-centred (condition 1 in Table 5.4) which, together with the 
remaining conditions indicated the possible space groups C2, Cm and C2/m. However, since CD 
molecules are chiral, the only possible space group is C2. This assignment, previously predicted 
above based on the PXRD method, was confirmed by the program XPREP.8  
Table 5.4: The conditions limiting possible reflections for the crystal of -CD·VAL. 
Number Conditions limiting possible reflections Deduction 
1 hkl: h+k = 2n C-centred 
2 [h0l: (h = 2n, redundant condition)] - 


















Structure solution and refinement 
The method of isomorphous replacement was used to solve the structure of the -CD·VAL inclusion 
complex. This was achieved by using the co-ordinates of a different -CD inclusion complex that 
had matching unit cell parameters. The methodology for isomorphous replacement is described in 
the Experimental Methods (Chapter 2) under section 2.5, p. 21. However, eventual failure to locate 
the guest molecule using the data collected at 173 K led to a decision to record the intensity data at 
100 K from a fresh crystal as a possible remedy, and the final analysis was based on these data. The 
host ‘skeleton’ (which consisted of seven glucose residues minus the conformationally flexible 
primary hydroxyl oxygen atoms) was imported from the CSD and was used as the trial model. It was 
refined with SHELXH-97,9 initially isotropically and subsequently anisotropically. From the 
subsequent difference electron density () map it was evident that five hydroxyl oxygen atoms at 
the C6 positions were disordered over two positions and were treated accordingly. The treatment 
involved assigning site-occupancies of x and 1-x to the major and minor disorder components of 
each disordered pair, with x treated as a free variable,  while the bond lengths C6-O6 and C6-O7 
were constrained to 1.40 Å with σ = 0.01 Å by means of a DFIX restraint. The major components of 
the disordered oxygen atoms, which included O6A1, O6A2, O6A4, O6A5 and O6A6, had site-
occupancy factors (s.o.f.s) of 0.85(2), 0.79(2), 0.54(3), 0.66(3) and 0.82(2) respectively after 
refinement. These disordered atoms were only refined isotropically. Furthermore, the hydrogen 
atoms were placed in idealised positions on the host molecule using the ‘maximum electron 
density’ model and an isotropic temperature factor of 1.2 times the value of the Uiso of its parent 
atom was assigned to each hydrogen atom. It was evident from inspection of subsequent  maps 
that the guest molecule was so severely disordered that it could not be located, the highest value of 









Table 5.5: The crystal data and refinement parameters for the -CD·VAL inclusion complex. 
Parameter Value 




Temperature (K) 100(2) 
Wavelength (Å) 0.71073 
Crystal system Monoclinic 
Space group C2 






















F (000) 3632 
Crystal size (mm) 0.120 x 0.150 x 0.270 
-Range scanned (
o
) 2.25 - 21.65
 
Index range h: -24, 24; k: -31, 31; l: -20, 20 
No. of reflections collected 29021 
No. of unique reflections 15385 
Data completeness (%) 98.6 
Data/restraints/parameters 15385/19/808 
S (Goodness-of-fit on F
2
) 1.118 
Final R indices R1, wR2,  [I > 2σ(I)] 0.0995, 0.2735 
R Indices, all data (R1, wR2) 0.1317, 0.3040 
Largest diff. peak and hole (e. Å
-3
) 1.27, -0.44 
 
The oxygen atoms of the water molecules were identified through the method that is described in 
the Experimental Methods (Chapter 2) under section 2.5, p. 21. Initially, the water molecules O1W, 
O3W and O4W were identified as having full site-occupancy, based on the large sizes of their 
difference electron density peaks, while O2W had a site-occupancy of 0.5, being located on the 
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twofold axis. In addition, these four water oxygen atoms were all refined anisotropically. The 
remaining disordered water molecules were placed systematically in a decreasing order of their 
difference electron density peaks. Initially, the thermal parameter (Uiso ) of the disordered water 
molecules was fixed at 0.061 Å2 (which was the average Uiso value for water molecules O1W - O4W) 
and their s.o.f.s were allowed to vary. When their values converged, the Uiso values of the water 
molecules were allowed to vary; however, a few water molecules still displayed high Uiso values and 
thus the latter were constrained. After consecutive refinements, O3W was subsequently discovered 
to be disordered over two sites and the two components were assigned partial site-occupancies 
and were refined isotropically. The refined values for the Uiso parameters, as well as the s.o.f.s for 
the water oxygen atoms, are displayed in Table 5.6. The number of water molecules per -CD 
molecule in the crystal structure model was 9.8, which was in close agreement with the TGA results 
which yielded a calculated value of 9.2 ± 0.8 water molecules per -CD complex unit.  
 
Table 5.6: The total number of water oxygen sites that were identified, with their respective s.o.f. 
and Uiso values.  
Atom s.o.f. Uiso (Å
2
) Atom s.o.f. Uiso (Å
2
) Atom s.o.f. Uiso (Å
2
) 
O1W 1.00 0.043(1) O9W 0.49(5) 0.11(1) O17W 0.36(4) 0.12(2) 
O2W 0.50 0.052(2) O10W 0.22(4) 0.05(1) O18W 0.36(5) 0.09(1) 
O3W 0.68(5) 0.044(4) O11W 0.40(3) 0.083(9) O19W 0.53(6) 0.14(1) 
O4W 1.00 0.069(2) O12W 0.18(3) 0.10(2) O20W 0.51(6) 0.13(1) 
O5W 0.36(4) 0.045(7) O13W 0.28(3) 0.08(1) O21W 0.39(5) 0.07(9) 
O6W 0.40(3) 0.045(6) O14W 0.22(2) 10.061* O22W 0.12(2) 10.061* 
O7W 0.32(4) 0.12(1) O15W 0.59(5) 0.13(1) O23W 0.53(5) 0.11(1) 
O8W 0.20(3) 10.061* O16W 0.13(2) 10.061*  










The asymmetric unit (ASU) of the -CD·VAL complex, displayed in Figure 5.14, consists of one -CD 
molecule, one valproic acid molecule (not located in the difference electron density map) and 9.8 
water molecules distributed over 23 sites. All the water molecules were within a permitted 
hydrogen bonding distance range of either the host molecule or neighbouring water oxygen atoms, 




Figure 5.14: The β-CD molecule and water molecule sites of β-CD·VAL.  
 
Unfortunately, the guest molecule could not be observed even though the data were collected at 
the lower temperature of 100(2) K, and as a result there appears to be a large discrepancy between 
the calculated and reported molecular mass of the complex in the checkCIF report (in the Electronic 
Supplementary Information) based on the final refinement. Figure 5.15 displays a stereo diagram of 
the -CD molecule and the water molecule sites. It is evident that the residual electron density did 
not resemble any relative positions that could correspond to the guest molecule, and as a result it 














The dimer of the β-CD·VAL inclusion complex has C2-symmetry and the dimeric structure is 
maintained by intermolecular O-HO hydrogen bonds that link the secondary rims of the β-CD 
molecules. This inclusion complex adopts a channel-type packing where the β-CD molecules stack 
themselves as dimeric units along the z-direction (Figure 5.16). This arrangement occurs in all other 
isostructural β-CD inclusion complexes that belong to the space group C2.7,10 In addition, the 
dimeric stacking arrangement of the β-CD molecules contains a small degree of lateral shifting 
between the tail-to-tail β-CD molecules of adjacent dimers. Lastly, the columns created by the 
stacked dimeric units are held together by intermolecular hydrogen bonding mediated by water 
molecules. The host cavities within each column form an infinitely long channel, in which the guest 
molecules are accommodated in a disordered fashion. As a result, the electron density of the guest 
molecule is diluted and it is thus not possible to locate it. This is a very common feature of many -




Figure 5.15: A stereoview of the host molecule highlighting the ‘empty’ cavity 

















A stereoview of the channels down the c-axis is displayed in Figure 5.17 which indicates that there 











Figure 5.16: The channel-packing arrangement along the z-direction. The β-CD molecules stack 
themselves in dimeric units, as displayed in the example of the two β-CD molecules in the unit cell. 





Host-host hydrogen bonding 
The hydroxyl groups on the secondary rim of β-CD molecules generally form hydrogen bonds of a 
‘flip-flop’ nature.11 These intramolecular hydrogen bonds can alternate between O2-HO3 and O3-
HO2. The β-CD·VAL crystal structure displays a belt of O2-HO3 intramolecular hydrogen bonds, 
which reinforces the heptagonal geometry and generally ‘round’ shape of the host molecule (Figure 
5.18). Intermolecular hydrogen bonding was also observed at the interface of the secondary rims 
between the O3-H hydroxyl groups of the one molecule and the O3-H or O2-H groups of the 








Table 5.7 displays the intramolecular and intermolecular hydrogen bonding parameters for the host 
molecules. It is evident that the intermolecular hydrogen bonds are strong and as a result this 
implies that the crystal structure is stable. The C-HO hydrogen bonds that involved CO distances 
larger than 3.00 Å were omitted owing to their relatively weak contribution in comparison to the 






Figure 5.18:  The intermolecular and intramolecular hydrogen bonding 






Table 5.7: The parameters for the hydrogen bond interactions in β-CD·VAL. 
Interaction type Hydrogen bond D-H (Å) HA (Å) DA (Å) D-HA (
o
) Symmetry Code 
O2-HO3 Hydrogen bonds 
Intramolecular O2A1-H2A2O3A7 0.84 2.12 2.767(8) 134 x, y, z 
Intramolecular O2A2-H2A3O3A1 0.84 2.00 2.826(8) 168 x, y, z 
Intramolecular O2A3-H2A4O3A2 0.84 2.03 2.856(7) 168 x, y, z 
Intramolecular O2A4-H2A5O3A4 0.84 2.53 2.877(9) 106 x, y, z 
Intermolecular O2A4-H2A5O3A4
 0.84 2.39 3.141(8) 149 1-x, y, 1-z 
Intramolecular O2A5-H2A6O3A4 0.84 2.07 2.81(1) 147 x, y, z 
Intramolecular O2A6-H2A8O3A5 0.84 2.11 2.857(8) 148 x, y, z 
Intramolecular O2A7-H2A7O3A6 0.84 1.96 2.783(7) 166 x, y, z 
O2-HO4 Hydrogen bonds 
Intramolecular O2A7-H2A7O4A6 0.84 2.40 2.821(6) 112 x, y, z 
Intramolecular O2A1-H2A2O4A7 0.84 2.46 2.762(7) 103 x, y, z 
Intramolecular O2A2-H2A3O4A1 0.84 2.38 2.799(9) 112 x, y, z 
Intramolecular O2A3-H2A4O4A2 0.84 2.35 2.775(8) 112 x, y, z 
Intramolecular O2A5-H2A6O4A4 0.84 2.48 2.789(9) 103 x, y, z 
Intramolecular O2A6-H2A8O4A5 0.84 2.46 2.80(1) 105 x, y, z 
O3-HO2 and O3-HO3 Hydrogen bonds 
Intramolecular O3A1-H3A2O2A1 0.84 2.57 2.879(8) 103 x, y, z 
Intermolecular O3A1-H3A2O3A7
 0.84 1.95 2.787(7) 170 1-x, y, 1-z 
Intermolecular O3A2-H3A3O3A6
 0.84 2.02 2.845(8) 168 1-x, y, 1-z 
Intermolecular O3A3-H3A9O3A5
 0.84 1.93 2.734(8) 160 1-x, y, 1-z 
Intramolecular O3A2-H3A3O2A2 0.84 2.59 2.899(7) 103 x, y, z 
O6-HO5 and O6-HO6 Hydrogen bonds 
Intermolecular O6A3-H1O5A1
 0.84 2.57 3.327(7) 151 ½-x, -½+y, -z 
Intermolecular O6A7-H2O6A3
 0.84 2.09 2.861(8) 152 ½+x, ½+y, z 
Intramolecular O6A2-H4O5A2 0.84 2.43 2.83(1) 109 x, y, z 
Intramolecular O6A5-H6O5A5 0.84 2.26 2.69(2) 112 x, y, z 
Intramolecular O6A6-H6AYO5A6 0.84 2.15 2.57(3) 111 x, y, z 
C-HO Hydrogen bonds 
Intramolecular C4A7-H4A7O6A7 1.00 2.54 2.921(9) 102 x, y, z 
Intramolecular C5A1-H5A1O4A7 1.00 2.48 2.84(1) 100 x, y, z 
Intramolecular C5A2-H5A2O4A1 1.00 2.46 2.82(1) 100 x, y, z 
Intramolecular C4A4-H4A4O6A4 1.00 2.57 2.96(2) 103 x, y, z 





Hydrogen bonds involving water molecules 
The hydrogen bonding involving the water molecules includes water-water and water-host 
interactions. Table 5.8 summarises the interactions where the water molecules are hydrogen bond 
acceptors of either an O3 or an O6 hydroxyl group from the host molecule.   
 
Table 5.8: The parameters for the intermolecular interactions in β-CD·VAL where the water 
molecules are the hydrogen bond acceptors.  
Hydrogen bond 
interaction 
D-H (Å) HA (Å) DA (Å) D-HA (
o
) Symmetry code 
O6A3-H1O1W 0.84 2.34 2.743(7) 110 x, y, z 
O3A7-H3A7O20W
 0.84 2.10 2.72(4) 130 1-x, y, 1-z 
O3A5-H12O3W
 0.84 2.07 2.85(1) 156 ½+x, -½+y, z 
O3A5-H12O20W
 0.84 1.96 2.78(3) 163 ½+x, -½+y, z 
O3A4-H3A5O23W 0.84 2.03 2.86(2) 173 x, y, z  
O3A6-H3A8O10W 0.84 2.26 2.96(3) 140 ½+x, ½+y, z 
 
Host molecular geometry   
The geometrical parameters that define the conformation of the O4-heptagon for the host 
molecule are described in Table 5.9. These parameters have been described in detail in Chapter 1 
under section 1.4.3, pp. 6 – 8.  
In a regular heptagon all the lengths and angles should be equal; however, the values of l, D and  
are not equal and instead vary very slightly. This indicates that the O4-heptagon is distorted, which 
is expected for CD molecules in a crystalline state. Furthermore, the results indicate that the degree 
of planarity of the O4-heptagon is high, since the variation in the torsion angles (d) and the 
deviations () are very small. The D3 values range between 2.767(8) Å and 2.857(8) Å which is 
expected for OO distances for O-HO hydrogen bonds. The values of the tilt angles for the 
glucose residues are similar, with the exception of A3 and A7, which are tilted to a lesser extent 
towards the centre of the cavity of the β-CD molecule. The average tilt angle for the uncomplexed 
β-CD molecule is 14(10)o and as a result it is noticeable that the tilt angles for β-CD·VAL are within 
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this range.12 Consequently, it is not apparent that any additional distortion occurred on host-guest 
complexation. 
Table 5.9: The geometrical parameters of the host molecule in the complex β-CD·VAL. 




A1 5.003 4.375 129.4 2.2 -0.030 2.767(8) 11.1 
A2 5.167 4.300 125.8 -0.5 0.043 2.826(8) 13.0 
A3 5.015 4.460 129.6 -0.3 -0.012 2.856(7) 8.5 
A4 4.956 4.338 130.1 -0.4 -0.017 2.805(9) 11.8 
A5 5.086 4.391 127.8 0.5 0.005 2.81(1) 12.0 
A6 5.118 4.311 127.0 1.2 0.020 2.857(8) 11.0 
A7 4.963 4.467 130.4 -2.7 -0.009 2.783(7) 5.1 
a 
mean esd: 0.004 Å; 
b




The PXRD pattern of -CD·VAL produced via co-precipitation is in reasonable correspondence with 
the calculated PXRD pattern from the single crystal X-ray structure (Figure 5.19). This indicates that 
the latter model is a reasonable representation of the bulk material. Discrepancies in the relative 
intensities of corresponding peaks are attributed to preferred orientation in the experimental 
sample.   
 
Figure 5.19: The PXRD pattern calculated from a single crystal X-ray structure of β-CD·VAL and the PXRD pattern of β-CD·VAL 
prepared via co-precipitation. 


















5.3.1.3) The -CD·VAL inclusion complex 
Method of preparation  
The initial preparation of the -CD·VAL inclusion complex involved an equimolar ratio of valproic 
acid and -CD. However, a 1H NMR analysis confirmed that the stoichiometric ratio was 4:3 (-CD : 
valproic acid) and as a result, this stoichiometric ratio was used to reproduce the -CD·VAL inclusion 
complex in all the subsequent experiments. Once again, the method of preparation followed the 
same procedure as described for the α-CD·VAL inclusion complex, where the mass of -CD, the 
volume of water and time taken to perform the synthesis were specifically tailored. Consequently, a 
mass of 59.96 mg (0.04623 mmol) of -CD was initially dissolved in 2 cm3 of water at 70 C and the 
resultant aqueous solution was stirred for 6 hours. The requisite amount of valproic acid added to 
this solution formed an oily immiscible layer on the surface and also coated the sides of the vial (as 
described in detail for the α-CD·VAL inclusion complex) eventually dissolving after a few hours. The 
crystals appeared after three days.  
Crystal morphology  
The -CD·VAL inclusion complex consisted of transparent rectangular-shaped crystals (Figure 5.20).  
These crystals were elongated, unlike the equant crystals of the β-CD·VAL inclusion complex.   
 
Figure 5.20: The crystal morphology of the -CD·VAL inclusion complex.
 
 
1H NMR analysis of -CD·VAL 
The 1H NMR solution-state spectral analysis for the -CD·VAL inclusion complex indicated a 4:3 
stoichiometry of -CD to valproic acid. This particular stoichiometric ratio is not uncommon for CD 
inclusion complexes.13 The results are listed in Table 5.10 below and the original 1H NMR spectra 
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can be viewed in the Appendix under section 9.3.1, p. 40. This experiment was performed at 298 K 
using the solvent DMSO-d6. 
Table 5.10: The 1H NMR analysis of -CD·VAL. 






2 x CH3 (valproic acid) 0.84-0.88 1.00* 6H 1.00 3 
4 x CH2 (valproic acid) 1.21-1.52 1.40 8H 1.05 3 
OH-6 (-CD) 4.49-4.52 1.02 8H 1.31 4 
CH-1 (-CD) 4.89-4.90 1.01 8H 1.32 4 
*reference integral  
 
Fourier Transform Infrared (FT-IR) spectroscopic analysis of -CD·VAL 
Similarly, as with the previous CD inclusion complex analyses, the FT-IR analysis also confirmed the 
formation of the -CD·VAL inclusion complex. The C=O stretching frequency of uncomplexed 
valproic acid occurs at 1702 cm-1 and in the case of the -CD·VAL inclusion complex, the same 
frequency was observed (Figure 5.21). This implies that the degree of hydrogen bonding between 
the host molecule and the C=O functional group of valproic acid remained the same in the complex, 
as compared with the extent of the intermolecular hydrogen bonding within pure valproic acid.6 It 
could be argued that the product is a physical mixture; however, the product material was 
confirmed to be a complex with PXRD analysis prior to the FT-IR analysis. The full FT-IR spectrum is 

















Powder X-ray Diffraction (PXRD) analysis of -CD·VAL 
The PXRD pattern for the -CD·VAL inclusion complex formed via co-precipitation correlated with 
the PXRD pattern for -CD inclusion complexes that crystallize in the tetragonal space group P4212.
7 
This can be observed in Figure 5.22 below. The same -CD·VAL inclusion complex could also be 
successfully synthesised via kneading the host and guest components in a 4:3 stoichiometry with a 
small amount of water for 30 minutes, as there was also a direct correlation with this PXRD pattern 
and the former PXRD patterns (Figure 5.22).   
Figure 5.21: A portion of the FT-IR spectra of -CD (red), valproic acid (blue) and -CD·VAL (black). 
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Figure 5.22: The PXRD patterns of an isostructural -CD inclusion complex that crystallizes in P4212, and the -CD·VAL inclusion 
complex produced via co-precipitation (4:3) and kneading (4:3).
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Hot Stage Microscopy (HSM) analysis for -CD·VAL 
Figure 5.23 displays a series of micrographs for the analysis of the complex crystals immersed in 
silicone oil and heated at 10 K.min-1. The first micrograph, Image 1, was recorded at 26.9 oC and 
depicts the features of the -CD·VAL inclusion complex crystal before heating. At 103.2 oC, (Image 2) 
the bubbling commenced slowly along with the onset of opacity. This indicates that the water lost 
through bubbling was water from the crystal structure, as the crystallinity simultaneously 
decreased as shown by the onset of opacity in the crystal. This image also suggests that there was 
no surface water on the crystal, since it became opaque with the first sign of bubbling, and thus is 
indicative of water loss only from the crystal structure. The bubbling reached a peak at 123.6 oC 
(Image 3) until it completely stopped at 153.7 oC (Image 4). Throughout both of these processes the 
opacity increased; however, full opacity was achieved at 199.6 oC as displayed in Image 5. In 
addition, the onset of decomposition occurred at 293.7 oC (Image 6) and decomposition bubbles 
were sighted at 305.7 oC (Image 7). The bubbling became vigorous at 333.9 oC (Image 8) until the 
crystal was fully decomposed at 375.7 oC, as depicted in Image 9. 
 
 







































Thermal Gravimetric Analysis (TGA) of -CD·VAL  
The TGA trace signified two distinct mass losses for the -CD·VAL inclusion complex which occurred 
over the temperature range 21.7 – 400.0 oC, as depicted in Figure 5.24. A mass loss of 16.4 ± 0.6 % 
(n = 3) was associated with the first thermal event, which took place between 21.7 and 112.3 oC. 
This initial mass loss was attributed to the loss of water molecules from the -CD·VAL inclusion 
complex. The second thermal event took place between 265.3 and 375.8 oC and was associated 
Image 1: The initial 




Image 2: At 103.2 
o
C the 
first appearance of 
bubbling, as well as the 
onset of opacity, occurred. 
Image 3: The most 
vigorous bubbling 
occurred at 123.6 
o
C. 
Image 4: The bubbling 




Image 5: Full opacity 
occurred at 199.6 
o
C. 
Image 6: The onset of 




Image 7:  Decomposition 
bubbles appeared at 305.7 
o
C. 





Image 9: At 375.7 
o
C the 




with a mass loss of 71.4 %, which represented the decomposition of the anhydrous -CD·VAL 
inclusion complex.  
In comparison, the loss of water only occurred between 103.2 and 153.7 oC in the HSM analysis, 
and thus it is evident that these results did not correlate. Furthermore, the onset of decomposition 
in the HSM analysis (which was at 293.7 oC) also did not correlate with the onset of decomposition 
in the TGA trace at 265.3 oC.  
The number of water molecules calculated to be present in the -CD·VAL inclusion complex was 
15.3 ± 0.6 as this corresponded to a water mass loss of 16.4 ± 0.6 % (n = 3). The calculation can be 
viewed in the Appendix under section 9.3.3, p. 41. 
In addition, the loss of water also occurred instantaneously after the experiment commenced, as 
with the α-CD·VAL inclusion complex. The method for drying the -CD·VAL inclusion complex 
crystals followed the same procedure as for the β-CD·VAL inclusion complex, since the overall 
morphology was similar. Once again this method revealed expected reproducible results and the 
immediate loss of water is thus a characteristic of the -CD·VAL inclusion complex. 
 



























Differential Scanning Calorimetry (DSC) analysis of -CD·VAL 
The DSC trace of -CD·VAL (n = 2) displayed a single endothermic peak with onset at 21.0 oC, while 
the peak occurred at 82.8 ± 0.1 oC (Figure 5.25). Unlike the DSC traces of α-CD·VAL and β-CD·VAL, 
that of -CD·VAL indicated the loss of water to be a single event. This is further confirmed by the 
TGA and HSM analyses. Firstly, in the TGA analysis, there was a single mass loss for dehydration 
between 21.7 and 112.3 oC, and this correlated well with that of the DSC analysis. Secondly, with 
reference to the HSM analysis, a single event of bubbling was observed. This was attributed to the 
loss of water which occurred between 103.2 and 153.7 oC. The temperature correlations between 
the HSM and DSC experiments were not precise; however, this tendency is often expected.  
 
 

































Single Crystal X-ray Diffraction (SCXRD) analysis 
Data-collection and space group determination  
The PXRD analysis of the complex had indicated the tetragonal space group P4212, and -CD 
complex crystals crystallizing in this space group generally have unit cell dimensions a ~ 23.8 Å, c ~ 
23.1 Å. However, careful determination of the unit cell of the -CD·VAL complex at the chosen data-
collection temperature of 173(2) K yielded a = 23.702(1) Å, c = 45.934(6) Å, i.e. a unit cell with a c-
axis length that is approximately double that usually observed.  This phenomenon is known to occur 
occasionally when a crystal is cooled to low temperatures. However, low-temperature data-
collection was pursued, since this has potential for revealing the guest molecule in -CD complex 
structures.  The intensity-weighted reciprocal lattice indicated that the Laue group was 4/mmm, 
confirming the tetragonal system previously deduced from the PXRD analysis described above.  
Likewise, the space group P4212, also deduced from the PXRD analysis, was confirmed from the 
conditions limiting possible reflections, as listed in Table 5.11. Even though this space group is 
extremely rare, it is the one which characterises the most common crystal packing arrangement of 
-CD inclusion complexes.14  
 
Table 5.11: The conditions limiting possible reflections for the crystal of -CD·VAL. 
Number Conditions limiting possible reflections Deduction 
1 hkl: none Primitive lattice 
2 h00: h = 2n, (0k0: k = 2n) Twofold screw axis parallel to the a-axis (and to the b-axis, 
which is identical to the a-axis by symmetry) 
3 00l: none - 
 
Structure solution and refinement 
The intensity-weighted reciprocal lattice was inspected and it was found that there was an 
alternation of high and low intensity reflections with increasing l-index (Figure 5.26). This indicated 
the presence of a pseudo-translation of c*/2 implying that the contents of the unit cell from z = 0 to 
½ was not identical to that in the interval z = ½ to 1, the differences between them resulting in the 
very weak intensities in the layers with l = 2n+1. However, this also indicated that a trial model for 
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the structure could be constructed by repeating the structural model contained within the interval z 










The method of isomorphous replacement was employed to obtain the trial model for the -CD·VAL 
inclusion complex. However, owing to the fact that the c-axis had doubled in length relative to the 
typical value, additional manipulation of the host atomic co-ordinates of a known -CD complex 
with a conventional unit cell was necessary to generate a trial model for the new complex. Thus, a 
-CD inclusion complex that crystallized in the same space group and had very similar unit cell 
parameters was selected as a template from the CSD. The co-ordinates of the asymmetric unit 
(ASU) of the template inclusion complex were placed in the .ins file of -CD·VAL. However,  in order 
to account for the approximately doubled c-axis length of the -CD·VAL complex, (a) the full unit cell 
content was generated by adding a duplicate set of co-ordinates with a translation of 0.5 added to 
each of their z-co-ordinates, and (b) the z-co-ordinates of all atoms were finally scaled by the factor 
c/c′, where c is the length of the unique axis of the -CD·VAL complex and c′ that of the template 
structure. The trial (ASU) thus generated is displayed in Figure 5.27 below. It consisted of six pairs of 
glucose rings. Operation of the fourfold rotational symmetry parallel to the c-axis generates six 




Figure 5.26: The intensity-weighted reciprocal lattice images indicating the alternating high and low intensity reflections in 










The trial structure was refined isotropically with SHELXL-97,9 resulting in reasonable thermal 
parameters for the majority of the atoms. However, attempts to refine the host atoms 
anisotropically in a stepwise manner failed, as indicated by ‘non-positive definite’ warnings and 
reversion to isotropic modelling followed in such cases. The hydrogen atoms were placed in 
idealised positions with Uiso values 1.2 times those of their parent atoms. Owing to the fourfold 
rotational symmetry axis running through the centre of the cavity of each CD molecule, it was not 
possible to locate the guest molecule (a typical situation with -CD complexes). There were only six 
difference electron density peaks (max = 1.0 e.Å
-3) that could be attributed to the guest molecule 
within the continuous channel formed by the six -CD molecules. In addition, 45 sites of water 
oxygen atoms were observed in the ASU, of which the majority were partially occupied (Figure 
5.28). The number of water molecules present per -CD molecule was 16.3 which correlated with 
the TGA results indicating 15.3 ± 0.6 water molecules per -CD molecule. Figure 5.28 also displays 





















As expected, the R1-factor for the -CD·VAL inclusion complex model was abnormally high at a value 
of 24.0 %. This was expected since the model was incomplete and could not be improved any 














Figure 5.28: The presence of the water molecules which are all external to the 
channel of -CD·VAL. For simplicity, only the ASU is shown. Hydrogen atoms were 





Table 5.12: The crystal data and refinement parameters for the -CD·VAL inclusion complex. 
Parameter Value 




Temperature (K) 173(2) 
Wavelength (Å) 0.71073 
Crystal system Tetragonal 
Space group P4212 
a (Å) 23.7023(14) 




















F (000) 10812 
Crystal size (mm) 0.200 x 0.210 x 0.360 
-Range scanned (
o
) 2.47 – 24.16 
Index range h: -28, 23; k: -23, 27; l: -54, 54 
No. of reflections collected 106046 
No. of unique reflections 22964 
Data completeness (%) 99.9 
Data/restraints/parameters 22964/16/772 
S (Goodness-of-fit on F
2
) 2.866 
Final R indices R1, wR2,  [I > 2σ(I)]  0.2403, 0.6031  
R Indices, all data (R1, wR2) 0.2631, 0.6214 
Largest diff. peak and hole (e. Å
-3









The -CD·VAL inclusion complex structure contains six independent -CD molecules, namely A, B, C 
and A′, B′, C′ (Figure 5.29). This unusual crystallographic repeat unit consists of two sets of three 
molecules in the ASU, which arrange themselves as shown.14 In other words, a head-to-tail motif 
occurs between C and A, a tail-to-tail motif occurs between the molecular pair B and C, and lastly, a 
head-to-head motif occurs between the molecular pair A and B.14 This type of structural 
arrangement, involving, however, just three molecules (A, B, C) in the ASU, has been observed in all 

















Figure 5.29: The packing arrangement of the host molecules in the complex -CD·VAL which displays the 
unique crystallographic repeat unit, as well as the fourfold axis parallel to the c-axis.  
y 
z o 








Figure 5.30 displays a view down the c-axis of the channels in the unit cell in which the guest 
molecules are included, but not observed. The water molecules occupy the spaces between the 
columns and they are responsible for the adhesion of the columns via water-water and water-host        












PXRD analysis  
The PXRD pattern of -CD·VAL produced by co-precipitation correlated very well with the calculated 
PXRD pattern of -CD·VAL with regard to the 2θ values. However, the intensities are significantly 
different, an effect attributed to preferred orientation. This is further promoted by the columnar 
morphology of the tetragonal complex which would even be evident in finely ground samples. 
Nevertheless, it can be concluded that the single crystal selected for the analysis was 
representative of the bulk material (Figure 5.31).  
 
Figure 5.30: A stereoview of -CD·VAL viewed down the c-axis which 
displays the packing arrangement of each CD molecule. Water molecules 






Figure 5.31: The PXRD pattern calculated from a single crystal X-ray structure of -CD·VAL and the PXRD pattern of -CD·VAL 
prepared via co-precipitation. 
 
In conclusion, it is evident that the molecular formula for the -CD·VAL inclusion complex is (-
CD)·(VAL)0.75·15.3H2O. Even though the results from the X-ray analysis were very limited and the 
model was incomplete, the present study, based on sound analytical techniques, has amply 
demonstrated the successful synthesis of the -CD·VAL inclusion complex. 
   
 


















5.3.1.4) Solubility analysis of the native CD inclusion complexes with valproic acid 
An aqueous solubility investigation was performed for the α-CD·VAL, β-CD·VAL and γ-CD·VAL 
inclusion complexes that were produced via co-precipitation as well as those produced via 
kneading. The method that was followed is described in the Experimental Methods (Chapter 2) 
under section 2.9.2, p. 24. Unfortunately, a more accurate solubility determination method, for 
example UV-vis spectrophotometry, could not be performed due to the λmax value of the guest, 
valproic acid, occurring below 200 nm. As a result, the ‘actual’ solubility value lies between the 
estimated values based on the penultimate and the final successive masses of complex material 
added to the solvent (water) of known volume (3.0 cm3) at 23 C. The solubility results obtained 
were compared to the solubility value of valproic acid quoted as 1.3 mg.cm-3,15 even though the 
temperature was unspecified. This literature value was presumably recorded at ‘room 
temperature’, since an experiment conducted by the author of this dissertation appeared to reflect 
this. Table 5.13 displays the solubility results, where Scomplex is the aqueous solubility of the CD 
complex with valproic acid, and SVA is the aqueous solubility of valproic acid.  A sample calculation 
can be viewed in the Appendix under section 9.4.1, p. 42.  
 
Table 5.13: Aqueous solubility investigation for the α-CD·VAL, β-CD·VAL and γ-CD·VAL inclusion 
complexes at 23 oC.  
Number CD complex Range of mass 
dissolved (mg) 







1 α-CD·VAL (produced via 
co-precipitation) 
24.14 – 24.54 0.497 – 0.505 0.39 
2 α-CD·VAL (produced via 
kneading) 
23.89 – 24.74 0.492 – 0.510 0.39 
3 β-CD·VAL (produced via 
co-precipitation) 
16.74 –  17.28 0.558 – 0.576 0.44 
4 β-CD·VAL (produced via 
kneading) 
15.56 – 16.27 0.519 – 0.543 0.41 
5 γ-CD·VAL (produced via co-
precipitation) 
16.61 – 17.23 0.356 – 0.369 0.28 
6 γ-CD·VAL (produced via 
kneading) 
24.37 – 25.26 0.522 – 0.541 0.41 
 
The approximate solubility enhancement ratio (Scomplex/SVA) was calculated by averaging the two 
values from each solubility range of valproic acid. The solubility values for both the kneaded and co-
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precipitated material of the same complex were very similar for α-CD·VAL and β-CD·VAL. However, 
the solubility values differed significantly between the γ-CD·VAL inclusion complexes that were 
prepared via kneading and co-precipitation. A possible explanation for this is that different textures 
were obtained for the two materials owing to the different methods employed; however, further 
experimentation would be needed to verify this.  
The solubility enhancement ratio indicated that there was an approximate 3 fold decrease in the 
aqueous solubility of valproic acid in all three inclusion complexes (produced via both co-
precipitation and kneading) in comparison to the native drug, namely valproic acid (1.3 mg.cm-3 at 
an unspecified temperature).15 Possible applications for a slow release form of valproic acid could 
be investigated owing to the fact that a lower aqueous solubility was obtained. General comments 
on the potential benefits of CD inclusion of valproic acid for drug delivery are provided in the final 
chapter of this dissertation. 
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5.3.2) Inclusion of valproic acid in methylated cyclodextrins 
The three methylated cyclodextrins (CDs), which include heptakis(2,6-di-O-methyl)--cyclodextrin 
(DMB), heptakis(2,3,6-tri-O-methyl)--cyclodextrin (TMB) and hexakis(2,3,6-tri-O-methyl)--
cyclodextrin (TMA), formed authentic inclusion complexes with valproic acid. These new products 
will be referred to as DMB·VAL, TMB·VAL and TMA·VAL. Furthermore, the DMB·VAL and TMA·VAL 
inclusion complexes produced adequate single crystals for analysis and structural characterisation.  
 
5.3.2.1) The DMB·VAL inclusion complex 
Method of preparation 
A DMB·VAL inclusion complex was successfully synthesized in an equimolar ratio, which was later 
confirmed by a 1H NMR analysis. This inclusion complex could be prepared by adding 46.16 mg 
(0.03467 mmol) of DMB to 0.6 cm3 of water which was stirred vigorously at 298 K until the DMB 
was fully dissolved. Subsequently, 5 mg (0.03467 mmol; 5.434 μl) of valproic acid was added to the 
vial containing the DMB solution. (The valproic acid was added in minimal excess in order to ensure 
that all the DMB had reacted). The resultant solution was stirred overnight at 298 K. Initially, when 
the valproic acid was added to the solution of DMB, it formed an oily immiscible layer, which 
subsequently coated the sides of the vial. This same incidence was observed for the native CD 
experiments as described previously and this immiscible oily layer dissolved after the overnight 
stirring. Even though the valproic acid was dissolved in the minimum volume of the aqueous 
solution, temperature cycling was still employed as a precaution, in case complexation had not 
taken place.a The solution was heated to 70 oC while stirring for 10 minutes and then rapidly cooled 
to 4 oC while stirring. This process was repeated four times and the solution in the vial was 
subsequently filtered into a clean vial, which was sealed and placed in the oven at 60 oC.  After 
three days, single crystals of the complex had precipitated. 
 
                                                          
a
 A subsequent experiment was performed where temperature cycling was not employed. The result was that an 
inclusion complex was not formed. One experiment cannot validate this, as multiple experiments would have to be 
performed to confirm it. However, owing to the expense of the material, this was considered inappropriate and thus 




Two distinct types of crystal morphologies were observed in the vial containing the DMB·VAL 
inclusion complex (Figures 5.32A and 5.32B). The crystals that grew on the bottom of the vial 
formed conglomerates of rhombic-shaped crystals where a few of them were slightly opaque 
instead of transparent (Figure 5.32A). However, the crystals that grew on the sides of the vial were 
plate-like and slightly powdery, and also ranged from transparent to slightly opaque (Figure 5.32B). 
Solutions prepared by dissolving crystals of each morphology in DMSO-d6 at 298 K were analysed 
separately by 1H NMR solution-state spectroscopy in order to establish their composition.   









1H NMR analysis of DMB·VAL 
The results of the 1H NMR solution-state spectral analysis revealed that crystals of both 
morphologies had host-guest stoichiometric composition 1:1 and thus appeared to represent 
complexes, generically named DMB·VAL. Representative spectral results are listed in Table 5.14 





Figure 5.32A: Crystal morphology of 
the DMB·VAL inclusion complex 
isolated from the bottom of the vial. 
Figure 5.32B: Crystal morphology of 
the DMB·VAL inclusion complex 
isolated from the sides of the vial. 
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Table 5.14: The 1H NMR analysis of DMB·VAL. 






2 x CH3 (valproic acid) 0.84-0.88 1.00* 6H 1.00 1 
4 x CH2 (valproic acid) 1.21-1.52 1.51 8H 1.13 1 
OME (DMB) 3.26 3.69 21H 1.05 1 
OME (DMB) 3.49-3.52 3.35 21H 1.04 1 
*reference integral 
 
Fourier Transform Infrared (FT-IR) spectroscopic analysis of DMB·VAL 
The identity of the material as a DMB·VAL inclusion complex was also confirmed with FT-IR 
spectroscopy (Figure 5.33). The full FT-IR spectrum can be viewed in the Appendix under section 
9.5.2, p. 43. The C=O stretching frequency of pure valproic acid occurred at 1702 cm-1, while in the 
putative complex it was observed at a significantly higher frequency of 1731 cm-1, indicating a 
reduction in the extent of hydrogen bonding of the C=O group in the complex relative to that in the 




















Powder X-ray Diffraction (PXRD) analysis of DMB·VAL 
Both morphological forms of DMB·VAL produced via co-precipitation were confirmed to be the 
same phase by PXRD analysis. The PXRD pattern of DMB·VAL, produced via co-precipitation 
indicated that it was not isostructural with any other β-CD derivative inclusion complexes. 
Furthermore, the DMB·VAL inclusion complex that was synthesized via co-precipitation was not 
replicated with the kneading experiment. An unknown species was produced via kneading, since its 
PXRD trace did not match the PXRD traces of either a known polymorph of DMB, DMB·VAL 
(produced by co-precipitation) or any inclusion complexes of β-CD derivatives. Consequently, this 
product may either be a new polymorph of DMB or a DMB complex with no isostructural 
counterparts. Furthermore, traces of DMB may also be present in the PXRD trace of the product 
obtained via kneading, as some peaks coincide with the peaks from the PXRD pattern of a known 
polymorph of DMB (Figure 5.34). The kneading method for this product followed the general 
Figure 5.33: FT-IR spectra of DMB (red), valproic acid (blue) and DMB·VAL (black). 
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procedure, where the starting reagents (DMB and valproic acid) were kneaded for 30 minutes in an 
equimolar ratio with a small amount of water (Figure 5.34). However, producing a PXRD trace 
displaying high product crystallinity presented certain difficulties, as the kneading process had to be 
very specific and involved a strict time limit of only 30 minutes (no more and no less). In addition, 
the sample could not dry out while kneading and it had to be applied as a slurry to the zero 
background holder in the diffractometer. Any deviations from this method led to the material 




Hot Stage Microscopy (HSM) analysis of DMB·VAL   
The DMB·VAL inclusion complex was subjected to a heating rate of 10 K.min-1 while placed in 
silicone oil. The loss of crystallinity and the onset of decomposition are observed in the progression 
of micrographs (Figure 5.35). The initial photograph, Image 1, was taken at 29.7 oC to depict the 
features of the DMB·VAL complex crystal before heating. The onset of opacity commenced at 59.2 
oC (Image 2) until it became fully opaque at 199.8 oC (Image 3) and this process is associated with 
the loss of crystallinity. Furthermore, the decomposition process is displayed by the following three 
images (Image 4, 5 and 6) where the onset of decomposition occurred at 294.4 oC, until it was fully 
decomposed at 342.8 oC.  
 
Figure 5.34: The PXRD patterns of the crystal form of DMB employed in this study (polymorph 1, CSD refcode 
QIYKEO), DMB·VAL produced via co-precipitation (1:1), and a product from kneading DMB and valproic acid. 
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Thermal Gravimetric Analysis (TGA) of DMB·VAL   
The TGA trace (n = 2) of the co-precipitated DMB·VAL inclusion complex indicated two prominent 
mass losses which occurred over the temperature range 23.1 – 400.0 oC, as depicted in Figure 5.36. 
A mass loss of 2.1 ± 0.3 % was associated with the first thermal event, which took place between 
23.1 and 41.9 oC. This was accredited to the loss of water molecules from the DMB·VAL inclusion 
complex. Furthermore, the second thermal event, which took place between 300.5 oC and 390.7 oC, 
was associated with a mass loss of 84.3 % and represented the decomposition of DMB·VAL. In 
comparison to the HSM analysis, the loss of water was not observed, possibly because there was a 
miniscule amount of sample present; however, with regard to the onset of decomposition, the HSM 
and TGA results correlated closely, within 6.1 oC.   
Image 1: The initial appearance 
of DMB·VAL at 29.7 
o
C. 




Image 3: The crystal became 
fully opaque at 199.8 
o
C. 
Image 4: The onset of 




Image 5: The continuation of 
decomposition at 333.8 
o
C. 
Image 6: The decomposition 





A water mass loss of 2.1 ± 0.3 % for this inclusion complex is equivalent to 1.8 ± 0.3 water 
molecules per complex unit. This calculation can be viewed in the Appendix under section 9.5.3, p. 
44. 
The method for drying the DMB·VAL crystals followed the same procedure as that for the β-CD·VAL 
complex as the morphology was very similar.  
 
 
Figure 5.36: Representative TGA trace of the DMB·VAL inclusion complex (n = 2). 
 
Differential Scanning Calorimetry (DSC) of DMB·VAL 
The DSC trace (n = 2) of DMB·VAL prepared by co-precipitation indicated only a single shoulder 
which occurred over the temperature range 25.5 – 49.0 oC (Figure 5.37). This endothermic event 
was characteristic of the loss of water, as it correlated with the temperature of the mass loss of 
water in the TGA trace. The DSC trace did not reflect any correlation with the HSM experiment over 

























Figure 5.37: Representative DSC trace of DMB·VAL (n = 2). 
 
 
Single Crystal X-ray Diffraction (SCXRD) analysis 
Data-collection and space group determination  
The intensity data for DMB·VAL were collected from a single, approximately cubic-shaped crystal at 
173(2) K. The symmetry of the intensity-weighted reciprocal lattice was1, indicating the triclinic 
crystal system. Since CD molecules are chiral, the only possible space group option was P1, an 
assignment that was confirmed by the value of lE2-1l, namely 0.774, obtained using the program 
XPREP. Furthermore, from density and unit cell volume considerations a value of Z = 2 was 
predicted, indicating that the asymmetric unit (ASU) contained two independent DMB molecules. 
Structure solution and refinement 
The structure was solved using SHELXD-97,9 since SHELXS-97 failed, even though the number of 
phase sets in the TREF command was set to very large numbers. With regard to SHELXD-97, the 
instruction “FIND 151” was inserted with the PLOP command ranging from 60 to 240 at intervals of 
20. This gave a solution with a CC value of 79.6 and most of the atoms of the two independent host 
molecules appeared in the E-map. The model was refined with SHELXL-97. The atoms of the host 

























several atoms whose thermal ellipsoids were physically unreasonable and for these, reversion to 
the isotropic model followed.  In addition, two primary hydroxyl oxygen atoms were disordered 
over two positions. The general treatment for this, as mentioned previously, involved assigning 
s.o.f.s of x and 1-x (x = a free variable) to the respective major and minor components of a 
disordered hydroxyl group. In addition, the bond lengths C6-O6 and C6-O7 were fixed at 1.40 Å with 
σ = 0.01 Å via a DFIX restraint. The s.o.f.s of the major components of the disordered oxygen atoms 
O6A4 and O7B4 refined to 0.55(2) and 0.58(2) respectively.    
Once the host molecules had been refined to an adequate level, the electron density peaks in the 
difference Fourier map that belonged to the respective guest molecules were assigned. The atoms 
were identified by studying the geometrical features of the  peaks, which had lower than normal 
intensities, indicating relatively high guest thermal motion. The C-C bonds were all constrained at a 
distance of 1.50 Å and the C-CO2 unit was constrained to be planar with an O-C-O angle of 120
o. The 
guest molecules were refined isotropically as they displayed very large Uiso values that ranged from 
0.2 to 0.4 Å2. Despite these high Uiso values, a full site-occupancy was assumed for all the guest 
atoms based on the 1H NMR results which had indicated 1:1 host-guest stoichiometry. Refinement 
of individual isotropic thermal parameters assigned to atoms of the guest molecules produced 
physically unreasonable and inconsistent values. Hence, global Uiso values were assigned to each 
guest molecule and these refined to 0.225(4) Å2 and 0.221(4) Å2 for guest molecules A and B 
respectively. These results implied a genuinely high overall thermal vibration of the valproic acid 
molecules relative to the host molecules. Finally, hydrogen atoms were placed in idealised positions 
in a riding model on the host and guest molecules and an isotropic temperature factor, which 
ranged between 1.2 and 1.5 times the value of the Uiso value of its parent atom, was assigned to 
each hydrogen atom. In addition, one of the glucose units in molecule B was fully methylated at the 
C3 position. This can occur since the DMB employed was only ≥ 98 % pure. The crystallographic 
data for DMB·VAL are summarised in Table 5.15, the formula in the table taking into account the 







Table 5.15: The crystal data and refinement parameters for the DMB·VAL inclusion complex. 
Parameter Value 




Temperature (K) 173(2) 
Wavelength (Å) 0.71073 
Crystal system Triclinic 
Space group P1 
a (Å) 10.396(2) 
b (Å) 15.111(3) 




















F (000) 1632 
Crystal size (mm) 0.100 x 0.220 x 0.510 
-Range scanned (
o
) 2.25 – 21.62 
Index range h:-12, 12; k:-17, 17; l:-30, 30 
No. of reflections collected 44688 
No. of unique reflections 26358 
Data completeness (%) 99.4   
Data/restraints/parameters 26358/29/1651 
S (Goodness-of-fit on F
2
) 1.205 
Final R indices R1, wR2,  [I > 2σ(I)] 0.1075, 0.2953 
R Indices, all data (R1, wR2) 0.1518, 0.3342 
Largest diff. peak and hole (e. Å
-3
) 0.84, -0.47 
 
The water molecules were also identified as described in the Experimental Methods (Chapter 2) 
under section 2.5, p. 21. A total of four sites were identified to be water oxygen atoms, which 
equated to 1.9 water molecules per DMB molecule. Table 5.16 lists the refined values for the s.o.f.s 
and the Uiso values for the water molecules. The positions of two of these were identified as having 
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full site-occupancy, and the remaining two water molecules were assigned partial site-occupancies 
in descending order of their electron density peaks. Initially, the Uiso values of the disordered water 
molecules were constrained to 0.090 Å2 (the average of the Uiso values of O1W and O2W) and their 
s.o.f.s were allowed to vary. Subsequently, the Uiso value was unconstrained and its value 
converged satisfactorily. The TGA analysis had indicated that 1.8 ± 0.3 water molecules were 
present per DMB molecule, which correlated very closely with the model which accounted for 1.9.   
 
Table 5.16: The total number of water oxygen sites that were identified, with their respective s.o.f.s 
and Uiso values.  
Atom s.o.f. Uiso (Å
2
) Atom s.o.f. Uiso (Å
2
) 
O1W 1.00 0.090(3) O3W 0.94(4) 0.101(5) 
O2W 1.00 0.102(3) O4W 0.85(4) 0.101(6) 
 
Molecular structure 
The ASU of DMB·VAL is displayed in Figure 5.38. It contains two crystallographically independent 
DMB molecules, each accommodating a guest molecule in the cavity. In addition, there are four 
sites that were identified for water molecules, of which two were disordered. The water molecules 
were located within hydrogen bonding distance of the host molecule and no hydrogen atoms were 








Figure 5.38: The ASU of DMB·VAL.  
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Host-guest hydrogen bond interactions 
Figure 5.39 is a stereoview showing the common mode of inclusion of each of the guest molecules 
in their respective host cavities. This involves hydrogen bonding of the guest –COOH group to a 
water molecule, which in turn is hydrogen bonded to an oxygen atom O2 of a glucose residue. 
Table 5.17 contains the hydrogen bonding data for these interactions as well as those for water-






















Table 5.17: The parameters for the intermolecular interactions with the water molecules in 
DMB·VAL. 
Hydrogen bond D-H (Å) HA (Å) DA (Å) D-HA (
o
) Symmetry Code 
O1A-H1AO4W 0.84 1.94 2.78(3) 174 x, y, z 
O4W-H*O2A1 N/A N/A 2.99(2) N/A x, y, z 
O1B-H1BO1W 0.84 2.05 2.88(3) 169 x, y, z 
O1W-H*O2B1 N/A N/A 2.95(1) N/A x, y, z 
O3W-H* O6A7 N/A N/A 2.73(2) N/A x, y, z 
O2W-H*O6B7 N/A N/A 2.76(2) N/A x, y, z 
*Hydrogen atom presence inferred (not located in  synthesis or included in the model) 
 
The absence of hydrogen bonding of the carbonyl oxygen atoms is consistent with the results that 
were obtained in the FT-IR analysis. Figure 5.39 indicates that there are no hydrogen bonds 
involving the carbonyl oxygen atoms and thus the C=O stretching frequency in the complex is 
significantly higher than CO in pure valproic acid. 
A more detailed view of the host-guest interactions is displayed in the space-filling cutaway 
representation (Figure 5.40). The guest-water-host hydrogen bonding interactions (e.g.                

















Figure 5.40: A space-filling representation of the cross-section of complex units A and B in the ASU of DMB·VAL that 




Guest molecule conformations 
The guest conformations in molecules A and B are slightly different, as displayed in the molecular 
overlay diagram in Figure 5.41. The diagram displays small differences in the guest conformations, 
which are confirmed by the RMSD value of 0.644 Å.  
 
 
Figure 5.41: The molecular overlap of the included valproic acid molecules A (green) and B (red).  
 
Host intramolecular and intermolecular hydrogen bonding  
A belt of O2-HO3′ intramolecular hydrogen bonds linking contiguous glucose residues was 
observed on the secondary rings of both DMB molecules (Figure 5.42). These hydrogen bonds 














The hydrogen bonds that involve the DMB molecules were mostly observed to be intramolecular 
and are mainly of the type O-H···O. There are no hydrogen bond interactions between molecules A 
and B in the ASU. However, there are a few weak intermolecular interactions, (but these were only 
of the type C-H···O) which were observed between symmetry generated molecules. These weak 
interactions occurred between molecules A-A, B-B, A-B and B-A and their respective CO 
distances ranged from 3.26(1) Å to 3.49(2) Å. The sum of the van der Waals radii of carbon and 
oxygen is 3.22 Å, which indicates that these interactions are weak. Nevertheless, collectively they 
play an important role in holding the DMB molecules of the crystal structure together. Their 
individual hydrogen bond parameters are summarised in Table 5.18A for molecule A and in Table 






















Interaction type Hydrogen bond D-H (Å) HA (Å) DA (Å) D-HA (
o
) Symmetry Code 
O3-HO2 Hydrogen bonds 
Intramolecular O3A4 -H1O2A5 0.84 2.11 2.79(1) 138 x, y, z 
Intramolecular O3A2-H3A2O2A3 0.84 2.11 2.83(1) 143 x, y, z 
Intramolecular O3A1-H3A1O2A2 0.84 1.97 2.81(1) 173 x, y, z 
Intramolecular O3A5-H3A5O2A6 0.84 2.16 2.81(1) 134 x, y, z 
Intramolecular O3A6-H3A6O2A7 0.84 2.07 2.84(1) 151 x, y, z 
Intramolecular O3A3-H3A4O2A4 0.84 2.16 2.95(2) 157 x, y, z 
Intramolecular O3A7-H3AYO2A1 0.84 2.14 2.97(1) 169 x, y, z 
O3-HO4 Hydrogen bonds 
Intramolecular O3A2-H3A2O4A2 0.84 2.47 2.79(1) 103 x, y, z 
Intramolecular O3A1-H3A1O4A1 0.84 2.52 2.91(1) 109 x, y, z 
Intramolecular O3A6-H3A6O4A6 0.84 2.46 2.84(1) 109 x, y, z 
Intramolecular O3A3-H3A4O4A3 0.84 2.48 2.82(1) 105 x, y, z 
Intramolecular O3A7-H3AYO4A7 0.84 2.59 2.91(1) 104 x, y, z 
C-HO Hydrogen bonds 
Intramolecular C4A7-H4A7O6A7 1.00 2.51 2.87(2) 101 x, y, z 
Intramolecular C5A1-H5A1O4A7 1.00 2.47 2.83(2) 101 x, y, z 
Intramolecular C5A6-H5A6O4A5 1.00 2.47 2.84(1) 101 x, y, z 
Intermolecular C2A2-H2A2O3A5
 1.00 2.42 3.26(1) 142 x, -1+y, z 
Intramolecular C6A2-H6A4O5A3 0.99 2.58 3.27(1) 126 x, y, z 
Intramolecular C6A3-H6A7O5A4 0.99 2.47 3.35(2) 148 x, y, z 
Intramolecular C7A1-H7A9O3A1 0.98 2.54 3.02(2) 111 x, y, z 
Intermolecular C2A7-H2A7O3B6
 1.00 2.59 3.49(2) 149 1+x, 1+y, z 
Intramolecular C7A5-H7AXO3A5 0.98 2.40 3.04(2) 122 x, y, z 
Intramolecular C7A3-H7AEO3A3 0.98 2.60 3.23(3) 122 x, y, z 
Intermolecular C7A4-H7AGO6A4
 0.98 2.35 3.32(2)  168 -1+x, y, z 
Intermolecular C8A1-H8A3O3A2
 0.98 2.51 3.49(1) 174 1+x, y, z 
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Interaction type Hydrogen bond D-H (Å) HA (Å) DA (Å) D-HA (
o
) Symmetry Code 
O3-HO2 Hydrogen bonds 
Intramolecular O3B1-H3B1O2B2 0.84 2.04 2.86(1) 166 x, y, z 
Intramolecular O3B5-H3B5O2B6 0.84 2.05 2.81(1) 150 x, y, z 
Intramolecular O3B4-H3B4O2B5 0.84 2.03 2.87(1) 172 x, y, z 
Intramolecular O3B6-H3B6O2B7 0.84 2.00 2.83(1) 165 x, y, z 
Intramolecular O3B7-H3B2O2B1 0.84 2.06 2.89(1) 173 x, y, z 
Intramolecular O3B3-H3BXO2B4 0.84 2.17 2.98(2) 164 x, y, z 
O3-HO4 Hydrogen bonds 
Intramolecular O3B1-H3B1O4B1 0.84 2.43 2.85(1) 112 x, y, z 
Intramolecular O3B5-H3B5O4B5 0.84 2.48 2.81(1) 105 x, y, z 
Intramolecular O3B4-H3B4O4B4 0.84 2.54 2.87(1) 105 x, y, z 
Intramolecular O3B6-H3B6O4B6 0.84 2.44 2.85(1) 111 x, y, z 
Intramolecular O3B7-H3B2O4B7 0.84 2.45 2.84(1) 109 x, y, z 
Intramolecular O3B3-H3BXO4B3 0.84 2.49 2.84(1) 106 x, y, z 
C-HO Hydrogen bonds 
Intramolecular C5B1-H5B1.O4B7 1.00 2.47 2.82(2) 101 x, y, z 
Intramolecular C5B3-H5B3O4B2 1.00 2.49 2.84(2) 100 x, y, z 
Intramolecular C5B2-H5B2O4B1 1.00 2.42 2.79(2) 101 x, y, z 
Intermolecular C2B7-H2B7O3A6
 1.00 2.51 3.38(2) 146 x, -1+y, z 
Intermolecular C2B2-H2B2O3B5
 1.00 2.52 3.34(1) 137 x, 1+y, z 
Intramolecular C6B2-H6B2O5B3 0.99 2.37 3.14(2) 134 x, y, z 
Intramolecular C6B2-H6B2O6B3 0.99 2.55 3.49(2) 157 x, y, z 
Intermolecular C7B6-H7B4O3A7
 0.98 2.60 3.36(2) 134 -1+x, -1+y, z 
Intramolecular C6B3-H6B9O5B4 0.99 2.53 3.34(2) 138 x, y, z 
Intramolecular C6B5-H6BYO5B6 0.99 2.54 3.35(2) 139 x, y, z 
Intermolecular C9B2-H9B2O5A4
 0.98 2.58 3.35(2) 135 x, y, -1+z 
Intramolecular C7B5-H7BFO3B5 0.98 2.38 3.01(3) 121 x, y, z 
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Host molecular geometry 
The geometrical parameters that define the conformation of the O4-heptagon for the host 
molecule are described in Table 5.19A for molecule A and Table 5.19B for molecule B. These 
parameters have been described in detail in Chapter 1 under section 1.4.3 (pp. 6 – 8). 
The small variations in the individual values of l, D and  of the O4-heptagon indicate that 
deviations have occurred from a regular heptagonal shape on complexation. In addition, the degree 
of planarity of the O4-heptagon is modified and the variations in the torsion angles and the 
deviations of the O4 atoms from the O4-heptagon () are more significant in comparison to the O4-
heptagon of β-CD·VAL. Furthermore, the D3 values which range between 2.79(1) Å and 2.97(1) Å for 
molecule A and 2.81(1) Å and 3.26(2) Å for molecule B, indicate that the steric hindrance from the 
methyl groups was not large enough to prevent hydrogen bonds from occurring. This is a well-
known feature of DMB.   
Table 5.19A: The geometrical parameters for the host molecule A in the complex DMB·VAL. 




A1 4.992 4.446 129.7 8.2 -0.083 2.97(1) 11.9 
A2 4.992 4.401 130.5 -3.1 -0.094 2.81(1) 6.9 
A3 5.207 4.340 124.8 -10.3 0.176 2.83(1) 19.0 
A4 5.046 4.427 129.5 16.0 0.019 2.95(2) 22.2 
A5 4.949 4.452 130.0 -8.2 -0.243 2.79(1) 3.9 
A6 5.112 4.316 127.2 0.3 0.189 2.81(1) 6.9 
A7 5.157 4.419 126.9 -2.8 0.036 2.84(1) 22.7 
a
 mean esd: 0.005 Å; 
b












Table 5.19B: The geometrical parameters for the host molecule B in the complex DMB·VAL. 




B1 5.001 4.425 129.1 12.4 -0.187 2.89(1) 11.8 
B2 5.074 4.441 129.0 -10.3 -0.096 2.86(1) 6.2 
B3 5.206 4.302 123.9 -8.0 0.307 3.26(2) 27.8 
B4 4.925 4.486 132.4 18.8 -0.072 2.98(2) 24.3 
B5 5.008 4.353 128.0 -9.3 -0.305 2.87(1) 4.0 
B6 5.154 4.341 126.0 -3.6 0.277 2.81(1) 8.6 
B7 5.061 4.467 128.9 -0.4 0.076 2.83(1) 25.3 
a
 mean esd: 0.006 Å; 
b
 mean esd: 0.4
o 
The tilt angles of the individual glucose units for both molecules vary significantly and are generally 
large. However, the average tilt angles of the uncomplexed DMB molecule is 14(8)o which also falls 
within this range of the DMB·VAL tilt angles.12 In addition, as mentioned previously the average tilt 
angles for β-CD are 14(10)o, which suggests that the addition of the single methyl group on the 
secondary ring of each glucose unit did not affect the tilt angle. The tilt angle becomes more 
pronounced with a molecule such as (fully-methylated) TMB, which has an average tilt angle of 
25(20)o. Therefore, β-CD and DMB inclusion complexes should have similar tilt angles, unless the 
guest molecule induces distortion. As a result, it can be concluded that valproic acid induced 
distortion in the DMB molecules of DMB·VAL, as the tilt angles are overall larger than the tilt angles 
that were observed for the β-CD·VAL inclusion complex.  
With regard to DMB·VAL, it is evident that the glucose units A3, A4, and A7 and similarly B3, B4 and 
B7 are tilted the most towards the centre of the cavity of the DMB molecules, in comparison to the 
remaining glucose units in the macrocycles. Furthermore, the level of distortion and sizes of the tilt 
angles on molecule B are overall larger than molecule A, which could be due to slightly different 
modes of inclusion of the guest molecule.   
Crystal packing 
Figure 5.43a indicates that a column arrangement of inclined monomeric units is adopted instead 
of ‘straight’ channel packing. Each CD molecule is displaced to a certain extent in the packing 
arrangement, which prevents the formation of an infinitely long channel, and a herringbone 
stacking pattern comprising A and B columns is observed. In addition, there is an equal distribution 
of methylated O6 residues that are directed towards and away from the cavity of each CD molecule 
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(A and B). Furthermore, a small amount of interpenetration occurs with the guest molecule and the 
cavity of the adjacent CD molecule within the column. Figure 5.43b displays a space-filling cutaway 














Finally, the PXRD pattern of the DMB·VAL inclusion complex, prepared by co-precipitation, 
corresponded with the calculated PXRD pattern of the DMB·VAL inclusion complex (Figure 5.44). 
There is generally a 1:1 correspondence with the 2θ angular precision of the peaks from both PXRD 
patterns. However, the intensities of a few corresponding peaks differ significantly, an effect which 
is most likely caused by preferred orientation in the experimental sample. Furthermore, there is a 
slight shift in the 2θ-positions of corresponding peaks, which is due to the different temperatures 
that were used to record the two PXRD patterns. Despite this, the single crystal that was selected 
for analysis is nevertheless reasonably representative of the bulk material. 
 
Figure 5.43a: The packing arrangement of 
molecules A and B in DMB·VAL. The guest 







Figure 5.43b: A cutaway space-filling 
representation of the guest molecule 
interpenetrating the adjacent CD molecule 
to a small extent. The two monomeric 
units of column A are displayed in green 





Figure 5.44: The PXRD pattern calculated from a single crystal X-ray structure of DMB·VAL and the PXRD pattern of DMB·VAL 
prepared via co-precipitation.  



















5.3.2.2) The TMB·VAL inclusion complex 
Method of preparation 
An inclusion complex between the host TMB and guest valproic acid was successfully synthesized in 
an equimolar ratio, as confirmed by a 1H NMR analysis. The method of preparation was identical to 
that followed for the DMB·VAL inclusion complex, except that the mass of TMB and volume of 
water were specifically adapted. A mass of 49.56 mg (0.03467 mmol) of TMB was dissolved in 0.8 
cm3 of water at 25 C. When the valproic acid was added to the CD solution, it formed an oily 
immiscible layer on the solution surface and the sides of the vial. However, after the overnight 
stirring, the immiscible valproic acid layer dissolved and thus, since valproic acid is poorly soluble in 
water, it was inferred that it had formed an inclusion complex with TMB. Despite this, temperature 
cycling was still employed as a precaution and the solution was heated to 70 oC while stirring the 
suspension for 10 minutes and then rapidly cooled to 7 oC while stirring. This process was repeated 
four times and the solution was subsequently filtered into a clean vial, sealed and placed in the 
oven at 60 oC, after which it took approximately 3 days for crystals to appear.   
Crystal morphology 
The crystal morphology of the TMB·VAL inclusion complex was that of fragmented, arbitrarily 
shaped lamellae (Figure 5.45). Unfortunately, as a result of the nature of the morphology it was not 
possible to perform a SCXRD analysis.  
 






1H NMR analysis of TMB·VAL 
A sample of the pure TMB·VAL inclusion complex was dissolved in DMSO-d6 at 298 K and the 
solution was subjected to 1H NMR spectral analysis, which indicated an equimolar ratio of TMB to 
valproic acid. The results are displayed in Table 5.20, while the original 1H NMR spectra can be 
viewed in the Appendix under section 9.6.1, p. 45. 
 
Table 5.20: The 1H NMR analysis of TMBVAL. 






2 x CH3 (valproic acid) 0.85-0.88 1.00* 6H 1.00 1 
4 x CH2 (valproic acid) 1.21-1.53 1.46 8H 1.09 1 
OME (TMB) 3.25 3.45 21 1.01 1 
OME (TMB) 3.40 3.42 21 1.02 1 
OME (TMB) 3.51 3.63 21 1.03 1 
*reference integral 
 
Fourier Transform Infrared (FT-IR) spectroscopic analysis of TMB·VAL 
FT-IR spectroscopic results were consistent with complexation between TMB and valproic acid 
(Figure 5.46). Interaction between these molecules resulted in a significant shift of the C=O 
frequency from 1702 cm-1 (uncomplexed valproic acid) to 1726 cm-1, indicating a stronger C=O 
bond in the complexed guest and hence the relative lack of engagement of the carbonyl oxygen 
atom in hydrogen bonding.6 This conclusion is supported by analogy with the findings reported for 
the DMB·VAL inclusion complex, where an increase in the C=O frequency of very similar magnitude 
was observed and the crystal structure revealed that the carbonyl bond was not involved in 
hydrogen bonding in the complexed state. (The full FT-IR spectrum can be viewed in the Appendix 
under section 9.6.2, p. 45).   
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Powder X-ray Diffraction (PXRD) analysis 
The PXRD pattern of the TMB·VAL inclusion complex produced via co-precipitation showed some 
resemblance to the PXRD pattern for a particular TMB inclusion complex (Figure 5.47), namely 
heptakis(2,3,6-tri-O-methyl)--cyclodextrin methylcyclohexane clathrate (refcode XAQJII), which 
crystallizes in the space group P212121 with the unit cell parameters a = 11.149, b = 25.664, c = 
29.427 Å.2,7 This correlation is only approximate, as some peaks correlate while there are a few that 
do not.  
A putative TMB inclusion complex containing valproic acid, distinct from TMB·VAL, could be 
synthesized via kneading the components for 30 minutes in an equimolar ratio with a small amount 
of water (Figure 5.47). Its PXRD trace did not match that of TMB·VAL, but it correlated fairly well 
Figure 5.46: A portion of the FT-IR spectra of TMB (red), valproic acid (blue) and TMB·VAL (black). 
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with the PXRD pattern exclusive for one isostructural series of TMB inclusion complexes that 
crystallize in the space group P212121 with approximate unit cell parameters a  15 Å, b  21 Å, c  
28 Å 2,7 (Figure 5.47).   
 
 
Figure 5.47: The PXRD patterns of a TMB complex that crystallizes in P212121 (refcode XAQJII), a TMB·VAL complex (1:1) produced 
via co-precipitation, a representative isostructural TMB inclusion complex that crystallized in P212121 (refcode PAFSOE, with 
different unit cell data from XAQJII) and a different TMB·VAL complex produced via kneading.
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Hot Stage Microscopy (HSM) analysis of TMB·VAL 
Figure 5.48 represents the thermal progression of TMB·VAL submerged in silicone oil and subjected 
to a heating rate of 10 K.min-1. The individual micrographs display the loss of the guest molecule 
(valproic acid), the melt of TMB and lastly, the onset of decomposition of the crystals. The initial 
micrograph, Image 1, was recorded at 29.6 oC, prior to heating. The onset of bubbling commenced 
at 80.3 oC as depicted in Image 2. The bubbling reached a peak at 104.3 oC (Image 3) and continued 
until it stopped at 122.1 oC (Image 5). However, simultaneously the onset of transparency occurred. 
This is represented in Image 3 at 104.3 oC where this event commenced until the crystals were 
completely transparent at 111.4 oC, as displayed in Image 4. The bubbling and the subsequent 
onset of transparency appeared to be due to the loss of the guest molecules only. The onset of the 
melt commenced at 137.1 oC (Image 6) until the crystals had completely melted at 141.1 oC (Image 
7). Lastly, the onset of decomposition occurred at 257.4 oC as displayed in Image 8.  
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Thermal Gravimetric Analysis (TGA) of TMB·VAL 
The surface water of the TMB·VAL complex was removed by pressing the material between two 
sheets of dry filter paper and then spreading it over the dry surface of the filter paper in order to 
ensure that all the surface moisture was absorbed. This method also yielded reproducible results.  
Image 1: The initial 




Image 2: The onset of 
bubbling began at 80.3 
o
C. 
Image 3: The bubbling 
reached a peak at 104.3 
o
C. 
In addition, the onset of 
transparency commenced. 
Image 4: The crystal 
became completely 
transparent, while 
bubbling, at 111.4 
o
C. 
Image 5: The bubbling 
stopped at 122.1 
o
C. 
Image 6: The onset of the melt 
commenced at 137.1 
o
C. 
Image 7: The crystal had 
completely melted at 141.1 
o
C. 
Image 8: The onset of 





The TGA traces (n = 2) for the TMB·VAL inclusion complex prepared via co-precipitation displayed 
two prominent mass losses, which occurred over the temperature range between 22.8 and 400.0 
oC, as depicted in Figure 5.49. A mass loss of 8.3 ± 0.9 % was associated with the first (apparently 
three-step) thermal event that took place between 110.5 and 239.0 oC. Unlike the interpretation 
given for the previously described valproic CD complexes, this mass loss was attributed to the loss 
of the guest molecule from the TMB·VAL inclusion complex. It is thus evident that this inclusion 
complex did not contain any water within the crystal structure. These results also correlated with 
the 1H NMR results that yielded an equimolar ratio of TMB to valproic acid. As stated above, the 8.3 
± 0.9 % mass loss of valproic acid correlated with the percentage ratio of valproic acid to an 
equimolar anhydrous complex, which is 9.2 %. This calculation can be viewed in the Appendix under 
section 9.6.3, p. 46. The second thermal event took place between 298.2 oC and 385.8 oC and was 
associated with a mass loss of 86.7 %, representing the decomposition of TMB.  
In the HSM analysis, the loss of the guest molecules was observed by the onset of bubbling and the 
subsequent onset of transparency, which took place between 80.3 and 122.1 oC. A portion of this 
thermal event overlapped with the corresponding thermal event in the TGA analysis; however, they 
did not directly correlate. In addition, the onset of decomposition in the HSM analysis (257.4 oC) did 
not correlate with the onset of decomposition in the TGA trace at 298.2 oC.   
 





















Temperature (oC)  
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Differential Scanning Calorimetry (DSC) analysis of TMB·VAL 
The DSC trace of the TMB·VAL complex (n = 3) prepared via co-precipitation, was significantly 
different from those of all the other CD/valproic acid inclusion complexes described previously 
(Figure 5.50). This trace displays only a sharp endotherm with the onset at 126.7 ± 0.8 oC (peak 
temperature 130.3 ± 0.1 oC) and this is characteristic of a melt. No water loss from the crystal 
structure was observed in the DSC trace which was also previously confirmed by the HSM and TGA 
results. In the HSM experiment, the onset of the melt occurred at 137.1 oC and neither melting 
points from the HSM or DSC results correspond with the literature melting point for the different 
forms of TMB (which are in the range 148 – 157 oC).16 A reason that these results did not correlate 
could have been due to the fact that the loss of the guest molecules was a composite process and 
as a result it could have caused the melt of TMB to occur earlier.   
 
Figure 5.50: Representative DSC trace of TMB·VAL (n = 3). 
 
In conclusion, a new anhydrous CD complex, with the formula TMB·VAL, was synthesized.  
However, analysis of its structure using X-ray analysis was not possible due to the intractable nature 



























Figure 5.51B: The crystal morphology of 
the TMA·VAL inclusion complex which had 
a more three-dimensional character. 
    
Figure 5.51A: The generally poor quality plate-like 
crystals obtained for the TMA·VAL inclusion 
complex. 
5.3.2.3) The TMA·VAL inclusion complex 
Method of preparation 
An inclusion complex containing TMA (host molecule) and valproic acid (guest molecule) was 
successfully synthesized in an equimolar ratio, as confirmed by a 1H NMR analysis. The equivalent 
method of preparation, as outlined for DMB·VAL, was followed for this experiment, except that the 
mass of TMA and the volume of water were specifically tailored. Thus, 42.48 mg (0.03467 mmol) of 
TMA was initially dissolved in 0.8 cm3 of water and the remainder of the method was followed as 
previously described. Crystals were formed within two days.      
 
Crystal morphology 
The crystal morphology of the TMA·VAL inclusion complex was generally of a very poor quality, as 
the crystals were frequently plate-like with irregular shapes (Figure 5.51A). Very few crystals grew 
significantly in the third dimension, and thus obtaining a crystal for a SCXRD analysis was 
exceedingly challenging. These few crystals, which contained a more three-dimensional character, 













1H NMR analysis of TMA·VAL 
The 1H NMR solution-state spectral analysis of single crystals of the inclusion complex dissolved in 
DMSO-d6 at 298 K indicated an equimolar ratio of TMA to valproic acid. The results are listed in 
Table 5.21 below, while the original 1H NMR spectra can be viewed in the Appendix under section 
9.7.1, p. 47.  
Table 5.21: The 1H NMR analysis of TMA·VAL. 






2xCH3 (valproic acid) 0.83-0.87 1.00* 6H 1.00 1 
4xCH2 (valproic acid) 1.21-1.52 1.36 8H 1.02 1 
OME (TMA) 3.24 2.93 18H 1.02 1 
OME (TMA) 3.38 3.07 18H 1.02 1 
OME (TMA) 3.50 2.83 18H 1.06 1 
*reference integral 
 
Fourier Transform Infrared (FT-IR) spectroscopic analysis of TMA·VAL 
The FT-IR analysis of the TMA·VAL inclusion complex also confirmed the identity of this inclusion 
complex. The C=O stretching frequency of valproic acid in the complex was shifted to a significantly 
higher frequency (1734 cm-1) in comparison to its stretching frequency in uncomplexed valproic 
acid (1702 cm-1). This indicates that the extent of the C=O hydrogen bonding in the complex was 
reduced in comparison to that of pure valproic acid.6 Figure 5.52 displays a section of the FT-IR 


















Powder X-ray Diffraction (PXRD) analysis of TMA·VAL 
The TMA·VAL inclusion complex could also be formed via kneading the host and guest components 
for 40 minutes in an equimolar stoichiometry with a small amount of water (Figure 5.53). This was 
evident since the 2θ-positions in the PXRD patterns of the TMA·VAL inclusion complex, produced 
via co-precipitation and kneading, directly correlated. The major difference is the peak intensity 
discrepancy at 2 = 8.0, which is attributed to preferred orientation in the co-precipitated sample. 
Proof for the latter conclusion is provided at the end of this chapter. It is important to note that the 
sample produced via kneading had to be applied as a dry powder to the zero background holder in 
the diffractometer.  
Figure 5.52: A portion of the FT-IR spectra of TMA (red), valproic acid (blue) and TMA·VAL (black). 
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Figure 5.53: The PXRD patterns of the TMA·VAL inclusion complex produced via co-precipitation (1:1) and kneading (1:1).
 
 
Hot Stage Microscopy (HSM) analysis of TMA·VAL 
The thermal progression of a TMA·VAL inclusion complex crystal and TMA crystals are displayed in 
the series of micrographs in Figure 5.54. These crystals were subjected to a constant heating rate of 
10 K.min-1, while immersed in silicone oil. This analysis displayed loss in the crystallinity of 
TMA·VAL, the melt of TMA and the onset of decomposition. The initial micrograph, Image 1, was 
recorded at 25.0 oC to depict the features of the TMA·VAL inclusion complex crystal (left) and TMA 
crystals (right) prior to heating. Image 2 depicts the onset of opacity at 98.8 oC for the TMA·VAL 
inclusion complex, the maximum opacity being achieved at 154.3 oC (Image 3). TMA remained 
unchanged during these thermal events. TMA·VAL began to melt very slowly at 173.4 oC (Image 4), 
while TMA remained unchanged. However, at 210.3 oC (Image 5) the melt for TMA commenced, 
and they were both completely melted at 271.5 oC (Image 6). This behaviour suggested that the 
heating process involved the removal of valproic acid from the TMA·VAL inclusion complex crystal 
and thus pure solid TMA remained. The boiling point of valproic acid is 219.5 oC,15 and thus valproic 
acid would have left the inclusion complex in liquid form and become dispersed within the silicone 
oil. As a result, it was expected that no bubbling would be observed. Consequently, the loss in 
crystallinity, which is represented by the onset of opacity for the TMA·VAL inclusion complex 
crystal, is most likely due to the guest molecules (valproic acid) leaving the crystal.  



















Furthermore, the onset of decomposition occurred at 287.5 oC (Image 7) and full decomposition 
was achieved at 356.4 oC (Image 8). It is clearly understood that both samples would have the same 
decomposition thermal events, as they had become the same substance.  
 



















Image 1: Initial appearance of 




Image 2: The onset of opacity for 
TMA·VAL (left) at 98.8 
o
C. TMA (right) 
remained unchanged. 
Image 3: The peak opacity occurred 
at 154.3 
o
C for TMA·VAL. TMA (right) 
remained unchanged. 
Image 4: At 173.4 
o
C the onset of the 
melt began very slowly for TMA·VAL 
(left). TMA (right) remained 
unchanged. 
Image 5: The continuation of the melt 
for TMA·VAL (left) at 210.3 
o
C. The 
melt for TMA (right) commenced. 
Image 6: Both compounds were 
completely melted at 271.5 
o
C. 
Image 7: The onset of decomposition 
commenced at 287.5 
o
C for both 
residues. 
Image 8: The decomposition was 
completed at 356.4 
o




Thermal Gravimetric Analysis (TGA) of TMA·VAL  
The general morphology of the TMA·VAL crystals was plate-like; however, there were occasionally a 
few more three-dimensional crystals in the batch. Removal of surface mother liquor for the 
purpose of estimating the crystal water content by TGA posed a challenge. In the first trial 
experiment, where the crystals were only pressed between the two sheets of filter paper, a 10 % 
mass loss due to water was recorded. A possible explanation for this is that surface water could 
have been trapped in between the plates of the crystals. In the latter experiments, where the 
crystals were pressed and spread across a sheet of filter paper, the results indicated a 1.5 % mass 
loss due to water, and these results were reproducible. 
The TGA traces (n = 2) signified three distinctive mass losses for the TMA·VAL inclusion complex 
which took place over the temperature range 20.8 – 400.0 oC as depicted in Figure 5.55. A mass loss 
of 1.5 ± 0.1 % was associated with the first thermal event which occurred between 20.8 oC and 38.2 
oC. This mass loss was attributed to the loss of water molecules from the TMA·VAL inclusion 
complex. (The absence of bubbling in the HSM analysis, in the dehydration temperature range, is 
assumed to have been due to the very small percentage of water present in the crystal). 
The second thermal event can be split into two processes – a sharp, large mass loss and then a very 
small gradual mass loss. Both of these events are attributed to the loss of guest molecules and it is 
evident that this is a consecutive two-stage process. The first stage took place between 99.4 oC and 
125.1 oC and was associated with a mass loss of 6.7 ± 0.9 %. The second stage occurred over the 
temperature range between 125.1 and 214.8 oC and represented a mass loss of 3.2 ± 0.4 %. The 
combined mass loss percentages of valproic acid (9.9 ± 0.7 %) correlated with the percentage ratio 
of valproic acid to an equimolar anhydrous complex (10.5 %). Thus, this further confirms the 
equimolar stoichiometry of TMA to valproic acid in the inclusion complex, as determined by the 1H 
NMR spectroscopy. This calculation can be viewed in the Appendix under section 9.7.3, p. 48.  
The last thermal event took place over the temperature range between 287.0 oC and 388.3 oC with 
an associated mass loss of 84.6 % and represents the decomposition of TMA. In addition, the loss of 
the guest molecules in the HSM analysis was observed by the onset of opacity at 98.8 oC. This event 
correlated very closely with the onset of the loss of the guest molecules in the TGA analysis, which 
was observed at 99.4 oC. The onset of decomposition in the HSM analysis directly correlated with 
the onset of decomposition in the TGA trace within a temperature range of 0.5 oC.  
172 
 
This analysis also allowed the number of water molecules to be calculated in the inclusion complex. 
Thus, a 1.5 ± 0.1 % mass loss of water amounted to 1.2 ± 0.1 water molecules. This calculation can 
be viewed in the Appendix under section 9.7.4, p. 48. 
    
 
Figure 5.55: Representative TGA trace of the TMA·VAL inclusion complex (n = 2). 
 
Differential Scanning Calorimetry (DSC) analysis of TMA·VAL 
The DSC traces of TMA·VAL (n = 2) indicated two complex endothermic events taking place (Figure 
5.56). Furthermore, the water loss was not observed due to the fact that the DSC instrument only 
equilibrated at 50 oC. The first complex endothermic event occurred over the temperature range 
between 95.1 ± 0.6 oC and 152.3 ± 0.1 oC and represented the loss of guest molecules from the 
inclusion complex. This complex endothermic event was a two-step process which is accompanied 
by a broad shoulder at the end. The onset temperatures of these consecutive events took place at 
95.1 ± 0.6 oC (where the peak occurred at 101.5 ± 0.5 oC), 108.3 ± 0.7 oC (where the peak occurred 
at 114.6 ± 0.1 oC), and the broad shoulder which spanned the range from 119.5 ± 0.1 oC to 152.3 ± 
0.1 oC. Overall, these temperature ranges represented the initial loss of the guest molecules 
periodically over two stages, and subsequently more of the guest molecules were lost over an 
extended period of time, as displayed by the broad shoulder endothermic event. This event 
























onset of opacity occurred at 98.8 oC, which was attributed to the loss of the guest molecules. In 
addition, with reference to the TGA analysis, this initial complex DSC endotherm correlated with 
the onset of the first stage of the loss of the guest molecules in the TGA experiment, which took 
place between 99.4 and 125.1 oC.  
The onset temperature of the second endothermic event occurred at 214.8 ± 2.2 oC (with the peak 
occurring at 220.0 ± 0.1 oC) and represented the melt of TMA. The peak of this endothermic event 
(the melt) correlated reasonably well with the literature value for the melting temperature of TMA, 
which has been reported as 217.6 ± 0.1 °C.17-18 The asymmetry of this endothermic peak could be 
attributed to the simultaneous loss of remaining guest molecules and melting of TMA, which would 
account for the gradual depression towards the peak at 220.0 ± 0.1 oC. This explanation arose from 
the results observed in the TGA analysis, where the second stage guest loss is occurring over a 
similar temperature range 125.1 – 214.8 oC. Furthermore, the HSM analysis had indicated the start 
of a slow melt at 173.4 oC, which corresponds to the negative deviation of the baseline towards 220 
± 0.1 oC in the DSC trace. Owing to the sensitivity of the DSC instrument to possible spillage of 
material from the pan, it was decided not to take the sample to decomposition.  
 






























Single Crystal X-ray Diffraction (SCXRD) analysis 
Data-collection and space group determination  
Three attempts were made to collect the intensity data of TMA·VAL in order to ensure that a 
successful crystal structure solution was achieved. The first crystal was cooled to 100 K; however, it 
was concluded that the crystal had been cooled too rapidly, since the b-axis tripled in length 
relative to the value measured at 294 K (room temperature). The structure refinement for the host 
molecule based on these data could not be completed as the geometries of the glucose rings were 
unstable, and as a result these intensity data were abandoned. A second crystal was selected and 
prepared for two consecutive data-collections; for the first collection the crystal was cooled to 220 
K and for the second, to 100 K. The data-collection at 220 K was performed as a precaution in the 
event that the b-axis might increase in multiplicity at a lower temperature, even though the 
temperature of the crystal was lowered extremely slowly during this attempt. The intensity data at 
220 K enabled the host to refine accurately; however, the electron density in the host cavity did not 
resemble the relevant atomic connectivities expected for the molecule of valproic acid, and thus 
the atoms of the guest molecule could not be assigned. Therefore, the crystal was cooled further 
very slowly to 100 K and it did not display any multiplication of the b-axis (which had previously 
occurred at 100 K). Intensity data-collection on this specimen proceeded and the structural model 
deduced from electron density maps based on these data revealed the host, guest and water 
molecules and was successfully refined.  Details of the structure solution and refinement follow. 
The Laue group of the intensity-weighted reciprocal lattice was mmm which indicated that the 
crystal system was orthorhombic. The lattice type was determined to be primitive and the space 
group P212121 was determined from the conditions limiting possible reflections, as listed in Table 








Table 5.22: The conditions limiting possible reflections for the crystal TMA·VAL 
Number Conditions limiting possible reflections Deduction 
1 hkl: none Primitive lattice 
2 0kl: none No glide plane  a 
3 h0l: none No glide plane  b 
4 hk0: none No glide plane  c 
5 h00: h = 2n 21-axis parallel to the a-axis 
6 0k0: k = 2n 21-axis parallel to the b-axis 
7 00l: l = 2n 21-axis parallel to the c-axis 
 
Structure solution and refinement  
 The structure was solved with SHELXS-979 and refined with SHELXL-97. The host molecule was fully 
ordered and the guest molecule was observed in the host cavity. Only the carboxylic acid group was 
disordered over two positions, the larger component accounting for 72 % of the site-occupancy. All 
the host and guest atoms were refined isotropically initially and subsequently anisotropically, 
except for the disordered –COOH group on the guest molecule, which was refined isotropically. The 
majority of the hydrogen atoms were placed in idealised positions on the host and guest molecules. 
However, the placement of the hydrogen atoms on the disordered –COOH group was non-routine, 
since sufficiently strong  peaks were absent. However, from the distribution of oxygen atoms in 
the vicinity of the disordered components of the –COOH acid group, it could be inferred that in 
each of these components, only one of the oxygen atoms could act as a donor in forming a 
hydrogen bond, while the other could not act as a donor or an acceptor. Placement of the acidic H 
atoms was thus based on the above considerations. An isotropic temperature factor between 1.2 
and 1.5 times the Uiso value of its parent atom was assigned to each hydrogen atom in the model. 







Table 5.23: The crystal data and refinement parameters for the TMA·VAL inclusion complex. 
Parameter Value 




Temperature (K) 100(2) 
Wavelength (Å) 0.71073 
Crystal system Orthorhombic 
Space group P212121 






















F (000) 3008 
Crystal size (mm) 0.162 x 0.192 x 0.426 
Θ Range scanned (
o
) 2.71 – 20.29
 
Index range h: -19, 19; k: -26, 25; l: -29, 29 
No. of reflections collected 67797 
No. of unique reflections 16293 
Data completeness (%) 99.2 
Data/restraints/parameters 16293/0/865 
S (Goodness-of-fit on F
2
) 1.014 
Final R indices R1, wR2,  [I > 2σ(I)] 0.0675, 0.1461 
R Indices, all data (R1, wR2) 0.1342, 0.1737 
Largest diff. peak and hole (e. Å
-3







Two sites were identified as locations of disordered water molecules. Initially, the thermal 
parameters (Uiso) of the water oxygen atoms were constrained and their site-occupancy factors 
(s.o.f.s) were allowed to vary. Subsequently, their Uiso values were unconstrained and both sets of 
parameters converged. The combined site-occupancy of the water molecules was 0.5 per TMA 
molecule, which did not correlate with TGA results that indicated the presence of 1.2 ± 0.1 water 
molecules per TMA molecule. A possible explanation is that there could have still been residual 
surface water in the samples used for the TGA analysis, despite the thorough drying process 
employed as explained above. The distance between these two water molecule sites was 1.07 Å 
and therefore this suggested that this could represent one site with large anisotropic motion. An 
attempt was made to treat it as one site, but the Uiso value of a single water oxygen site was not 
stable. Consequently, the former model with two partially occupied water molecule sites treated 
isotropically, was reinstated. In addition, no attempts were made to place hydrogen atoms on these 
partial water molecules owing to their disorder. Table 5.24 summarises the refined values for the 
Uiso parameters, as well as the s.o.f.s for the water oxygen atoms.   
Table 5.24: The total number of water oxygen sites that were identified, along with their respective 
s.o.f.s and Uiso values.  
Atom s.o.f. Uiso (Å
2
) 
O1W 0.19(2) 0.031(8) 
O2W 0.32(2) 0.10(1) 
 
Molecular Structure 
The asymmetric unit (ASU) of TMA·VAL contains one TMA molecule, one valproic acid molecule and 
two water oxygen atoms located at sites that have a combined site-occupancy of 0.5 water 
molecules, as shown in Figure 5.57 below.  It should be noted that guest inclusion involves insertion 
of only one of the propyl groups within the host cavity, while the rest of the molecule protrudes 
from the secondary side of the TMA molecule. This is most evident from the Figure 5.57 (right). Also 
noteworthy is that this X-ray analysis presents the only accurate model for the valproic acid 
molecule determined to date, those contained in the two DMB·VAL complex units displaying very 










Figure 5.57: The ASU of TMA·VAL: A ball-and-stick model of the guest and host molecules is displayed on the left (hydrogen atoms 
and water molecules are omitted for clarity), while a space-filling model of the ASU is displayed in the centre, and a cross-section 
of TMA·VAL is displayed on the right. 
 
Hydrogen bonding 
The hydrogen bonding of the host molecule in the TMA·VAL inclusion complex involved both 
intermolecular and intramolecular interactions of the type C-HO. This was to be expected as the 
TMA molecule is fully methylated and thus does not contain any hydroxyl donor or acceptor 
groups. The majority of these C-HO bonds are rather weak; however, collectively they have an 
important role. These interactions are listed in Table 5.25.  
Further details of the unusual guest inclusion mode observed here, as well as the host-guest 
interactions follow. The aliphatic chain of the valproic acid molecule is in a fully extended 
conformation (Figure 5.58) and only one of the propyl groups is included within the cavity of the 
TMA molecule, while the two disordered components of the carboxylic acid group and the second 
propyl group protrude from the secondary side of the host molecule. Thus, neither of the 
disordered –COOH components engages with the TMA molecule of the asymmetric unit; instead, 
for one of them, the –OH group is directly hydrogen bonded to atom O6F of a symmetry-related 
TMA molecule, while for the other, the –OH group is hydrogen bonded to water oxygen atom O1W, 
which in turn donates a H-bond to atom O6B of a second symmetry-related TMA molecule 




Table 5.25: The parameters for the hydrogen bond interactions in TMA·VAL. 









Interaction type Hydrogen bond D-H H…A D…A D-H…A (
o
) Symmetry Code 
C-HO Hydrogen bonds 
Intermolecular C2A-H2AO6B
 1.00 2.44 3.416(7) 165 ½+x, ½-y, -z 
Intermolecular C2B-H2BO5A
 1.00 2.34 3.318(6) 165 x-½, ½-y, -z 
Intermolecular C2D-H2DO6E
 1.00 2.45 3.418(6) 164 x-½, ½-y, 1-z 
Intermolecular C2E-H2EO5D
 1.00 2.57 3.542(6) 165 ½+x, ½-y, 1-z 
Intramolecular C4E-H4EO6E 1.00 2.49 2.852(7) 101 x, y, z 
Intramolecular C5B-H5BO4A 1.00 2.38 2.780(5) 103 x, y, z 
Intramolecular C6A-H6A1O5B 0.99 2.29 3.193(7) 151 x, y, z 
Intramolecular C6E-H6E2O5F 0.99 2.53 3.286(7) 134 x, y, z 
Intramolecular C6B-H6B2O5C 0.99 2.46 3.180(7) 129 x, y, z 
Intramolecular C6F-H6F1O5A 0.99 2.52 3.351(8) 141 x, y, z 
Intramolecular C6F-H6F1O6A 0.99 2.60 3.475(8) 147 x, y, z 
Intramolecular C6D-H6D1O5E 0.99 2.31 3.206(7) 150 x, y, z 
Intermolecular C7F-H7F3O3C
 0.98 2.45 3.260(7) 140 1+x, y, z 
Intramolecular C7E-H7E3O3E 0.98 2.51 3.121(8) 120 x, y, z 
Intramolecular C8C-H8C3O2C 0.98 2.42 3.044(8) 121 x, y, z 
Intramolecular C8F-H8F3O2F 0.98 2.45 3.070(8) 121 x, y, z 
Intramolecular C9C-H9C1O6D 0.98 2.58 3.488(8) 154 x, y, z 
Intramolecular C9F-H9F3O6A 0.98 2.55 3.451(8) 153 x, y, z 
Hydrogen bonds involving the guest molecule 
Intermolecular O1G-H1GO6F
 0.84 2.05 2.829(8) 154 -x, ½+y, ½-z 
Intermolecular O2H-H2HO1W 0.84 1.95 2.78(2)  170 x, y, z 










The observed host-guest interactions, involving exclusively the –OH groups of the disordered           
–COOH components, are also consistent with the results obtained by FT-IR analysis. These indicated 
that the extent of hydrogen bonding involving the valproic acid C=O group in the inclusion complex 
was much less than that in the uncomplexed acid. These results parallel those which were reported 
earlier in Chapter 5, pp. 140 – 141 for the DMB·VAL complex.         
Host molecular geometry 
The conformation of the O4-hexagon for the host molecule is described by the parameters in Table 
5.26. These parameters have been described in detail in Chapter 1 under section 1.4.3, pp. 6 – 8. 
The lengths and angles in a regular hexagon are all equal; however, the values of l, D and  of the 
O4-hexagon are not equal and vary somewhat. This is expected since the O4-hexagon becomes 
distorted in a crystalline state,12 and this distortion is further enhanced by complexation. 
Furthermore, the results indicate that the degree of planarity of the O4-hexagon is modified, since 
the variation in the torsion angles (d) and the atomic deviations from the O4-plane (α) are more 
significant. The O4-hexagon is less planar than the O4-heptagon of β-CD·VAL and the O4-hexagon is 
distorted to about the same extent as the O4-heptagon of DMB·VAL. This is owing to the steric 
interactions of the methyl groups in TMA. This is further confirmed by the D3 values which range 
between 3.156 Å and 3.441 Å and indicate that the steric repulsive effects between these methyl 
groups have caused these distances to increase significantly from the value of around 2.8 Å, 
observed in native CDs.  
Figure 5.58: A stereoview of the hydrogen bonding (green lines) involving the guest 
molecule. The TMA molecule of the ASU is shown at the top of the figure. The guest and 




The tilt angles of the glucose units vary significantly and are generally large, due to the steric 
interactions between the secondary methyl groups. These results complement those for previously 
reported TMA inclusion complexes as the tilt angles follow a very similar trend.18 It is evident from 
Table 5.26 that the glucose units C and F are tilted the most towards the centre of the cavity of the 
TMA molecule. The tilt angles of uncomplexed TMA have an average value of 18(12)o which 
suggests that there was no significant change in distortion upon complexation in TMA·VAL.12 This is 
due to the fact that only one propyl group of the valproic acid molecule is located within the host 
cavity and that the host-guest interactions are consequently minimal, as shown by the data in Table 
5.25. Generally, the distortion of the α-CD family of molecules can be affected by host-guest 
interactions; however, in this case it is not obviously apparent.12 This further confirms that the large 
tilt angles are mainly caused by the steric strain of methyl groups and that the inclusion of the guest 
molecule had a negligible contribution.  
 
Table 5.26: The geometrical parameters of the host molecule in the complex TMA·VAL. 




A 4.380 4.376 115.6 -6.4 0.282 3.316 9.1 
B 4.123 4.240 123.0 -9.7 -0.245 3.427 17.5 
C 4.273 4.211 120.2 17.3 -0.041 3.277 33.5 
D 4.384 4.334 114.9 -7.9 0.294 3.278 7.2 
E 4.084 4.241 124.3 -8.6 -0.260 3.440 17.2 










The TMA molecules pack themselves in layers according to a brickwork (monomeric) arrangement, 
where one of the monomeric units centres itself above the void space created by three monomeric 
units in the layer below (Figure 5.59a). As noted previously, the aliphatic chain of valproic acid is 
fully extended through the centre of the CD cavity, half of the aliphatic chain being included in the 
CD cavity and the remaining half being centrally positioned in the void space between the three 




















Figure 5.60 shows the computed PXRD pattern based on the single-crystal X-ray data and the 
experimental pattern obtained from the co-precipitated TMA·VAL complex. Since the respective 
temperatures to which these traces correspond are different (100 K and 294 K), there are small 
shifts in the angular positions of corresponding peaks (generally in the direction of increasing 2 in 
the computed pattern, as expected). In addition, it is evident that the intensities of several peaks in 
the experimental pattern suffer from preferred orientation effects, the most serious case being that 
involving the peak at 2 = 8.0. (This, incidentally, vindicates the conclusion in the description of 
Figure 5.59a: A stereoview showing a packing feature of TMA·VAL. The guest and 
water molecules in the lower CD layer are omitted for clarity.  
Figure 5.59b: A steroview which displays half of the fully extended aliphatic chain of 
valproic acid penetrating into the void between the three monomeric units in the lower 
layer. The guest and water molecules in the lower CD layer are omitted for clarity. 
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Figure 5.53 above that it was the co-precipitated product, rather than the complex prepared by 
kneading, whose abnormally high peak intensity at this angular position was due to preferred 
orientation).    
 
Figure 5.60: The PXRD pattern calculated from a single crystal X-ray structure of TMA·VAL and the PXRD pattern of TMA·VAL 
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In summary, the author of this Master’s dissertation discovered and fully characterized a new 
polymorph of isonicotinamide, namely polymorph 6, and also synthesized six new CD inclusion 
complexes, namely -CD·VAL (2:1), -CD·VAL (1:1), -CD·VAL (4:3), DMB·VAL (1:1), TMB·VAL (1:1) 
and TMA·VAL (1:1). In addition, the aqueous solubilities of the -CD·VAL, -CD·VAL and -CD·VAL 
inclusion complexes were assessed, the results indicating that they were generally approximately 
30 % that of valproic acid. Further details and comments on the above results are provided below. 
6.1.1) Allopurinol and 6-thioguanine 
The attempts to produce either co-crystals or CD inclusion complexes with allopurinol and 6-
thioguanine failed. However, there were a few preliminary results that displayed the formation of 
new material during the co-crystallization experiments with allopurinol, but unfortunately, none of 
these products could be further analysed.  
A possible explanation for the formation of a few preliminary new phases with allopurinol, but not 
with 6-thioguanine, could be due to small chemical differences between the two molecules, and 
the fact that the aqueous solubility of 6-thioguanine is an order of magnitude lower than that of 
allopurinol.1-2 The CD inclusion complex experiments all failed despite the different methods 
employed. The adverse physical properties, such as the high melting points (due to the extensive 
hydrogen bonding in the crystal structures and the resulting high lattice energies) and consequently 
low aqueous solubilities of these compounds, could have also contributed to the lack of any new CD 
complex products. Consequently, a hypothetical co-crystal or CD inclusion complex with either of 
the APIs would most likely be thermodynamically less stable than the individual crystals of each 
component.3-5 
However, the attempted co-crystallization experiments with allopurinol led to the serendipitous 
discovery of a new polymorph of isonicotinamide (polymorph 6).  Isonicotinamide is a widely used 
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co-former in the research field of co-crystallization, and therefore the detailed characterisation of 
the X-ray crystal structure of polymorph 6 serves to alert researchers working with isonicotinamide 
to the possible unexpected formation of this polymorph in their research. ‘Serendipitous 
polymorphs’ of isonicotinamide have occurred previously6 and it is imperative to provide 
researchers with the crystallographic data of such new crystal forms, so that a new product will not 
be mistaken for a co-crystal when it is rather a polymorph of the co-former.  
6.1.2) Valproic acid 
The results with regard to the ability of valproic acid to form co-crystals with the twelve selected 
co-formers are inconclusive. This is due to the fact that the focus on valproic acid was shifted 
towards CD inclusion complexation and thus the co-crystallization experiments were abandoned in 
favour of this more productive avenue. Only one set of co-precipitation experiments was 
performed using EtOH as the solvent medium, yet only the respective co-formers precipitated and 
thus those experiments did not produce the desired results.  
In contrast, with regard to CD complexation, it was possible to form six new CD complexes with 
valproic acid, of which four of them were amenable to X-ray crystal structure elucidation. These are 
the first X-ray crystal structures of CD complexes with valproic acid and also the first documented 
crystal structures containing valproic acid.7  
Valproic acid is known to cause pre-absorption gastrointestinal discomfort owing to the carboxylic 
acid functionality;8-9 however, CD inclusion could mask the acidic residue (as observed in the 
relevant crystal structures reported here), thus reducing these gastrointestinal effects. From a 
commercial perspective CD inclusion could improve the efficacy of the drug and it could therefore 
possibly be prescribed to a larger group of patients. The pre-absorption side effects have been cited 
as a major disadvantage of valproic acid and previous attempts to prevent these side effects have 
been reported.8-9 In addition, pure valproic acid is in the liquid state over a wide range of ‘ambient’ 
temperatures, while its CD complexes are crystalline solids, which are more convenient from the 
perspective of administration. Furthermore, the fact that a lower aqueous solubility was obtained 
for the CD complexes of valproic acid, indicates that there is the possible commercial application of 
a slow release form of valproic acid. However, partly due to paucity of the API, the method of 
solubility assessment of representative CD complexes undertaken here was rather rudimentary and 
the results should be viewed as preliminary only and worthy of re-investigation.     
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6.2) Future Work 
 
6.2.1) Allopurinol and 6-thioguanine  
Large numbers of co-crystallization experiments under a wide variety of differing conditions were 
performed for both allopurinol and 6-thioguanine. It may appear that not much more scope for this 
kind of research is left for these two drugs; however, different methodologies of preparation, as 
well as a different selection of co-formers, can be attempted in the future.  
A very extensive variety of CD inclusion experiments were also performed under different 
conditions. However, future studies could extend the variety of non-crystalline CDs to include host 
compounds such as the sulfobutylether -CD sodium salt, for possible interaction with allopurinol 
and 6-thioguanine.  
6.2.2) Valproic acid 
With regard to co-crystallization, multiple co-crystallization experiments that incorporate a wide 
range of methods, as well as the use of different co-formers, should be performed. Only one set of 
twelve individual experiments was performed during this Master’s project, and the results obtained 
were not conclusive with regard to what could potentially be synthesized with different co-formers, 
methods and experimental conditions.  
With reference to CD inclusion, the aqueous solubilities of the DMB·VAL, TMB·VAL and TMA·VAL 
complexes should be determined accurately, and more pertinent solubility values for -CD·VAL, -
CD·VAL and -CD·VAL should be obtained, preferably using synthetic gastrointestinal fluids and 
ultimately in mouse models and human subjects. Likewise, for all six CD-valproic acid complexes 
reported here, assessment of their potential to reduce pre-absorption side effects is warranted and 
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Section 1: General 
Table 1.1: List of available co-formers in the supramolecular laboratory at the 
University of Cape Town. 
Number Co-former Number Co-former 
1 Adipic acid 19 L-Valine 
2 Aspartic acid 20 Maleic acid 
3 Benzamide 21 Malonic acid 
4 Caffeine 22 Nicotinic acid 
5 Cinnamamide 23 Nicotinamide 
6 Citric acid 24 Orotic acid 
7 D-Tartaric acid 25 Oxalic acid 
8 Fumaric acid 26 Piperazine 
9 Glutaric acid 27 Propionamide 
10 Glycine 28 Pyrazinecarboxamide 
11 Isonicotinamide 29 L-Pyroglutamic acid 
12 Lactic acid 30 Saccharin 
13 L-Arginine 31 Salicylic acid 
14 L-Ascorbic acid 32 Sorbic acid 
15 L-Glutamic acid 33 Suberic acid 
16 L-Malic acid 34 Succinic acid 
17 L-Proline 35 Uracil 









Section 2: Co-crystallization of allopurinol 
 











Co-grinding experiments with allopurinol 
Extensive co-grinding experiments were performed in order to attempt to produce a new 
crystalline phase by co-grinding allopurinol with each of the variety of 11 co-formers that were 
selected. Initially, dry co-grinding experiments were performed, where three of the experiments 
verified formation of a new crystalline phase (Table 2.2). These included the experimental 
combinations of allopurinol and isonicotinamide, allopurinol and piperazine, as well as allopurinol 
and maleic acid.  
 
 
Number Selected co-former 
1 Benzamide 
2 Benzoic acid 
3 Fumaric acid 
4 Glutaric acid 
5 Isonicotinamide 








Table 2.2: Dry co-grinding experiments with allopurinol and the selected co-formers.  
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Isonicotinamide New crystalline phase 
6 Allopurinol Maleic acid New crystalline phase 
7 Allopurinol Nicotinamide Physical mixture 
8 Allopurinol Piperazine New crystalline phase 
9 Allopurinol Propionamide Physical mixture 
10 Allopurinol D-Tartaric acid Physical mixture 
11 Allopurinol Urea Physical mixture 
 
With regard to the PXRD pattern of the product of dry co-grinding allopurinol and isonicotinamide 
in an equimolar ratio, distinctive new peaks appeared which represented the new crystalline phase 
(Figure 2.1). However, there were still peaks from the remaining original reagents. This either 
suggested that a longer grinding time would have been required to complete the reaction to fully 
produce the new crystalline phase, or that a different stoichiometric ratio of allopurinol and 
isonicotinamide was required. 
 
Figure 2.1: PXRD patterns of allopurinol, isonicotinamide, and the product of dry co-grinding these components in a 1:1 molar 
ratio for 15 minutes. 
As a result, different stoichiometric ratios of allopurinol and isonicotinamide, as well as longer 
grinding times, were attempted. Consequently, the combination that revealed a pure, new 
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crystalline phase was achieved with the components present in an equimolar ratio and dry co-
ground for 35 minutes (Figure 2.2). The 2θ-positions of this new crystalline phase are 7.5o, 10.2o, 




Figure 2.2: PXRD patterns of allopurinol, isonicotinamide, and the product of dry co-grinding these components in a 1:1 molar 
ratio for 35 minutes. 
Furthermore, as mentioned above, the PXRD pattern of the product of dry co-grinding allopurinol 
and piperazine in an equimolar ratio for 15 minutes also indicated the development of a new 
crystalline phase (Figure 2.3). However, it is evident that the peaks that represent allopurinol are 
still present and consequently experiments with different stoichiometric ratios of allopurinol and 
piperazine were attempted in order to generate the pure, new, crystalline phase. 
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Figure 2.3: PXRD patterns of allopurinol, piperazine, and the product of dry co-grinding these components in a 1:1 molar ratio for 
15 minutes. 
As a result, the experiment that produced the pure, crystalline product was a 1:3 stoichiometric 
ratio of allopurinol to piperazine dry co-ground for 15 minutes (Figure 2.4). The 2θ-positions of this 
new crystalline phase occurred at 10.9o, 12.2o, 16.5o, 18.8o, 21.0o, 24.5o, 25.2o, 26.2o, 27.0o, 29.0o, 
32.5o, 33.0o and 39.0o. The peak that could possibly still belong to allopurinol is the peak at 28.0o. 
This particular peak displayed a significant decrease in intensity from the experiment performed in 
an equimolar ratio (Figure 2.3) in comparison to the experiment conducted in a 1:3 stoichiometric 
ratio (Figure 2.4). Therefore, it could be attributed to negligible trace amounts of allopurinol 
remaining.   
 
Figure 2.4: PXRD patterns of allopurinol, piperazine, and the product of dry co-grinding these components in a 1:3 molar ratio for 
15 minutes. 
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However, an unexpected phenomenon occurred with this new crystalline phase as time 
progressed: it disintegrated and separated, only the presence of allopurinol being evident in the 
final PXRD trace (Figure 2.5). When allopurinol and piperazine were dry co-ground for 15 minutes, a 
liquid-based paste formed, which was representative of the new, product crystalline phase. 
However, when this paste dried, the phase separated and only allopurinol was observed. 
Presumably, piperazine became amorphous during the co-grinding procedure and thus a physical 
mixture of the original components was produced.  
 
Figure 2.5: PXRD patterns of allopurinol, piperazine, and the product of dry co-grinding these components in a 1:3 molar ratio for 
15 minutes and subsequently left to dry. 
 
In addition, the product PXRD pattern resulting from dry co-grinding allopurinol and maleic acid in 
an equimolar ratio for 15 minutes also indicated the presence of a new and seemingly pure 
crystalline phase (Figure 2.6). The 2θ-positions of the new peaks are at 6.5o, 11.5o, 13.0o, 14.6o, 
18.5o, 18.8o, 19.5o, 20.5o, 22.5o, 23.8o, 24.5o, 25.2o, 26.2o, 26.9o, 27.6o, 29.2o, 31.1o, 32.0o, 33.0o and 
34.2o.  
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Figure 2.6: PXRD patterns of allopurinol, maleic acid, and the product of dry co-grinding these components in a 1:1 molar ratio for 
15 minutes. 
The remaining PXRD patterns produced from dry co-grinding indicated that only a physical mixture 
of allopurinol and the respective co-former resulted. This was confirmed since the peaks from the 
PXRD patterns of the starting material directly overlapped with the peaks from the PXRD patterns 
of the co-ground material. Furthermore, liquid-assisted grinding (LAG) experiments were also 
performed with a variety of different solvents with the expectation of producing new crystalline 
phases. This was executed with the combinations from the unsuccessful dry co-grinding 
experiments. The role of the solvent in LAG is not well understood; however, it is thought that the 
solvent coating the reacting particles allows the reagents to diffuse in order to interact to form the 
product by acting as an interface which assists in solubility.1 The different solvents that were 
selected included EtOH, ethyl acetate, hexane, dimethyl sulfoxide (DMSO) and chloroform. The 
total volume of solvent added for each LAG experiment ranged between 0.5 – 6.0 l per mg of API, 
depending on the volatility of the solvent. All five sets of these LAG experiments only mimicked the 
results that were obtained from the dry co-grinding experiments, with the exception that 
allopurinol and propionamide with DMSO became slightly amorphous with LAG. The results are 
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Table 2.3: The results from the LAG experiments of allopurinol and eight of the selected co-formers 
with EtOH.   
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Nicotinamide Physical mixture 
6 Allopurinol Propionamide Physical mixture 
7 Allopurinol D-Tartaric acid Physical mixture 
8 Allopurinol Urea Physical mixture 
 
Table 2.4: The results from the LAG experiments of allopurinol and eight of the selected co-formers 
with ethyl acetate. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Nicotinamide Physical mixture 
6 Allopurinol Propionamide Physical mixture 
7 Allopurinol D-Tartaric acid Physical mixture 









Table 2.5: The results from the LAG experiments of allopurinol and eight of the selected co-formers 
with hexane. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Nicotinamide Physical mixture 
6 Allopurinol Propionamide Physical mixture 
7 Allopurinol D-Tartaric acid Physical mixture 
8 Allopurinol Urea Physical mixture 
 
Table 2.6: The results from the LAG experiments of allopurinol and eight of the selected co-formers 
with DMSO. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Nicotinamide Physical mixture 
6 Allopurinol Propionamide Physical mixture became slightly amorphous 
7 Allopurinol D-Tartaric acid Physical mixture 









Table 2.7: The results from the LAG experiments of allopurinol and eight of the selected co-formers 
with chloroform. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Nicotinamide Physical mixture 
6 Allopurinol Propionamide Physical mixture 
7 Allopurinol D-Tartaric acid Physical mixture 
8 Allopurinol Urea Physical mixture 
 
Co-precipitation experiments with allopurinol  
A full co-precipitation analysis was performed with all the selected allopurinol and co-former 
combinations. This was in spite of the fact that the majority of the PXRD dry co-grinding results and 
all of the LAG results were unsuccessful in forming new crystalline material. 
It is not necessarily conclusive that new crystalline material cannot be created through co-
precipitation experiments, even if the dry co-grinding and LAG experiments indicated otherwise.2 
As a result, co-precipitation experiments, were performed according to the method outlined in the 
Experimental Methods (Chapter 2 in the main dissertation) under section 2.2.4 on pp. 18 – 19, with 
the solvents chloroform and DMSO. One of the co-precipitation experiments with DMSO 
incorporated the use of different stoichiometric ratios.  
As already discussed in the main dissertation, the majority of the results from both the organic 
solvent sets did not reveal any new crystalline material (Tables 2.8 – 2.11). However, there was one 
experiment (in which allopurinol and the respective co-former were dissolved in chloroform) which 
revealed a new crystalline phase. This involved allopurinol and isonicotinamide, where a new 
polymorph of isonicotinamide was produced serendipitously. This is discussed in detail in the main 




Table 2.8: Co-precipitation of allopurinol with various co-formers prepared in a 1:1 molar ratio in 
chloroform via slow evaporation. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Isonicotinamide A new polymorph of isonicotinamide formed 
6 Allopurinol Maleic acid Physical mixture 
7 Allopurinol Nicotinamide Physical mixture 
8 Allopurinol Piperazine Physical mixture 
9 Allopurinol Propionamide Physical mixture 
10 Allopurinol D-Tartaric acid Physical mixture 
11 Allopurinol Urea Physical mixture 
 
 
Table 2.9: Co-precipitation of allopurinol with various co-formers prepared in a 1:1 molar ratio in 
DMSO via slow evaporation. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Fumaric acid Physical mixture 
4 Allopurinol Glutaric acid Physical mixture 
5 Allopurinol Isonicotinamide Physical mixture 
6 Allopurinol Maleic acid Physical mixture 
7 Allopurinol Nicotinamide Physical mixture 
8 Allopurinol Piperazine Physical mixture 
9 Allopurinol Propionamide Physical mixture 
10 Allopurinol D-Tartaric acid Physical mixture 





Table 2.10: Co-precipitation of allopurinol with various co-formers prepared in a 1:1 molar ratio in 
DMSO via slow cooling followed by slow evaporation. 
Number API Selected co-former Result 
1 Allopurinol Benzamide Physical mixture 
2 Allopurinol Benzoic acid Physical mixture 
3 Allopurinol Isonicotinamide Physical mixture 
4 Allopurinol Nicotinamide Physical mixture 
5 Allopurinol Piperazine Physical mixture 
6 Allopurinol Propionamide Physical mixture 
7 Allopurinol D-Tartaric acid Physical mixture 
8 Allopurinol Urea Physical mixture 
 
 
Table 2.11: Co-precipitation of allopurinol with three selected co-formers that were prepared in 
different stoichiometric ratios (performed in the solvent DMSO via slow evaporation). 
Number API Selected co-former Stoichiometric 
ratio 
Result 
1 Allopurinol Isonicotinamide 1:3 A physical mixture with a variety of 
known polymorphs of isonicotinamide 
2 Allopurinol Isonicotinamide 1:5 A physical mixture with a variety of 
known polymorphs of isonicotinamide 
3 Allopurinol Isonicotinamide 3:1 Physical mixture 
4 Allopurinol Isonicotinamide 5:1 Physical mixture 
5 Allopurinol Piperazine 1:3 Physical mixture 
6 Allopurinol Piperazine 1:5 Physical mixture 
7 Allopurinol Piperazine 3:1 Physical mixture 
8 Allopurinol Piperazine 5:1 Physical mixture 
9 Allopurinol Maleic acid 1:3 Physical mixture 
10 Allopurinol Maleic acid 1:5 Physical mixture 
11 Allopurinol Maleic acid 3:1 Physical mixture 




Recrystallization of products initially obtained from dry co-grinding 
experiments 
Furthermore, experiments were performed which involved recrystallizing some of the new material 
that was produced from the various dry co-ground experiments (Table 2.12). The two systems in 
question were allopurinol and isonicotinamide dry co-ground for 35 minutes in an equimolar ratio, 
and allopurinol and piperazine dry co-ground for 15 minutes in a 1:3 stoichiometric ratio. In the 
latter case, the product was dissolved in the respective solvents before it dried. The aim of the 
recrystallization experiments was to produce single crystals of the new material for further analysis. 
Furthermore, the new material that was produced via dry co-grinding allopurinol and maleic acid 
could not be reproduced for this experiment. Unfortunately, the reasons for the inconsistency of 
reproducing this species remained unknown. However, this new phase could have been pressure-
dependent when the dry co-grinding experiment was performed. Unfortunately, the results 
indicated that the new crystalline phase in all the experiments dissolved and the original reagents 
recrystallized (Table 2.12). 
Table 2.12: Results of the recrystallization of the products from the dry co-grinding of allopurinol 
and isonicotinamide (1:1) for 35 minutes, as well as dry co-grinding of allopurinol and piperazine 
(1:3) for 15 minutes. 
Number Material recrystallized Solvent Result 
1 Allopurinol with isonicotinamide (1:1) dry 
co-ground for 35 minutes 
EtOH The original reagents crystallized 
2 Allopurinol with isonicotinamide (1:1) dry 
co-ground for 35 minutes 
Chloroform The original reagents crystallized 
3 Allopurinol with isonicotinamide (1:1) dry 
co-ground for 35 minutes 
Water The original reagents crystallized 
4 Allopurinol with piperazine (1:1) dry co-
ground for 15 minutes 
EtOH The original reagents crystallized 
5 Allopurinol with piperazine (1:3) dry co-
ground for 15 minutes 
EtOH The original reagents crystallized 
6 Allopurinol with piperazine (1:3) dry co-
ground for 15 minutes 
Water The original reagents crystallized 
7 Allopurinol with piperazine (1:3) dry co-
ground for 15 minutes 
DMSO The original reagents crystallized 
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Section 3: Cyclodextrin inclusion with 
allopurinol 
Native cyclodextrin inclusion with allopurinol 
 
Kneading experiments with allopurinol  
Kneading experiments were attempted with the aim of including allopurinol in the native CDs, 
namely -CD, -CD and -CD (Table 3.1). A mixture containing an equimolar ratio of each CD and 
allopurinol (5 mg, 0.0367 mmol) was prepared and kneaded using small additions of water as the 
medium for 30 minutes.  
Table 3.1: The results from the kneading experiments of the native CDs with allopurinol. 
Number API Cyclodextrin Result 
1 Allopurinol -cyclodextrin Physical mixture 
2 Allopurinol -cyclodextrin Physical mixture 
3 Allopurinol -cyclodextrin Physical mixture 
 
Unfortunately, the results did not indicate any inclusion taking place, since the resultant PXRD 
patterns were the sum of the PXRD patterns of the original reagents.  
Co-precipitation experiments with allopurinol 
CD inclusion co-precipitation experiments of allopurinol were also attempted with the native CDs. 
An equimolar ratio and a 2:1 molar ratio of CD and allopurinol (5 mg, 0.0367 mmol) was prepared 
for each native CD. Each CD was dissolved in the respective amount of water depending on the 
stoichiometric ratio used. For -CD, 0.8 cm3 of water was used for both stoichiometric ratios, while 
for -CD and -CD, 2 cm3 and 4 cm3 of water were used for the 1:1 and 2:1 stoichiometric ratios 
respectively. The reagents were heated to 75 oC while stirring.3 The 5 mg of allopurinol was slowly 
added to each aqueous solution of pre-dissolved CD while stirring at 75 oC. The solutions were 
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further stirred and capped for 3 hours, while maintaining a temperature of 75 oC. The saturated 
solutions were filtered into clean vials and prepared for slow cooling. This entire experiment was 
repeated twice, except that a small measured volume of EtOH was added to the resultant solution 
for the first repetition, and a drop of Tween 80 was added to the resultant solution for the second 
repetition. The results are displayed in Tables 3.2 – 3.4. 
Table 3.2: The results from the various native CD co-precipitation experiments with allopurinol, co-
precipitated in water. 
Number System Result 
1 -CD and allopurinol (1:1) The original reagents precipitated 
2 -CD and allopurinol (2:1) The original reagents precipitated 
3 -CD and allopurinol (1:1) The original reagents precipitated 
4 -CD and allopurinol (2:1) The original reagents precipitated 
5 -CD and allopurinol (1:1) The original reagents precipitated 
6 -CD and allopurinol (2:1) The original reagents precipitated 
 
Table 3.3: The results from the various native CD co-precipitation experiments with allopurinol, co-
precipitated in water with a few drops of EtOH. 
Number System Result 
1 -CD and allopurinol (1:1) The original reagents precipitated 
2 -CD and allopurinol (2:1) The original reagents precipitated 
3 -CD and allopurinol (1:1) The original reagents precipitated 
4 -CD and allopurinol (2:1) The original reagents precipitated 
5 -CD and allopurinol (1:1) The original reagents precipitated 








Table 3.4: The results from the various native CD co-precipitation experiments with allopurinol, co-
precipitated in water with a drop of Tween 80. 
Number System Result 
1 -CD and allopurinol (1:1) A Tween 80 -CD inclusion complex precipitated 
2 -CD and allopurinol (2:1) A Tween 80 -CD inclusion complex precipitated 
3 -CD and allopurinol (1:1) A Tween 80 -CD inclusion complex precipitated 
4 -CD and allopurinol (2:1) A Tween 80 -CD inclusion complex precipitated 
5 -CD and allopurinol (1:1) A Tween 80 -CD inclusion complex precipitated 
6 -CD and allopurinol (2:1) A Tween 80 -CD inclusion complex precipitated 
 
Unfortunately, the results did not yield any desired CD inclusion complexes, even though different 
stoichiometric ratios and solvent media were employed.  
Furthermore, a final attempt to produce a -CD inclusion complex with allopurinol was performed 
using a 0.1 M solution of KOH. Allopurinol is very soluble in a basic solution and thus a liquid 
formulation of allopurinol and KOH was added dropwise into an aqueous -CD solution.4 A base will 
only hydrolyse a CD molecule if the pH of the solution exceeds 12.5 According to Jiménez et al., a -
CD·allopurinol inclusion complex was synthesized in D2O with a minimal amount of KOH. The pH of 
the solution was 10.5.6 
Thus, 5 mg (0.0367 mmol) of allopurinol was pre-dissolved in 0.2 cm3 of 0.1 M KOH solution and 
added dropwise to a 1.8 cm3 aqueous solution of -CD. This experiment was performed in duplicate 
where one vial was allowed to stir at 55 oC and the other vial was left to stir at room temperature. 
The resultant solutions were left to stir for 2 days, and their pH was subsequently measured after 
filtering and the solutions were then prepared for slow evaporation.a The results are summarised in 
Table 3.5. 
 
                                                          
a The pH measurements were performed on the Crison micropH 2000 pH meter, which was 




Table 3.5: Co-precipitation of -CD and allopurinol, where allopurinol was pre-dissolved in 0.2 cm3 
of aqueous KOH solution. 
Number System pH Result 
1 Allopurinol and -CD stirred at 55 
o
C 9.29 The original reagents 
precipitated 
2 Allopurinol and -CD stirred at room temperature 9.21 The original reagents 
precipitated 
 
As indicated, the results were unsatisfactory and thus the experiment was repeated; however, the 
aim was to raise the pH of the overall solution in order to assess whether a higher pH might 
influence inclusion complexation. Furthermore, according to the paper by Jiménez et al., the 
authors obtained a resultant solution with a pH of 10.5.6 As a result, the same procedure was 
followed as described above, although 0.4 cm3 of KOH solution was used to pre-dissolve the 
allopurinol instead of 0.2 cm3.  The results are displayed in Table 3.6. 
Table 3.6: Co-precipitation of -CD and allopurinol, where allopurinol was pre-dissolved in 0.4 cm3 
of aqueous KOH solution. 
Number System pH Result 
1 Allopurinol and -CD stirred at 55 
o
C 11.30 The original reagents 
precipitated 
2 Allopurinol and -CD stirred at room temperature 10.21 The original reagents 
precipitated 
 
Unfortunately, the results replicated those obtained previously. The higher pH, of 11.30, obtained 
in experiment number 1 (Table 3.6), in comparison to the pH of 10.21 as obtained in experiment 
number 2 (Table 3.6), was most likely owing to errors in the volume measurements of the 
respective solutions when preparing the system. Consequently, the overall experimentation that 





Methylated cyclodextrin inclusion with allopurinol  
Kneading experiments with allopurinol 
CD inclusion kneading experiments of allopurinol were attempted with the methylated CDs, namely 
DMB, TMB and TMA. Equimolar amounts of each methylated CD and allopurinol (5 mg, 0.0367 
mmol), were prepared and the three combinations were kneaded for 30 minutes. Unfortunately, 
the results were unsuccessful and they are summarised in Table 3.7.  
Table 3.7: The results from the kneading experiments with the methylated cyclodextrins and 
allopurinol. 
Number API Cyclodextrin Result 
1 Allopurinol DMB Became amorphous 
2 Allopurinol TMB Physical mixture 
3 Allopurinol TMA Physical mixture 
 
Co-precipitation experiments with allopurinol 
CD inclusion co-precipitation experiments of allopurinol were attempted with the same methylated 
CDs as in the kneading experiments described above. Equimolar amounts of each methylated CD 
and allopurinol (5 mg, 0.0367 mmol), were prepared. Masses of 48.91 mg (0.0367 mmols) of DMB, 
52.51 mg (0.0367 mmols) of TMB and 45.01 mg (0.0367 mmol) of TMA were dissolved in 1.5 cm3 of 
water in separate vials at room temperature while stirring. The allopurinol was added very slowly to 
each solution which contained the dissolved methylated CD. Owing to the fact that not all of the 
allopurinol dissolved, temperature cycling was employed. The stirring solutions were heated to 70 
oC for 15 minutes and thereafter rapidly cooled in the cold room to 4 oC. This process was repeated 
eight times.  The saturated solutions were filtered immediately after being removed from the cold 
room. The filtered solutions were sealed and placed in the oven at 60 oC and left undisturbed in 
order to induce crystallization. The products of these experiments were precipitated crystals of the 
pure methylated CD, as confirmed by 1H NMR.  
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Section 4: Solubility experiments with 
allopurinol 
 
4.1) Calculation of the error in mass from the calibration curve 
 
 y = 0.0796 x – 0.0041     equation 1 
 y = 0.0796     equation 2 
A point selected at y = 0.447, therefore: 
 0.447 = 0.0796 x – 0.0041    
x = 5.66708542171  10-8 mol.cm-3   from equation 1 
 0.447 = 0.0796  
x = 5.6155778894  10-8 mol.cm-3  from equation 2 
The absolute value determined from the subtraction of the two x values: 
 / x equation 2 – x equation 1 /  = 5.15075323  10
-10 mol.cm-3  
Obtaining the mass from the concentration: 
 5.15075323  10-10 mol.cm-3 = number of moles / 5 cm3 
number of moles = 2.575376625  10-9 mols 
Therefore: 
2.575376625  10-9 mols = mass / 136.112 g.mol-1 
Error mass = 3.505396597792  10-7 g 




4.2) Phase solubility analysis of allopurinol with -CD, HPBCD and RAMEB 
 
A predetermined mass of each CD was dissolved in water in a volumetric flask. With regard to -CD, 
a mass of 1.19232 g (9.19206 x 10-4 mol) was dissolved in water in a 50 cm3 volumetric flask. While, 
with regard to HPBCD and RAMEB, masses of 2.69189g (1.92767 x 10-3 mol) and 2.51149 g (1.92747 
x 10-3 mol) respectively were separately dissolved in 100 cm3 volumetric flasks. The method was 
followed according to the Experimental Methods (Chapter 2 in the main dissertation) under section 
2.9.1 on pp. 23 – 24. The resultant phase solubility curves are displayed below (Figure 4.1 – 4.3).  
 













































Figure 4.2: Phase solubility curve of the concentration of allopurinol versus the concentration of HPBCD. 
 
 
Figure 4.3: Phase solubility curve of the concentration of allopurinol versus the concentration of RAMEB. 
 
As a result, it is evident that the solubility of allopurinol was not improved, despite the varied 


















































































Concentration of RAMEB (x 10-5 mol.cm-3) 
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Section 5: Co-crystallization of                    
6-thioguanine 
 










Numerous co-grinding experiments were performed in order to attempt to produce a new 
crystalline phase with 6-thioguanine and each of the 11 co-formers that were selected. Initially, dry 
co-grinding experiments were performed; however, none of the results yielded a new crystalline 
phase, as displayed in Table 5.2. This was confirmed since the peaks from the PXRD patterns of the 





Number Selected co-former 
1 Benzamide 
2 Benzoic acid 
3 Fumaric acid 
4 Glutaric acid 
5 Isonicotinamide 








Table 5.2: Dry co-grinding experiments with 6-thioguanine and the eleven selected co-formers.  
Number API Selected co-former Result 
1 6-Thioguanine Benzamide Physical mixture 
2 6-Thioguanine Benzoic acid Physical mixture 
3 6-Thioguanine Fumaric acid Physical mixture 
4 6-Thioguanine Glutaric acid Physical mixture 
5 6-Thioguanine Isonicotinamide Physical mixture 
6 6-Thioguanine Maleic acid Physical mixture 
7 6-Thioguanine Nicotinamide Physical mixture 
8 6-Thioguanine Piperazine Physical mixture 
9 6-Thioguanine Propionamide Physical mixture 
10 6-Thioguanine D-Tartaric acid Physical mixture 
11 6-Thioguanine Urea Physical mixture 
 
Subsequently, liquid-assisted grinding (LAG) experiments were also performed with EtOH as the 
medium, added in very small volumes (approximately 3 l per mg of API). These LAG experiments 
produced only physical mixtures of the two respective reagents used. The results are summarised in 












Table 5.3: The results from the LAG experiments of 6-thioguanine and the eleven selected co-
formers with EtOH. 
Number API Selected co-former Result 
1 6-Thioguanine Benzamide Physical mixture 
2 6-Thioguanine Benzoic acid Physical mixture 
3 6-Thioguanine Fumaric acid Physical mixture 
4 6-Thioguanine Glutaric acid Physical mixture 
5 6-Thioguanine Isonicotinamide Physical mixture 
6 6-Thioguanine Maleic acid Physical mixture 
7 6-Thioguanine Nicotinamide Physical mixture 
8 6-Thioguanine Piperazine Physical mixture 
9 6-Thioguanine Propionamide Physical mixture 
10 6-Thioguanine D-Tartaric acid Physical mixture 
11 6-Thioguanine Urea Physical mixture 
 
 
Co-Precipitation experiments with 6-thioguanine 
A full set of co-precipitation experiments was performed for all selected 6-thioguanine and co-
former combinations, despite all of the co-grinding experiments having been unsuccessful. 
Furthermore, as mentioned previously, it is not necessarily conclusive that new crystalline material 
cannot be created through co-precipitation experiments, even if the dry co-grinding and LAG 
experiments indicated otherwise.2 As a result, equimolar co-precipitation experiments were 
performed with DMSO as the solvent, according to the method outlined in the Experimental 
Methods (Chapter 2 in the main dissertation) under section 2.2.4 pp. 18 – 19. DMSO was selected 
owing to the fact that 6-thioguanine was rather insoluble in every other organic solvent. The 
majority of the results from all the organic solvent sets did not reveal any new crystalline material. 






Table 5.4: Co-precipitation of 6-thioguanine with the selected co-formers prepared in a 1:1 molar 
ratio in DMSO via slow evaporation. 
Number API Selected co-former Result 
1 6-Thioguanine Benzamide Physical mixture 
2 6-Thioguanine Benzoic acid Physical mixture 
3 6-Thioguanine Fumaric acid Physical mixture 
4 6-Thioguanine Glutaric acid Physical mixture 
5 6-Thioguanine Isonicotinamide Physical mixture 
6 6-Thioguanine Maleic acid Physical mixture 
7 6-Thioguanine Nicotinamide Physical mixture 
8 6-Thioguanine Piperazine Physical mixture 
9 6-Thioguanine Propionamide Physical mixture 
10 6-Thioguanine D-Tartaric acid Physical mixture 















Section 6: Cyclodextrin inclusion with       
6-thioguanine 
 
The native and methylated CD experiments in this section were identical replicates of those that 
were performed for allopurinol in Section 3, pp. 15 – 19 of this Appendix. In addition, the results 
that were obtained for these replicated experiments were also very similar.  As a result, a summary 
of the results is tabulated for each experiment, where the full description of the methodology and 
explanation for the results are provided in the Section 3 (pp. 15 – 19) dedicated to allopurinol in 
this Appendix. For all the CD experiments involving 6-thioguanine, 5 mg (0.0299 mmol) of the drug 
was used with the corresponding molar amount (or a multiple thereof) for the native and 
methylated CDs.  
 
Native cyclodextrin inclusion with 6-thioguanine 
 
Kneading experiments with 6-thioguanine 
Table 6.1: The results from the kneading experiments of the native cyclodextrins with 6-
thioguanine. 
Number API Cyclodextrin Result 
1 6-Thioguanine -cyclodextrin Physical mixture 
2 6-Thioguanine -cyclodextrin Physical mixture 







Co-precipitation experiments with 6-thioguanine 
 
Table 6.2: The results from the various native CD co-precipitation experiments with 6-thioguanine, 
co-precipitated in water. 
Number System Result 
1 -CD and 6-thioguanine (1:1) The original reagents precipitated 
2 -CD and 6-thioguanine (2:1) The original reagents precipitated 
3 -CD and 6-thioguanine (1:1) The original reagents precipitated 
4 -CD and 6-thioguanine (2:1) The original reagents precipitated 
5 -CD and 6-thioguanine (1:1) The original reagents precipitated 
6 -CD and 6-thioguanine (2:1) The original reagents precipitated 
 
Table 6.3: The results from the various native CD co-precipitation experiments with 6-thioguanine, 
co-precipitated in water with a few drops of EtOH. 
Number System Result 
1 -CD and 6-thioguanine (1:1) The original reagents precipitated 
2 -CD and 6-thioguanine (2:1) The original reagents precipitated 
3 -CD and 6-thioguanine (1:1) The original reagents precipitated 
4 -CD and 6-thioguanine (2:1) The original reagents precipitated 
5 -CD and 6-thioguanine (1:1) The original reagents precipitated 









Table 6.4: The results from the various native CD co-precipitation experiments with 6-thioguanine, 
co-precipitated in water with a drop of Tween 80. 
Number System Result 
1 -CD and 6-thioguanine (1:1) A Tween 80 -CD inclusion complex precipitated 
2 -CD and 6-thioguanine (2:1) A Tween 80 -CD inclusion complex precipitated 
3 -CD and 6-thioguanine (1:1) A Tween 80 -CD inclusion complex precipitated 
4 -CD and 6-thioguanine (2:1) A Tween 80 -CD inclusion complex precipitated 
5 -CD and 6-thioguanine (1:1) A Tween 80 -CD inclusion complex precipitated 
6 -CD and 6-thioguanine (2:1) A Tween 80 -CD inclusion complex precipitated 
 
Table 6.5: Co-precipitation of -CD and 6-thioguanine, where 6-thioguanine was pre-dissolved in 
0.2 cm3 of aqueous KOH solution. 
Number System pH Result 
1 6-thioguanine and -CD stirred at 55 
o
C 8.80 The original reagents precipitated 
2 6-thioguanine and -CD stirred at room 
temperature 
8.90 The original reagents precipitated 
 
Table 6.6: Co-precipitation of -CD and 6-thioguanine, where 6-thioguanine was pre-dissolved in 
0.4 cm3 of aqueous KOH solution. 
Number System pH Result 
1 6-thioguanine and -CD stirred at 55 
o
C 9.38 The original reagents precipitated 
2 6-thioguanine and -CD stirred at room 
temperature 









Methylated cyclodextrin inclusion with 6-thioguanine 
 
Kneading experiments with 6-thioguanine  
Table 6.7: The results from the kneading experiments of the methylated cyclodextrins with                       
6-thioguanine. 
Number API Cyclodextrin Result 
1 6-Thioguanine DMB Became amorphous 
2 6-Thioguanine TMB Physical mixture 
3 6-Thioguanine TMA Physical mixture 
 
Co-precipitation experiments with 6-thioguanine 
Table 6.7: The results from the co-precipitation experiments of the methylated cyclodextrins with                       
6-thioguanine. 
Number API Cyclodextrin Result 
1 6-Thioguanine DMB DMB crystallized  
2 6-Thioguanine TMB TMB crystallized 












Section 7: Solubility experiments with       
6-thioguanine 
7.1) Calculation of the error in mass from the calibration curve 
 
 y = 0.2126 x + 0.0013    equation 1 
 y = 0.2126 x     equation 2 
A point selected at y = 0.225, therefore: 
 0.225 = 0.2126 x + 0.0013   
x = 1.0522107244  10-8 mol.cm-3   from equation 1 
 0.225 = 0.2126 x 
x = 1.0583254939  10-8 mol.cm-3  from equation 2 
The absolute value determined from the subtraction of the two x values: 
 / x equation 2 – x equation 1 /  = 6.1147695  10
-11 mol.cm-3 
Obtaining the mass from the concentration: 
 6.1147695  10-11 mol.cm-3 = number of moles / 5 cm3 
number of moles = 3.05738475  10-10 mols 
Therefore: 
3.05738475  10-10 mols = mass / 167.193 g.mol-1 
Error mass = 5.111732850675  10-8 g 




7.2) Phase solubility analysis of 6-thioguanine with -CD, HPBCD and 
RAMEB 
 
The method described in the Experimental Methods (Chapter 2 in the main dissertation) under 
section 2.9.1 on pp. 23 – 24 was followed in order to perform this experiment. A predetermined 
mass of each CD was dissolved in water in a volumetric flask. For -CD, a mass of 1.19848 g 
(9.23893 x 10-4 mol) was dissolved in water in a 50 cm3 volumetric flask, while for HPBCD and 
RAMEB, masses of 2.64816 g (1.89635 x 10-3 mol) and 2.44570 g (1.87698 x 10-3 mol) respectively 
were separately dissolved in 100 cm3 volumetric flasks. The resultant phase solubility curves are 
provided below (Figure 7.1 – 7.3).  
 
 













































Figure 7.2: Phase solubility curve of the concentration of 6-thioguanine versus the concentration of HPBCD. 
 
 
Figure 7.3: Phase solubility curve of the concentration of 6-thioguanine versus the concentration of RAMEB. 
 
As a result, even though a variety of different CDs with varying solution concentrations were 

















































































Concentration of RAMEB (x 10-5 mol.cm-3) 
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Section 8: Co-crystallization of          
valproic acid 
 
Table 8.1: The selected co-formers for co-crystallization screening experiments with valproic acid. 
Number Co-former 
1 Adipic acid 
2 Citric acid 
3 Glutaric acid 
4 Isonicotinamide 
5 Maleic acid 
6 Malic acid 
7 Nicotinamide 
8 Pimelic acid 
9 Piperazine 
10 Propionamide 
11 Pyroglutamic acid 
12 D-Tartaric acid 
 
Co-precipitation experiments with valproic acid  
 
Co-precipitation experiments were executed with equimolar combinations of valproic acid and the 
selected co-formers (Table 8.1) in attempts to synthesize co-crystals. Consequently, 5 mg           
(3.467 x 10-3 mol; 5.434 μl) of valproic acid and an equimolar mass of a co-former were separately 
dissolved in 1 cm3 of EtOH at 50 oC while stirring. The solutions were subsequently filtered into a 
clean, common vial and prepared for slow evaporation. These results are summarised in Table 8.2 




Table 8.2: Co-precipitation of valproic acid with various co-formers prepared in a 1:1 molar ratio in 
EtOH via slow evaporation. 
Number API Co-former Result 
1 Valproic acid Adipic acid The co-former crystallised 
2 Valproic acid Citric acid The co-former crystallised 
3 Valproic acid Glutaric acid The co-former crystallised 
4 Valproic acid Isonicotinamide The co-former crystallised 
5 Valproic acid Maleic acid The co-former crystallised 
6 Valproic acid Malic acid The co-former crystallised 
7 Valproic acid Nicotinamide The co-former crystallised 
8 Valproic acid Pimelic acid The co-former crystallised 
9 Valproic acid Piperazine The co-former crystallised 
10 Valproic acid Propionamide The co-former crystallised 
11 Valproic acid Pyroglutamic acid The co-former crystallised 
12 Valproic acid D-Tartaric acid The co-former crystallised 
 
Unfortunately, no new product was obtained and with all the results, only the co-former was 











Section 9: Cyclodextrin inclusion 
complexation with valproic acid 
9.1) Supplementary data for the -CD·VAL inclusion complex  
 












9.1.2) The FT-IR Spectrum of -CD·VAL 
 
9.1.3) Calculation of the number of water molecules in (-CD)2·VAL·nH2O, and the 
number of water molecules per -CD molecule (from the TGA analysis). 
10.4 % =  
𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
2(𝑀𝑊( − 𝐶𝐷)) + 𝑀𝑊(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑) + 𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
 
 
0.104 =  
18.016𝑛
2(972.846) + 144.211 + 18.016𝑛
 
     
𝒏 = 𝟏𝟑. 𝟓 𝒘𝒂𝒕𝒆𝒓 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔   
 
Therefore there are 6.7 water molecules per -CD molecule.  
 
A-CD new
Valproic acid lower intensity
a-CD and Valproic acid complex without washing full spectrum
Name
Sample 004 By spectrum Date Friday, September 15 2017
Sample 000 By spectrum Date Friday, November 24 2017
Sample 049 By spectrum Date Wednesday, October 05 2016
Description


















valproic acid  












9.2) Supplementary data for the β-CD·VAL inclusion complex 
 
9.2.1) The 1H NMR spectrum of -CD·VAL 
 
 












Valproic acid lower intensity
B CD VAL new
Name
Sample 006 By spectrum Date Friday, September 15 2017
Sample 000 By spectrum Date Friday, November 24 2017
Sample 007 By spectrum Date Friday, September 15 2017
Description
































9.2.3) Calculation of the number of water molecules in -CD·VAL·nH2O, and the 
number of water molecules per -CD molecule (from the TGA analysis). 
11.5 % =  
𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
(𝑀𝑊( − 𝐶𝐷)) + 𝑀𝑊(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑) + 𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
 
 
0.115 =  
18.016𝑛
1134.987 + 144.211 + 18.016𝑛
 
     
𝒏 = 𝟗. 𝟐 𝒘𝒂𝒕𝒆𝒓 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔   
 















9.3) Supplementary data for the -CD·VAL inclusion complex 
 
9.3.1) The 1H NMR spectrum of -CD·VAL 
 
 




Valproic acid lower intensity
Gamma-CDVAL
Name
Sample 076 By spectrum Date Tuesday, April 05 2005
Sample 000 By spectrum Date Friday, November 24 2017
Sample 079 By spectrum Date Tuesday, April 05 2005
Description


































9.3.3) Calculation of the number of water molecules in (-CD)4/3·VAL·nH2O, and the 
number of water molecules per -CD molecule (from the TGA analysis). 




( − 𝐶𝐷)) + 𝑀𝑊(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑) + 𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
 
 
0.164 =  
18.016𝑛
4
3 (1297.128) + 144.211 + 18.016𝑛
 
     
𝒏 = 𝟐𝟎. 𝟒 𝒘𝒂𝒕𝒆𝒓 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔   
 













9.4) Solubility calculations  
 
9.4.1) Sample calculation for the mass of valproic acid dissolved per cm3 from the 
co-precipitated hydrated α-CD·VAL.  
Molar mass of valproic acid: 144.211 g.mol-1 
Molar mass of α-CD: 972.846 g.mol-1  
Mass of 6.7 mol of water (from complex formula): 119.548 g 
 
Percentage of valproic acid in a 2:1 α-CD·VAL complex: 
 
144.211
144.211 + 2(972.846) + 119.548
× 100 = 6.527 % 
 
Therefore, 0.06527 x 24.14 mg = 1.576 mg in 3 cm3 of water (lower limit) 
Therefore, 0.06527 x 24.54 mg = 1.602 mg in 3 cm3 of water (upper limit) 












9.5) Supplementary data for the DMB·VAL inclusion complex 
 
9.5.1) The 1H NMR spectrum of DMB·VAL 
 




Valproic acid lower intensity
DIMEBVAL crystals from vial bottom
Name
Sample 074 By spectrum Date Tuesday, April 05 2005
Sample 000 By spectrum Date Friday, November 24 2017
Sample 038 By spectrum Date Friday, October 13 2017
Description



































9.5.3) Calculation of the number of water molecules in DMB·VAL·nH2O, and the 
number of water molecules per DMB molecule (from the TGA analysis). 
2.1 % =  
𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
𝑀𝑊(𝐷𝑀𝐵) + 𝑀𝑊(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑) + 𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
 
 
0.021 =  
18.016𝑛
1331.36 + 144.211 + 18.016𝑛
 
     
𝒏 = 𝟏. 𝟖 𝒘𝒂𝒕𝒆𝒓 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔   
 

















9.6) Supplementary data for the TMB·VAL inclusion complex 
 
9.6.1) The 1H NMR spectrum of TMB·VAL 
 
 
9.6.2) The FT-IR Spectrum of TMB·VAL 
 
TRIMEB
Valproic acid lower intensity
TRIMEBVAL
Name
Sample 070 By spectrum Date Tuesday, April 05 2005
Sample 000 By spectrum Date Friday, November 24 2017
Sample 073 By spectrum Date Tuesday, April 05 2005
Description




































9.6.3) Calculation for determining the stoichiometry of the anhydrous TMB·VAL 
inclusion complex (from the TGA analysis). 
Percentage mass loss of valproic acid: 8.3 ± 0.9 % 
Ratio of valproic acid to an equimolar anhydrous inclusion complex: 
𝑀(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑)






















9.7) Supplementary data for the TMA·VAL inclusion complex 
 
9.7.1) The 1H NMR spectrum of TMA·VAL 
 
 
9.7.2) The FT-IR Spectrum of TMA·VAL 
 
TRIMEA full
Valproic acid lower intensity
TRIMEAVAL complex full
Name
Sample 070 By spectrum Date Wednesday, March 16 2005
Sample 000 By spectrum Date Friday, November 24 2017
Sample 071 By spectrum Date Wednesday, March 16 2005
Description































9.7.3) Calculation for determining the stoichiometry of the anhydrous TMA·VAL 
inclusion complex (from the TGA analysis) 
Total percentage mass loss of valproic acid: 9.9 ± 0.7 % 
Ratio of valproic acid to an equimolar anhydrous inclusion complex: 
𝑀(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑)




× 100 =  10.5 % 
 
9.7.4) Calculation of the number of water molecules in TMA·VAL·nH2O, and the 
number of water molecules per TMA molecule (from the TGA analysis). 
1.5 % =  
𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
𝑀𝑊(𝑇𝑀𝐴) + 𝑀𝑊(𝑉𝑎𝑙𝑝𝑟𝑜𝑖𝑐 𝑎𝑐𝑖𝑑) + 𝑀𝑊(𝑊𝑎𝑡𝑒𝑟)𝑛
 
 
0.015 =  
18.016𝑛
1225.32 + 144.211 + 18.016𝑛
 
     
𝒏 = 𝟏. 𝟐 𝒘𝒂𝒕𝒆𝒓 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔   
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